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Abstract
Cardiac arrhythmia are a widely spread global health burden. Currently, the standard treatments are
anti-arrhythmic drugs and radio-frequency catheter ablation. The latter is an invasive procedure with
varying success rates. For the treatment of atrial fibrillation, the most common cardiac disorder, repe-
titions of the procedure are necessary in a significant amount of cases. Furthermore, radio-frequency
catheter ablation is particularly ineffective against ventricular tachycardia, another common cardiac ar-
rhythmia, as the thickness of the myocardium in the ventricles often prevents transmural scar formation.
A promising alternative is the use of radiotherapy. During the last few years, several studies showed
that ionizing radiation can alter electrical pathways within the heart muscle. The use of carbon ions
instead of photons should offer significant dosimetric advantages, due to the inverse depth-dose profile.
Accurate treatment of moving targets with scanned ion beams remains challenging and is still not a clin-
ical routine. For the high doses needed for cardiac targets, careful consideration of motion mitigation is
necessary.
In this work, the first in-vivo feasibility study in pigs using scanned carbon ions to induce targeted
changes of the cardiac electrophysiology is presented. The focus lies on the 4D treatment planning
approach and the motion mitigation techniques applied in the study. In total, 15 pigs were irradiated
in three different target groups: atrioventricular node (AVN), pulmonary vein, and left ventricular free-
wall. In each group, a specific heart structure was ablated using single-fraction doses of 40 Gy, except
for the AVN group were doses of 25, 40 and 55 Gy were applied to carry out a dose escalation study.
Electrophysiological changes were found in all target groups after the experiment. Nevertheless, due
to heterogeneous results among animals of the same dose group, the success rate was not satisfactory.
A critical discussion of 4D treatment planning and delivery revealed the accuracy of deformable image
registration as a potential source of error. The influence on 4D dose calculation could potentially explain
limited results in single pigs and dose groups. Furthermore, a scan path optimization was developed
to reduce treatment time while improving interplay reduction compared to methods employed in the
in-vivo study. This optimization could also facilitate single-fraction and hypofractionated treatments in
clinical radiotherapy. The scan path optimization and a dynamic intensity control were implemented in
a simulation software which was subsequently validated and tested at the Heidelberg Ion-Beam Therapy
Center (Germany).
This work summarizes the current status of ion beam cardiac ablations and identifies and realizes
possible improvements for future in-vivo studies in support of a fast clinical transition of catheter-free
ablation using carbon ions.
I

Zusammenfassung
Herzrhythmusstörungen sind ein weitverbreitetes Gesundheitsproblem mit steigender Inzidenz auf-
grund einer alternden Bevölkerung. Die heutige Standardbehandlung für Herzrhythmusstörungen ist,
neben der Gabe von Medikamenten, die Katheterablation. Die Erfolgsaussichten der Katheterablation
sind vor allem abhängig von der behandelten Herzregion. Während Behandlungen von Vorhofflimmern,
der am häufigsten auftretenden Herzrhythmusstörung, zwar oftmals wiederholt werden müssen, bietet
die Katheterablation dennoch eine Möglichkeit der Heilung für einen großen Teil der Patienten. Deut-
lich schlechter hingegen sind die Aussichten für die Behandlung von ventrikulären Tachykardien, da
aufgrund der Dicke des Myokards oftmals keine transmurale Narbe induziert werden kann.
Eine vielversprechende Alternative ist die strahlentherapeutische Behandlung. In den letzten Jahren
wurden mehrere Studien publiziert, welche die Möglichkeit erforschen, die elektrische Leitfähigkeit des
Myokards durch Bestrahlung zu verändern. Hierfür sollte die Verwendung von Kohlenstoffionen durch
das inverse Tiefendosisprofil große Vorteile bieten. Allerdings stellt die konforme Bestrahlung von beweg-
ten Zielen immer noch eine große Herausforderung dar und wird noch nicht in der klinischen Routine
angewendet. Besonders für die hohen Dosen, die für die Behandlung von Herzrhythmusstörungen nö-
tig sind, ist eine sorgfältige Bewegungskompensation notwendig. In dieser Arbeit wird die erste in-vivo
Studie zur Behandlung von Herzrhythmusstörungen mit gescannten Kohlenstoffionen, mit dem Ziel elek-
trophysiologische Änderungen im Herzmuskel zu induzieren, vorgestellt. Eine Gesamtübersicht über das
Experiment und die Ergebnisse befinden sich in dieser Arbeit, der Fokus liegt hierbei auf der durchgeführ-
ten 4D Bestrahlungsplanung und Bewegungskompensation. Insgesamt wurden 15 Schweine bestrahlt,
welche in drei Gruppen aufgeteilt wurden: atrioventrikulärer Knoten (AVN), freie Wand des linken Ven-
trikels und obere Pulmonalvene. In allen Gruppen wurden Tiere mit Einzelfraktionsdosen von 40 Gy
bestrahlt, mit Ausnahme der AVN Gruppe. In dieser Gruppe wurden Tiere mit Dosen von 25, 40 und 55
Gy behandelt.
In der vorgestellten Studie war eine erfolgreiche Bestrahlungen für alle Ziele möglich. Dennoch waren
die Ergebnisse auch für gleiche Dosisgruppen heterogen und dementsprechend die Erfolgsraten nicht zu-
friedenstellend. Eine kritische Diskussion über 4D Bestrahlungsplanung und Strahlapplikation zeigte auf,
dass die deformierbare Bildregistrierung eine potentielle Fehlerquelle darstellt. Dies könnte potentielle
Einschränkungen der Ergebnisse erklären. Zusätzlich wurden nach dem Experiment verschiedene Strate-
gien entwickelt, um die Behandlungszeiten von bewegten, einzelfraktionierten oder hypofraktionierten
Plänen zu verringern und zusätzlich Interplay Effekte besser zu kompensieren als die in der präsentier-
ten Studie verwendeten Methoden. Diese Ansätze wurden in einem Simulationstool implementiert und
anschließend an der Heidelberger Ionenstrahl-Therapie Anlage getestet und validiert.
Diese Arbeit fasst den aktuellen Stand der katheterlosen Ablation mit Kohlenstoffionen zusammen und
stellt nötige Änderungen für zukünftige in-vivo Studien in diesem Feld dar. Dies unterstützt eine zügige
Translation der katheterlosen Ablation mit Kohlenstoffionen in die klinische Routine.
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Motivation
Cardiac arrhythmia are a widely spread global health burden caused by changes in the hearts’ conduction
system. Due to an aging society the incidence of cardiac disorders has been increasing over the last
decades. Depending on the type of cardiac arrhythmia, the severity of the symptoms as well as the
influence on the patients’ quality of life varies significantly. Transient, mild forms can be harmless, not
requiring any treatment; but others advanced forms are associated with severe complications, such as
stroke, heart failure or even sudden cardiac death. To make matters worse, specific cardiac disorders,
as for instance, atrial fibrillation (AF), can occur silently [Cam10] and are often only diagnosed after
severe complications. The incidence of AF, the most common cardiac disorder, is 2 % in the European
population, causing about 5 % of the diagnosed strokes every year [Rah14]. Due to the strong association
with age, it is expected that between 14 to 17 million people will suffer from AF in 2030 [ZB14].
Another common type of cardiac arrhythmia is ventricular tachycardia (VT), which is estimated to be
responsible for 50 % to 85 % of all sudden cardiac deaths. Thus, VT poses a serious health problem with
higher absolute mortality than breast, lung and colon cancer combined [Hai16].
Treatment modalities for AF and, especially, VT are limited. Even though anti-arrhythmic drugs can
reduce the symptoms, they often induce severe side effects and thus, patient compliance is low. To cure
cardiac arrhythmia, it is necessary to alter electrical pathways in the heart muscle, which is currently
only possible using catheter ablation. However, the procedure is time intensive, invasive and can have
major complications. In addition, due to a poor general state of health, a lot of patients cannot undergo
the procedure. Furthermore, a recurrence of the symptoms cannot be avoided in a large number of
patients [Cap05,Cap10,Wis12,Din14].
Even though catheter ablation could cure some patients suffering from VT, in many cases the thickness
of the ventricular wall does not allow a successful treatment, as the penetration depth is not sufficient to
create transmural scar tissue. To overcome this limitation epi- as well as endo-cardial catheter ablation
has to be combined. Although this method shows increased success rates, the number of clinics providing
this approach is extremely limited. Furthermore, the risk of complications is increased [Di 12]. Therefore
the standard treatment for VT is still the implantable cardioverter-defibrillator (ICD) [Bah13] interrupt-
ing acute VT episodes and, hence, reducing the risk of sudden cardiac death. However, an ICD does not
actually cure VT and the defibrillation shocks are painful, can cause anxiety and occur unnecessarily in
30 % of the cases [Bor13].
A promising non-invasive alternative to treat cardiac arrhythmia is radiotherapy. In 2010, Sharma
et al. showed that photon irradiation has the potential to alter electrical pathways in the myocardium
[Sha10b]. Inspired by the success of carbon ion cancer therapy, especially for the treatment of deep
seated tumors and those close to critical structures, Bert at al. proposed the use of carbon ions to ablate
cardiac structures in 2012 [Ber12]. The inverse depth-dose profile of carbon ions combined with the
precision of the raster scanning system [Hab93] provides a highly conformal therapy with a superior
depth dose distribution compared to conventional photon treatments. A feasibility study irradiating
Langendorff-perfused pig hearts was carried out in 2013 [Leh15,Pra15] and a first carbon ion treatment
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planning study was published in 2014 [Con14, Con16]. Both indicate that carbon ions are an excellent
choice for catheter-free ablation. Motivated by the previous findings, a first in-vivo experiment was
designed to demonstrate the feasibility of ablating cardiac structures using carbon ions.
Scope of this Work
This thesis presents the results of the first in-vivo feasibility study using carbon ions to ablate cardiac
structures, carried out at GSI Helmholtz Center for Heavy Ion Research (GSI) in July 2014 by an in-
terdisciplinary team. My work during this time focused on the 4D treatment planning process and the
applied motion mitigation techniques necessary to allow a successful irradiation of beating hearts.
A combination of rescanning and repeated breath-holds was chosen to overcome cardiac and respira-
tory motion, respectively. Three different anatomical sites were targeted in single-fraction treatments to
investigate the feasibility of carbon ions for catheter-free ablations. The aim was to ablate the atrioven-
tricular node (AVN) and the superior pulmonary vein (SPV) as well as to induce a homogeneous and
transmural scar in the left ventricular free-wall (LV).
The study results were heterogeneous and motivated a critical investigation of the deformable im-
age registration (DIR) used for 4D treatment planning, dose calculation and dose reconstruction of the
feasibility study. Different alternative approaches to improve the DIR results were tested. Finally, the in-
fluence of the registration uncertainties on the dose distributions was determined to estimate the impact
of the registration problems on the study outcome.
To support the transition of catheter-free ablation into clinical routine, new approaches are warranted
to reduce the treatment time; both to ensure the patients’ comfort and to increase the number of patients
treated yearly. The main factor influencing treatment duration is the maximum beam intensity which
still permits accurate detection of small beam spots. The irradiation times for the catheter-free ablation
with a traditional rescanning scheme were lengthy. Thus, a new rescanning scheme was applied with the
drawback of a slightly reduced target coverage. Within this work a scan path optimization was developed
to overcome these limitations. For this approach as well as for the dynamic intensity control (DIC)
implemented at Heidelberg Ion-Beam Therapy Center (HIT), the influence on 4D dose distributions due
to the changes in the beam delivery sequence (BDS) were investigated. For realistic simulations a beam
delivery sequence simulation (DSim) Software, capable of calculating BDSs for different accelerator
settings and the scan path optimization (SPO) algorithm, was validated. In addition, the developed
strategies can also be applied to hypofractionated or single-fraction treatments of cancerous disease
using particles. Hence, the potential time saving is also determined for lung cancer patients.
The presented work is structured as follows. In Chapter 1, an overview of the underlying physical and
radiobiological basics of radiotherapy is given. In addition, photon and particle therapy are compared,
followed by a discussion about problems of motion in particle therapy and how to overcome interplay
effects. The first chapter is closed with an overview of different types of cardiac arrhythmia and conven-
tional and new treatment modalities. In Chapter 2, the in-vivo feasibility study of catheter free-ablation
in pigs is described focusing on the treatment planning process. In Chapter 3 problems of the deformable
image registration for the pig study are discussed including an estimate of the uncertainties of the study
outcome. Finally, in Chapter 5 new techniques to decrease the treatment time of rescanned treatments
with a high target dose are presented and their influence on 4D dose distributions is discussed. In
Chapter 5 the results of this work are discussed and an outlook is given.
2 Motivation
1 Scientific background
The following chapter gives an overview of the relevant physical processes involved in radiotherapy,
explaining the concept and advantages of heavy ion therapy. Furthermore, this chapter provides back-
ground information for the understanding of the following chapters.
The chapter is separated into two sections. In the first part the physical, biological and technical
background of particle therapy are explained, focusing on the advantages, the process of treatment
planning and the influence of motion in particle therapy. The second part addresses the fundamentals
of the heart conduction system and different kinds of cardiac arrhythmia, which are important for the
understanding of Chapter 2. In addition, a short overview of already published data on using radiation
to ablate cardiac structures is given.
1.1 Radiotherapy
The history of radiotherapy goes back to the discovery of the X-rays in 1895 by Wilhelm Conrad Roentgen
[Rön95]. Only seven months after, first patients suffering from eczema and lupus were treated using X-
rays. The first treatment of malignant tissues followed shortly afterwards. First targets were superficial
tumors as the penetration depth of X-rays is limited [Con09].
Later on, in 1946, the use of protons was proposed due to the inverse depth-dose profile. Already in
the 1950’s first patients were treated [Wil46]. From there on, the development of photon and particle
therapy continued in parallel. Over the next decades, the achievements of radiotherapy improved the
survival of patients suffering from cancerous disease. A more detailed overview on the history and the
development of both therapy alternatives follows in the next two sections.
1.1.1 Photon Therapy
The first attempts in radiotherapy used X-rays produced by an X-ray tube, which was positioned in
close proximity to the patient. The number of cured patients was small and always connected with a
high damage to the healthy tissue, as the available energies were too low to reach deep seated tumors
without severely damaging the skin [Hel96]. In 1913 the heated X-ray tube was invented enabling
external beam radiotherapy [Pat48].
As an alternative for deep seated tumors, brachytherapy was invented shortly after the discovery of
the radioactive element radium. During the 1920’s, brachytherapy was widely used to treat accessible
tumors inside the body, for instance, ovarian cancer [Cur50].
After the 50 keV equipment was invented by Philipps it was possible to treat not only superficial
tumors. The next big step forward in radiotherapy was the installation of the first machine using Cobalt-
60 for photon production in 1948. With this machine it was possible to deposit a high dose (45 - 60
Gy) to deep seated tumors without violating organ at risk (OAR) limits due to the 1.2 MeV photon
3
beams emitted by Cobalt-60. In the early 1950’s, first linear accelerators became available, which could
produce 6 - 20 MeV beams for deep seated lesions as well as electron beams for superficial lesions. Up
to this time, all treatment planning was performed in 2D and in the 1970’s treatment planning was
improved by 2D simulators. A major step forward was achieved using computed tomographys (CTs) for
a 3D treatment planning. Also the introduction of the multileaf collimator, which transformed the 2D
external-beam radiotherapy to a 3D conformal therapy, was a big step towards modern radiotherapy. A
detailed description of the multileaf collimator can be found in [Moh95].
In 1996, the development of intensity-modulated radiation therapy (IMRT), combined with the mul-
tileaf collimator, enabled inverse dose planning and dose sculpting around concave volumes. The devel-
opment of radiotherapy continued with the introduction of stereotactic body radiation therapy (SBRT).
The latest development in photon therapy is volumetric arc therapy (VMAT), which further improved
the volume conformity. More detailed reviews targeting the history and developments of conventional
radiotherapy can be found in [Tha12,Con09]
1.1.2 Particle Therapy
During the last decades, particle therapy has developed to a promising branch of radiotherapy. Particle
therapy offers a highly conformal dose distribution within the targeted volume while depositing less dose
in the surrounding healthy tissue compared to photon therapy. In Figure 1.1 a comparison of an IMRT
and an intensity-modulated particle therapy (IMPT) dose distribution is shown, indicating the reduced
dose to healthy tissue using particle therapy.
Robert R. Wilson was the first who proposed the use of an inverse depth-dose profile for an application
in radiotherapy [Wil46]. Only a few years later, in the 1950’s, the first patient treatments with proton
beams were conducted at the Lawrence Berkeley Laboratory (LBL), USA. After the physical and biological
properties of protons were investigated in several research projects, a proton trial was successfully carried1870 U Amaldi and G Kraft
Figure 4. Comparison of treatment plans with 2 fields of carbon ion (IMPT—left panel) and with
9 fields of x-rays (IMRT—right panel) [23]. In both cases the conformity to the target volume is
good but for carbon ions the dose to the normal tissues is much smaller.
can be determined from the intrinsic repair capacity as given by the parameters α and β of the
dose response curve of the same tissue to the photons. The very successful experience of more
than two hundred patients treated till now at GSI with this treatment planning fully confirms
the basic rationale of these calculations.
The IMPT plan of figure 2 has been obtained by making use of the properties mentioned
under points (1), (2) and (3). In this case, and in most others, the advantage of an inverse dose
profile, with the high dose and high LET at the end of the range (figure 1), allows reducing the
dose to the normal tissues outside the target volume by a factor of 2–3. This applies also to
protons, yet carbon ions are more effective for radio-resistant tumours. These types of tumours
are thus the elective targets in a carbon ion facility, while protontherapy is well adapted to other
cases in which a tumour is close to the organs at risk that cannot be irradiated. These arguments
are important since a protontherapy facility is about 30% cheaper than a carbon ion centre,
which requires a total investment cost of about 100 Me.
How is IMPT implemented in practice? The inverse dose distribution of particles having
a well defined range allows division of the target volume into slices of equal particle energy
and treatment of each slice separately by moving the beam in a raster-like pattern over the
area where the raster pattern is sub-divided into small volumes called voxels. The necessary
particle fluence for each voxel is calculated before the treatment and the beam in it moved
from one position to the next when this number of particles is reached. When one slice is
treated, the energy of the beam is reduced for the next slice. In practice, the complete target
volume consists of 10 000–30 000 voxels (i.e. three-dimensional pixels), which are treated
in 2–6 min. Intensity control raster (or voxel) scanning was introduced by GSI for carbon
ions (in three dimensions) and by PSI for protons (in a two-dimensional version, in which
the third dimension is scanned by moving the patient’s bed), as described in [6, 7]. All the
newly built hadrontherapy facilities will have the possibility of treating patients with active
three-dimensional scanning systems.
Scanning allows treating any irregular shaped tumour with a precision given by half the
width of the beam. In figure 5 the iso-energy slices of a tumour are shown together with one iso-
energy slice in an enlarged scale where the calculated beam positions are given as circles and
the measured ones as points. In order to reach a good homogeneity, the pencil beam has a half
width that covers approximately three beam positions in the vertical and horizontal directions.
A last advantage—point (4)—of particle beams, and especially of ions like carbon, is
the ‘in situ’ production of positron emitters like carbons 10 and 11 and oxygen 15. Because
Figure 1.1.: Comparison of a photon and a carbon ion treatment plan for a skull tumor. To reach a
conformal dose coverage intensity-modulated photon therapy needs 9 fields causing a dose
bath in the healthy tissue. In contrast to this, carbon ion therapy significantly reduces the
dose to normal tissue using only two fields [Ama05].
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out. The first clinical proton facility started operation in 1990 at Loma Linda University Medical Center,
USA. Soon after, several other centres were established. Today 60 proton centres are operating world
wide and 29 additional ones are under construction [PTC].
In the 1970’s, research on the use of heavier ions for particle therapy started at LBL. The idea behind
this step was to benefit from an increased biological effectiveness of ions like helium and neon. After the
treatment of 3000 patients at LBL, the therapy program was stopped in 1993 due to the shutdown of
the accelerator. In 1994 the National Institute of Radiological Sciences, Chiba (Japan), started treating
patients using similar techniques as previously used at LBL. At the same time, the Paul Scherrer Institut
(PSI), Villigen (Switzerland), and the GSI Helmholtz Center for Heavy Ion Research (GSI), Darmstadt
(Germany), investigated more advanced and conformal delivery systems for protons and carbon ions,
respectively.
A pilot study using scanned carbon ions was carried out at GSI in collaboration with the German Cancer
Research Center (DKFZ), the University Clinic Heidelberg (UCHD) and the Helmholtzcenter Dresden
Rossendorf (HZDR) from 1997 to 2008. Over 440 patients, most of them suffering from tumors in the
head and neck region or at the skull base, were treated during the study. For skull-based chordoma
the 5 year survival rate could be increased from roughly 20 % using photons or 60 % using protons to
almost 100 % using carbon ions. This success became possible by significantly increasing the median
dose deposited in the tumor volume increased without increasing the damage to the healthy tissue
[SE07]. The range of treated tumors was extended to prostate and spinal cord tumors within the pilot
project. For treatment planning, an in-house treatment planning system was developed, which includes
biological modeling for the increased relative biological effectiveness (RBE) of carbon ions. Clinical
follow-up examinations showed high clinical success rates and low side effects. These findings enabled
the construction and planning of several heavy ion centers following the basic concepts of the treatment
room at GSI. The first clinical heavy ion center using scanned carbon ions, Heidelberg Ion-Beam Therapy
Center (HIT), started operation in 2009. In the following years several other facilities either upgraded
their system to scanned carbon ions or directly started operation using raster scanning. In Europe Centro
Nazionale di Adroterapia Oncologica (CNAO) and Marburg Ion-Beam Therapy Center (MIT) started
operation in 2011 and 2015, respectively, and MedAustron is planned to follow in 2016. Nowadays,
10 carbon ion facilities are running worldwide and over 70 proton facilities are in operation, under
construction or in the planning state. For carbon ions as well as for protons the trend goes to the use of
scanned particles and about 50 % of all facilities are already using this technique [PTC].
The following sections give a brief explanation of the physical, biological and technical basics of par-
ticle therapy. It starts with an introduction to the underlying physics, continues with an overview of
radio-biology and ends with relevant technical knowledge on beam delivery, focusing on the active beam
delivery system.
1.1.2.1 Physical Basics
The advantage of using charged particles in radiotherapy lies in the favorable depth-dose profile, the
so-called Bragg Peak. A comparison of the depth-dose distributions of photons and carbon ions is given
in Figure 1.2 showing the beneficial depth-dose profile of carbon ions.
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skin. In contrast to photons, the dose profiles of protons
and heavier ions are characterized by a distinct narrow
peak !“Bragg peak”" at the end of their path. The posi-
tion of this peak can be precisely adjusted to the desired
depth in tissue by changing the kinetic energy of the
incident ions. Protons and heavier ions differ in two fea-
tures essentially: First, protons have a similar biological
effect as photons !at the same absorbed dose", while
heavy ions show higher effectiveness, ranging from low
RBE values in the plateau region to a significant en-
hancement in the Bragg peak !Kraft, 2000". Second,
heavy ions !unlike protons" exhibit a characteristic dose
tail behind the Bragg peak, which is caused by second-
ary fragments produced in nuclear reactions along the
stopping path of the ions, resulting in a complex radia-
tion field !Schardt et al., 1996".
The dose deposited in tissue is the most important
physical quantity in radiotherapy. It is defined !ICRU,
1993" by the term absorbed dose !unit Gray #Gy$" as the
mean energy d! deposited by ionizing radiation in a
mass element dm,
D =
d!
dm
#1 Gy = 1 J/kg$ . !1"
In radiation therapy !RT" water is used as tissue ref-
erence medium. Dose measurements are normally per-
formed with air-filled ionization chambers and have to
be converted to the absorbed dose in water by correc-
tion factors. For a parallel beam with particle fluence F
the dose deposited in a thin slice of an absorber material
with mass density " can be calculated as follows:
D#Gy$ = 1.6# 10−9#
dE
dx %keV$m &# F#cm−2$
#
1
"
% cm3g & , !2"
where dE /dx is the energy loss of the particles per unit
path length !specific energy loss or “stopping power”". A
similar related quantity is the linear energy transfer
!LET", unit keV/$m, which refers to the energy depos-
ited in the stopping medium by the slowing-down par-
ticle.
For particle therapy the photon-equivalent dose,
sometimes referred to as biological dose or Gray-
equivalent dose, defined as the product of absorbed dose
and RBE, is most significant because it includes the
larger efficacy of ions. The units are named Cobalt-
Gray-Equivalent !CGE" or Gray-Equivalent !GyE". Ac-
cording to recent recommendations !ICRU, 2007" for
proton beam therapy, now the term ‘‘RBE-weighted’’
dose and the unit Gy !RBE" should be used. Similar
recommendations for heavy-ion therapy are in progress,
but presently still the unit GyE is commonly used within
the clinical community.
1. Stopping of high-energy ions
In this section the basic formulas describing the stop-
ping of ions in a thick absorber are recalled. The theory
of stopping and range of ions in matter has been treated
in extended reviews !Fano, 1963; Ahlen, 1980; Sigmund,
2004; Ziegler et al., 2008". Radiotherapy of deep-seated
tumors requires ion beam ranges in tissue of up to 30 cm
corresponding to specific energies up to 220 MeV/u for
protons and helium ions, 430 MeV/u for carbon ions,
and 600 MeV/u for neon ions with particle velocities %
'v /c(0.7. At these velocities the energy-loss rate
dE /dx in the slowing-down process is dominated by in-
elastic collisions with the target electrons !electronic
stopping" and can be well described by the Bethe-Bloch
formula !Bethe, 1930; Bloch, 1933a, 1933b", here given
in the relativistic version described by Fano !1963", in-
cluding the shell correction term C/Zt and the density
effect correction term & /2,
dE
dx
=
4'e4ZtZp
2
mev2
%ln2mev2)I* − ln!1 − %2"
− %2 −
C
Zt
−
&
2& . !3"
Zp and Zt denote the nuclear charges of the projectile
and target, me and e are the mass and charge of the
electron, and )I* is the mean ionization energy of the
target atom or molecule. For liquid water the value )I*
=79.7 eV was obtained from energy-loss measurements
with 70 MeV protons !Bichsel and Hiraoka, 1992; Bich-
sel et al., 2000". From recent precision Bragg curve mea-
surements for protons and various heavier ions values of
75–78 eV were deduced !Kumazaki et al., 2007; Paul,
2007; Schardt et al., 2008". Stopping-power curves for
FIG. 1. !Color online" Depth-dose profiles of 60Co ( radiation,
megavolt photons, and 12C ions in water.
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Figure 1.2.: Depth-dose profiles f r photons and carbon ions at different energies in water. While the
depth-dose curve of photons shows an exponential decay after penetrating a short distance
through water (build-up effect), the deposited dose for carbon ions shows a sharp maximum
at the penetration depth, which is determined by the initial beam energy. The reduced Bragg
peak height at higher energies is caused by the increased energy straggling. The dose tail
after the Bragg peak is caused by fragments created in nuclear reactions [Sch10].
Compared to photons, charged ions deposit a significantly lower amount of dose in the entrance
channel and additionally a sharp dose fall-off a the end of their range allowing a successful sparing of
healthy tissue.
Interactions of Ions with Matter
Two effects, not influencing the structure of the ion itself, are important for the interaction of ions with
matter in particle therapy. They can either interact via elastic Coulomb scattering ( uclear stopping)
or via inelastic collisions with target electrons (electronic stopping). For the particle energies used
for radiotherapy the most likely effect for interactions is electronic stopping, ausing ionization and
excitation of target electrons. The stopping power is defined as
S = −dE
dx
, (1.1)
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where dE is the energy loss over the length dx . For a description of the specific energy loss the Bethe-
Bloch [Bet30] formula is used.
S =
4pie4z2Z
mec2β2

ln

2 mec
2β2
I(1− β2)

− β2 − C
Z

. (1.2)
The quantities me and z represent the electron mass and the charge of the primary particle; z and
Z are the nuclear charges of the projectile and the target, respectively; me and e are the rest mass
and charge of the electron; β = v/c is the velocity v of the incident particle normalized to the speed
of light c. The parameter I denotes the average excitation and ionization potential of the absorber
and has to be determined experimentally. For further details of the relativistic corrections the reader
is referred to [Zie99]. A decreasing particle velocity yields an increasing stopping power. For non-
relativistic incoming particles the energy loss is increasing with 1/v 2 or 1/E. The reason of this behavior
is rather simple. Due to the lower velocity of the ion the interaction time increases, i.e the particle
spends more time close to the electrons and thus the energy transfer increases. For a given velocity, the
energy loss increases with increasing ion charge. Materials with a high electron density (high density,
high atomic number) are characterized by a larger linear stopping power.
The Bethe-Bloch equation becomes inexact and eventually fails when the particle energy decreases
below a certain threshold. In this region the charge exchange between the incoming particles and the
absorber material cannot be neglected anymore. The parameter z has to be replaced by the effective
charge zeff which takes into account the charge changes through ionization and recombination. The
effective charge zeff can be calculated using Barkas’ formula [Bar63].
Dose Definition
The absorbed dose D, an important quantity for radiotherapy, is given by the deposited energy dE per
mass element dm:
D =
dE
dm
[1G y = 1
J
kg
]. (1.3)
Range Straggling and Lateral Spreading
A Bragg curve depicts the energy loss of a charged particle over the thickness of the traversed absorber
material. The energy of the incoming ion determines the range of the particle and at the end of the track
sharp peak, the so-called Bragg peak, occurs. Due to statistical fluctuations the energy released by each
ion varies slightly, causing a broadening of the Bragg peak. The equation
σR
R
=
1p
M
f

E
M c2

(1.4)
describes the ratio of the energy straggling width σR and the mean particle range R. The function
f depends on the absorber material while E and M denote the mass and the energy of the particle,
respectively. The term 1/
p
M indicates that the range straggling is higher for lighter ions [Ros52].
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Together with range straggling, also lateral spreading of a beam has to be taken into account for
treatment planning. The lateral spreading is caused by elastic Coulomb interactions with the target nuclei
and is higher for lighter particles. This process can be described by Moliere’s theory [Mol48]. As a rough
approximation it can be assumed that the effect is proportional to
Zproj
Aproj
× vproj, where Zproj,Aproj and vproj
are the atomic number, the number of nucleons and the velocity of the projectile, respectively [Kra00a].
Nuclear Fragmentation
For an accurate description of the depth-dose profile, especially for the fragment tail after the Bragg Peak,
nuclear fragmentation has to be taken into account. The probability of nuclear fragmentation is propor-
tional to the penetration depth. In such a process both nuclei, the projectile as well as the target, can
change their charge due to nucleon loss and thus secondary particles (fragments) are created. Nuclear
fragmentation can be described as a two step process by the abrasion-ablation model of Serber [Ser47].
Figure 1.3 shows a schematic of the abrasion-ablation process. In the first step, called abrasion, the
projectile and the target collide with a certain overlap. The nucleons in the overlapping region, typically
called ’reaction zone’, are abraded. The nucleons outside the reaction zone are almost unaffected by the
collision, although the target and projectile fragments are now in a highly excited state. The nucleons
involved in the collision are called ’fireball’. In a second step, called ablation, deexcitation processes in
the target and the projectile cause evaporation of nucleons or nucleon clusters.
confirmed these calculations !Weber, 1996". It should be
kept in mind, however, that in irradiations of tissues with
large density inhomogeneities even a small lateral
spread may translate into a considerable range broaden-
ing.
4. Nuclear fragmentation
While the stopping process of high-energy ions pen-
etrating a thick absorber is governed by collisions with
atomic electrons, the probability of nuclear reactions is
much smaller, but leads to significant effects at large
penetration depths. At energies of several hundred
MeV/u violent nuclear spallation reactions may result in
a complete disintegration of both projectile and target
nuclei !e.g., in central head-on collisions" or in partial
fragmentations. For geometrical reasons peripheral col-
lisions, where the beam particle loses one or several
nucleons, are the most frequent nuclear reactions occur-
ing along the stopping path of the ions. They can be well
described by the abrasion-ablation model !Serber, 1947"
as a two-step process !Fig. 6".
In the first step nucleons are abraded in the overlap-
ping reaction zone !the “fireball”" while the outer
!“spectator”" nucleons are only slightly affected. The re-
maining projectile and target fragments then deexcite by
evaporation of nucleons or clusters in the second step
!ablation". Fragmentation reactions have been exten-
sively studied in nuclear physics #see, e.g., Goldhaber
and Heckman !1978", Hüfner !1985", and Lynch !1987"$
and experimental data are available for many projectile-
target combinations and for a wide range of beam ener-
gies !Friedländer and Heckmann, 1985". Some impor-
tant conclusions can be drawn for the effects of
fragmentation relevant to radiotherapy with high-energy
ion beams: !i" Nuclear reactions cause a loss of primary
beam particles and a buildup of lower-Z fragments,
these effects becoming more and more important with
increasing penetration depth. !ii" The secondary !or
higher-order" projectilelike fragments are moving with
about the same velocity as the primary ions. They have
in general longer ranges and produce a dose tail behind
the Bragg peak. !iii" The angular distributions of frag-
ments are mainly determined by reaction kinematics and
forward directed, but much broader than the lateral
spread of the primary ions caused by multiple Coulomb
scattering !Golovkov et al., 1997; Matsufuji et al., 2005".
Dedicated fragmentation studies for applications in
radiotherapy began at Princeton !Maccabee and Ritter,
1974" and were performed over many years at the Beva-
lac at LBL Berkeley !Schimmerling et al., 1983, 2008;
Llacer, Tobias, et al., 1984; Llacer et al., 1990". for the
characterization of 670 MeV/u beams of 20Ne which
were used for patient treatments. The measured fluence
and LET data !Shavers et al., 1990, 1993" as a function of
depth in water were compared with transport theories
!Wilson et al., 1984, 1990".
Similar fragmentation studies were performed later at
the
HIMAC facility and at the SIS-18 synchrotron at GSI
Darmstadt. In a comparative experimental study of the
fragmentation characteristics of 10B, 12C, 14N, 16O, and
20Ne, the total !nuclear" cross section for reactions
changing the proton number Z was found to be even
smaller for 12C than that of 10B, while the value for 14N
was relatively high !Schall et al., 1996". This indicates
that shell-structure effects are still visible in high-energy
reactions. Nevertheless, at larger penetration depths a
substantial fraction of primary ions is lost by nuclear
reactions. For a 400 MeV/u 20Ne beam, for example,
only 38% of the primary ions reach the Bragg peak at
16 cm depth in water, the number of surviving 12C ions
at the same range being 52%. Regarding fragmentation,
carbon ions thus offer relatively good conditions. Fur-
thermore, the positron-emitting fragments 10C and 11C
can be utilized for in vivo range monitoring with posi-
tion emission tomography !PET" techniques !see Sec.
II.C.2".
The total reaction cross sections !R at high energies
can be well described by semiempirical geometrical
models !Kox et al., 1987; Sihver et al., 1993; Tsao et al.,
1993" and are almost constant over a wide energy range
down to about 100 MeV/u. Typical values for various
ions and the corresponding mean free paths in water are
shown in Table I. At lower energies !R rises due to the
contributions of other reaction mechanisms like deep-
inelastic collisions or fusion reactions.
The partial cross sections for production of lower-Z
fragments can be derived from the characteristic shapes
of their fluence profiles as a function of depth. These
buildup and decay curves can be described by solutions
of a diffusion equation, the so-called “transport equa-
tion,” which is in a similar way applied to the transport
vf ~ vp
n
Ablation
vp
Abrasion
projectile
target
projectile fragment
fireball
target fragment
evap.
p,d,t
α
FIG. 6. !Color online" Illustration of the abrasion-ablation
model of peripheral collisions at high energies according to
Serber !1947". Adapted from Gunzert-Marx et al. !2008".
TABLE I. Total reaction cross section !R !Kox et al., 1987"
and mean free path in water " of high-energy ions with about
25 cm range in water.
Ion
E
!MeV/u"
!R
!mb"
"
!cm"
p 200 352 85.2
4He 200 767 38.6
12C 380 1424 20.8
20Ne 530 1929 15.5
388 Schardt, Elsässer, and Schulz-Ertner: Heavy-ion tumor therapy: Physical and …
Rev. Mod. Phys., Vol. 82, No. 1, January–March 2010
Figure 1.3.: Schematic of the abrasion-ablation model [Sch10]
Even though the cross sections for nuclear fragmentation are orders of magnitude smaller compared
to Coulomb interactions, they cannot be neglected for particle therapy especially for larger penetration
depths. For ions heavier than protons nuclear fragmentation, especially projectile fragmentation, con-
tributes mainly to the dose tail after the Bragg peak. The contribution of target fragments is significantly
smaller.
In ion beam therapy three different effects related to fragmentation are relevant [Sch10]:
• The amount of primary ions reaching the target volume decreases with increasing tumor depth,
while the amount of low Z fragments is increasing.
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• Light ions produced by fragmentation have almost the same momentum as the primary ions. As
lighter particles have a higher range than the primary ions, fragmentation causes a dose tail behind
the Bragg peak.
• Even if most fragments are produced in beam direction, their angular distribution adds to the
lateral spread of the depth-dose distribution.
Track Structure
The energy loss of ions in the therapeutic energy range is mainly caused by ionization and excitation of
the target material. The liberated electrons, called δ-electrons, undergo elastic and inelastic scattering
processes, in which additional electrons can be created, depending on the initial energy. For δ-electrons
with energies higher than 50 eV, ionization is the dominant process [Kra00a,Sch10].
The track structure is defined by the energy distribution of the δ-electrons. The energy distribution
of the secondary electrons influences the radial dose profile of the track as well as the track diameter.
As the momentum transfer is generally low and mainly in forward direction, most energy is deposited
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Fig. 1. (Color online) Depth dose distributions (left hand side) and lateral spread (right hand side) of various beam modalities.
2 Physical beam model
The complexity of interactions of ion beams with living
matter makes it difficult to provide purely experimental
base data sets for treatment planning. Hence one has to
rely on sufficiently accurate – and fast – calculations to
obtain base data like depth dose distributions and parti-
cle spectra. The requirements of a physical model can be
summarized as follows:
– handle all ions of therapeutical interest, i.e. Z <= 8;
– work on a three-dimensional grid, i.e. the millions of
voxels of a computed tomography (CT);
– the accuracy of the dose distribution should be ≈5%
(average), ≈7% (max);
– the position of single Bragg peaks should be repro-
duced within 0.5 mm (1/2 CT voxel);
– the calculation of complete treatment plans based on
a physical model should be reasonably fast, a few sec-
onds or minutes per patient plan for a single CPU.
2.1 Microscopic calculations
Given the stochastic nature of the basic interactions of
the charged projectiles with the atoms and molecules of
the traversed matter, one might be tempted to apply ab
initio methods such as Monte Carlo simulations. Various
such attempts exist, for example the code PARTRAC [3]
which is dedicated to describe the damage to DNA or
the GSI grown TRAX [4,5], used to calculate ion track
structure and related quantities. Such codes use a set of
cross sections for elementary interactions, typically elas-
tic scattering, ionization, excitation, rather than relying
on condensed random walk. Their design is usually aimed
towards “track segment conditions”, i.e. short slabs (mi-
cro/nanometer) of matter with almost negligible energy
loss, and negligible probability of nuclear reactions. These
are difficult to include anyway, because electromagnetic
cross sections are of the order of σem ≈ 10−16 cm2,
whereas nuclear interaction cross sections are of the order
σnucl ≈ 10−24 cm2, i.e. eight orders of magnitudes lower.
Figure 2 shows TRAX simulations of δ-electrons from ions
Fig. 2. (Color online) Simulated paths of δ-electrons created
by ions of various energies in water.
of various energies. The dense emission pattern of ions at
low energies can be seen. Most electrons have very low
energies, below 100 eV. The inserted DNA schematics
emphasizes the scale of the simulation, i.e. nanometers.
Although such visual simulations do not readily provide
quantitative measures, they nevertheless have been veri-
fied experimentally, by means of the so called OPAC (op-
tical avalanche chambers) which is able to visualize ion
tracks in gas at low pressure [6,7].
Figure 1.4.: Simulation of track structure of protons (left) and carbon ions (right) at different energies.
The energies of the created secondary electrons can be distinguished by different colors. A
sketch of a DNA molecule is included for scale. Figure courtesy of Michael Krämer.
1.1. Radiotherapy 9
in a small cylinder around the track. Several models can be used to predict the radial dose fall off
[Cha76,Kat99]. In addition, track structures can be simulated with Monte-Carlo methods [Krä05,Par86].
All methods consistently predict a radial dose fall-off with a 1r2 dependence, which was also confirmed
by measurements [Var77]. In general, the range of δ-electrons is restricted by the kinematics of the
collision between projectile and target electron. The maximum range can be approximated empirically
by rmax ∝ E1.7 [Kie86], where E is the Energy of the incoming primary ion. As the energy deposition
depends on the kind of incoming ion and the initial energy, that is, a dependence on 1r2 and z
2 in
equation 1.2, the track structure depends on the incoming ion type as well as the initial energy of the
ion. Figure 1.4 shows a Monte-Carlo simulation of the track structure for protons and carbon ions at
different energies [Krä10].
The energy deposited in the material by the δ-electrons is often described as linear energy transfer
(LET) or restricted energy loss. The LET is given by dE/dx and describes the energy locally transferred
to the absorber material. The contributions of electrons with a higher energy than a certain threshold
are not taken into account for the LET calculations [ICR93, ICR95].
1.1.2.2 Radiobiology
Radiotherapy aims to kill tumor cells to inhibit a further growth of malignant tissue. The actual damage
to a single cell depends heavily on the location of the particle tracks within the cell. The most critical
damage is observed when radiation damage occurs within the cell nucleus, especially within the de-
oxyribonucleic acid (DNA). The DNA carries the genetic information of the cell and a damaged DNA can
cause cell mutations, carcinogenesis or cell death. The DNA is compounded of two sugar and phosphate
backbones and for different bases (adenine (A), cytosine (C), guanine (G) and thymine (T)). This four
bases always form base pairs allowing only the combination of A and T or C and G. Depending on the
structures hit, the incident radiation can cause different kinds of radiation damage.
The following different kinds of DNA damage can be distinguished:
• single strand break (SSB) - SSBs are defined as one destroyed DNA strand, which can be repaired
without errors.
• double strand break (DSB) - DSBs are defined as breaks in both strands within a short distance.
Repair is not always possible and repair mistakes are possible.
• clustered double strand break (CDSB) - CDSBs are defined as several breaks in both strands
within a few base pairs. The available repair mechanisms cannot repair this kind of damage suc-
cessfully.
• base damage (BD) - BDs occur when bases are knocked out of the DNA structure. Depending on
the amount of released bases the repair is possible, even without mistakes if the number of knocked
out bases is small.
DNA damage is usually caused by the production of δ-electrons. Two different ways to create radiation
damage can are distinguished. Direct effects occur due to ionization of compounds of the DNA and
indirect effects are caused by hydroxyl groups which are created through the hydrolysis of water on the
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particle track, which can travel for up to two nanometres. Indirect effects mainly appear after low linear
energy transfer (LET) radiation as, for instance, photons, whereas direct effects are the main cause for
DNA damage under high LET radiation, for instance, heavy ions. Nevertheless, both kinds of effects
occur in parallel and can cause unrepairable damage. The structure of the DNA as well as a scheme of
the direct and indirect effect are shown in Figure 1.5.
Figure 1.5.: In a) direct and indirect damage due to ionizing radiation is shown. While direct damage is
caused by electrons liberated from ions in ionizing processes, indirect damage occurs due to
free hydroxyl radicals created during the hydrolysis of water. In b) a scheme of different types
of DNA damage is given. Figure taken from [Ric12].
The knowledge of radiation effects in cells and tissue is mainly gained from studies with photon
radiation. As the interactions are assumed to be comparable for photons and ions and only the dose
pattern changes, the differences between both radiation types can be expressed using the RBE. The RBE
is defined as
RBEisoeffect =
Dref
Dion
(1.5)
where Dion is the absorbed heavy ion dose and Dref is the absorbed dose of a reference radiation, usually
photons, yielding the same cell survival as Dion. The RBE expresses the increased biological effectiveness
of ions and can be only determined for the same biological endpoint.
The relevant endpoint of radiotherapy is the cell survival and therefore cell survival curves of different
cell types, for different dose levels and different radiation types are compared. An example for a cell
survival comparing photons and heavy ions is given in Figure 1.6. In general the survival curves of ions
are steeper and the ones of photons have a more pronounced shoulder before they start to drop almost
linearly.
To compare the outcome of treatment or OAR doses for photon and ion radiation, the photon equiva-
lent dose is defined and can be expressed either as GyE or Gy (RBE). The latter is the one recommended
by the ICRU. To be able to predict the outcome for a treatment, simulations of cell survival are necessary,
especially as the RBE depends on the LET and is highly variable over the whole depth-dose distribution.
The cell survival can be approximated with the linear quadratic model
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ing factor considers the radiosensitivity of different or-
gans. In order to determine the equivalent dose !in
Sievert", both weighting factors must be taken into ac-
count. These are maximum values chosen to assess the
radiation risk in the most conservative way. However,
they should not be confused with the RBE, which is a
much more powerful and versatile concept taking into
account the radiation quality and tissue-specific re-
sponse as well as the biological end point and the dose
level of the radiation.
The RBE is defined as the ratio of the dose of a ref-
erence radiation !typically x rays or ! rays" to the dose
of the radiation in question !e.g., ions" to produce an
identical biological effect !isoeffect",
RBEiso =
Dref
Dion
. !15"
It is important to note that the statement of a RBE
value requires both the specification of the reference ra-
diation and the level of the biological effect. In Fig. 25
we show the determination of the RBE by typical cell
survival curves for x rays and heavy ions. The RBE val-
ues for cell inactivation are indicated for two effect lev-
els, namely 10% and 1% cell survival.
The RBE is the most important quantity in biological
treatment planning of heavy-ion therapy, since it deter-
mines the photon-equivalent dose by multiplication with
the absorbed !physical" dose. The photon-equivalent
dose, sometimes abbreviated as biological dose, quanti-
fies the dose of conventional radiation that would yield
the same biological effect as the applied radiation. It is
conveniently used to compare the results of conven-
tional radiation with other radiation qualities such as
neutrons, protons, or carbon ions. The RBE can be used
for many biological end points such as DNA strand
breaks, mutations, or transformations. In the scope of
heavy-ion therapy, however, the RBE for cell killing and
normal-tissue complications are most relevant.
3. Dependencies of RBE
In contrast to proton therapy, where the low LET of
protons is believed to allow the application of a single
factor !RBE=1.1" throughout the entire radiation field
!Paganetti et al., 2002", the situation in heavy-ion
therapy is much more complex because of the large
variations of LET. From the previous section, we know
that the mixed radiation field of a carbon-ion SOBP is
comprised not only of carbon ions with a large energy
spread but also of lighter fragments. Additionally, the
levels of absorbed dose can vary largely within single
fractions and between different tumor sites. Therefore,
we need to understand how the biological effect of
heavy ions depends on the parameters relevant for ra-
diotherapy.
First, the RBE depends on the dose level as already
shown in Fig. 25. In general, it is higher for lower dose
levels and lower for larger doses owing to the shoulder
shape of the photon response curve !Weyrather et al.,
1999; Furusawa et al., 2000". For application in ion
therapy that means that the biological differences be-
tween conventional radiation and particle beams dimin-
ish if the dose is escalated.
Second, the response of cellular systems depends on
the energy or LET of the penetrating particle. Figure 26
presenting a compilation of different cell survival experi-
ments with V79 hamster cells !a frequently used cell line
in radiobiology laboratories" reveals that the RBE in-
creases with LET up to an ion-dependent maximum
value and decreases for higher LET values !Belli et al.,
1998; Furusawa et al., 2000". According to the higher
ionization density in the track center of particles with a
larger LET, the radiation damage is more severe, thus
increasing the RBE. However, at a certain LET value
the dose deposition is so large that a single-particle tra-
versal sufficiently reduces the cell survival probability. In
that case, the additional dose deposited by ions with a
larger LET is wasted and we would not expect a larger
FIG. 25. !Color online" Determination of RBE for cell inacti-
vation for 10% and 1% survival level for a typical heavy ion
irradiation. FIG. 26. Dependence of RBE"="ion/" on LET and particle
type, where " and "ion are the linear part of the survival curve
for photons and ions, respectively. Data are redrawn from Belli
et al. !1998" and Furusawa et al. !2000". From Scholz, 2003.
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Figure 1.6.: The cell survival curve indicates the differences between photon and ion survival curves and
explains how the RBE can be calculated using a cell survival curve. Figure taken from [Sch10].
S(D) = e(−αD−βD2), (1.6)
where S is the survival depending on the deposited dose D, and α and β are tissue dependent values.
For biological treatment pla ning, a mod l was developed at GSI to consider the changing RBE within
the whole dose distribution to deposit a homogeneous biological dose to the patient. The local eff ct
model (LEM) was developed within the context of the pilot project [Krä06, Krä00b, Sch97] and has
received revisions over the years [Els07,Fri12]. Different versions of the model are in use for carbon ion
therapy and recently a company started implementing LEM for proton and carbon therapy [Ray]. While
a LET dependent RBE for carbon ions has b en accepted f r years, it is still a heavily discussed topic for
proton therapy, where a constant RBE of 1.1 is still used in the clinical routine.
1.1.2.3 Beam Delivery Systems
Particle therapy requires a complex acc lerator to deliver therapeutic ions. The maximum particle range
necessary is about 30 cm, requiring that protons are accelerated up to 200 MeV/u and carbon ions
up to 430 MeV/u. The beam needs to be transported from the accelerator to treatment rooms and a
high precision delivery on the target volume must to be guaranteed. Nowadays mainly two kinds of
accelerators are in use for this task:
• Cyclotron - The big advantage of cyclotrons is their compact design and they are used for most
of the proton facilities. Cyclotrons offer a beam with a constant energy and intensity. Therefore,
passive degraders are necessary to adjust the beam energy and the particle intensity, resulting in a
high loss of primary ions.
• Synchrotron - A fully active spill-by-spill energy variation can be performed with a synchrotron.
All heavy ion facilities ar using a synchrotron, even though complicated on optics are necessary
to control and adjust the beam to meet therapy quality standards.
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To deliver a conformal and homogeneous treatment plan, an energy and intensity variation is not suf-
ficient. Additionally, lateral and longitudinal beam shaping is necessary to obtain a patient-specific
spread-out Bragg peak (SOBP). Two main beam shaping techniques are used - active and passive beam
shaping. However, today the trend goes toward active scanning systems, which provide a superior dose
conformity.
Passive Beam Delivery
The passive beam delivery system was the first method available for treating patients with heavy ions.
Passive beam shaping offered a reliable method, especially in times, when particle therapy was only
applied at research facilities and accelerators were less stable and sophisticated than today.
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Figure 1.7.: Scheme of a passive beam delivery system. In the first step, the narrow beam is scattered
to the required lateral width. A system composed of range modulator, range shifter and
collimator ensures the adaption of the beam shape to the lateral and longitudinal extend.
Finally, the distal edge is determined by a patient-specific compensator. The hatched area
in front of the tumor volume indicates the volume of irradiated healthy tissue. Figure taken
from [Ric12].
For a passive beam delivery system several devices need to be placed in the beam line to adjust the
narrow incoming beam in lateral and longitudinal direction. A scheme of a passive beam delivery set-up
is shown in Figure 1.7. The first step is to laterally scatter the narrow incoming beam to a certain width
to reach a broad and flat beam profile. Passive double scattering or a magnetic wobbler are typically
used in this case [Kra00a]. In the next step, range modulators are used to extend the beam in depth
to create a SOBP with the depth of the target volume. This can be done by either using ridge filters or
rotating wheels, for details see [Chu93]. After that, the beam energy is reduced with a range shifter, a
passive absorber, to reach the needed penetration depth. All devices up to this point in the beam-line are
required for every patient and are installed permanently. However, different settings are necessary for
each patient.
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In the next step, patient-specific devices are used to adjust the SOBP as precisely as possible to the
specific patient geometry. A collimator determines the lateral extend of the SOBP and a compensator
forms the distal edge of the SOBP. A large variety of devices is used to achieve a conformal dose distri-
bution. H However, a passive beam delivery system is always limited in dose conformity, as doses as high
as the target dose are delivered to the healthy tissue in front of the targeted volume. Besides the limited
conformity, additional drawbacks are the necessity of a patient-specific hardware and the production
of fragments, especially neutrons, in the beam shaping devices. For a more detailed description of the
passive beam delivery method see [Chu93,Kra00a]. Even though the passive beam delivery system was
significantly improved over the last decades, it is still inferior to an active scanning system regarding
dose shaping.
Active Beam Delivery
An active beam delivery system deflects the beam via dipole magnets to reach a highly conformal depth-
dose distribution. The technology needed for beam scanning is more advanced compared to a passive
scattering system and brings the following advantages:
• No additional devices are needed in the beam line to shape the beam reducing the additional
neutron dose [Kad12]
• No patient-specific hardware needs to be manufactured
• Increased volume conformity, especially in front of the target volume
The basic idea of beam scanning is to divide the target volume in several iso-energy slices (IESs) and
rasterize each slice, yielding a grid of raster points covering the volume. A pencil beam is then used to
deposit a predetermined number of particles at each raster point.
This allows to integrate a variable RBE in the planning process, as each raster point is optimized sepa-
rately in the treatment planning system (TPS). Hence, it is possible to deliver not only a highly conformal
but also biologically homogeneous dose to the patient. Two different kinds of scanning techniques have
been developed in parallel in the 1990s: spot scanning [Ped95] and raster scanning [Hab93].
The idea of PSI was to use a cyclotron and passive degraders to adjust the beam energy. In addition,
the beam was scanned in horizontal direction by dipole magnets, while the vertical displacement was
reached by a couch shift. Between the single raster points the beam was always switched on and off.
In the next generation of the gantry at PSI, scanning was performed in vertical and horizontal direction
by beam deflection. The raster scanning approach developed at GSI offers a fully active 3D scanning
system, with spill-by-spill energy variation and scanning in vertical and horizontal direction. A schematic
overview of the GSI raster scanning system is shown in Figure 1.8.
A narrow pencil beam with a fixed energy is extracted from the synchrotron. Using the mono-energetic
beam, the dose is delivered to each IES. The beam is continuously scanned over each IES following a
predefined path. Two dipole magnets are responsible for the horizontal and vertical deflection of the
beam. The beam stays on each position until the planned number or particles is delivered. This is
controlled by a beam monitoring system that checks and, if necessary, adjusts the number of particles as
well as the beam position.
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Figure 1.8.: Scheme of the GSI raster scanner. The target volume is divided in iso-energy slices and the
beam is moved across the slice following a predetermined scan path. A treatment control
system always checks the beam position to avoid deviations between planned and irradiated
dose. Figure taken from [Krä09].
The target dose homogeneity is achieved with the help of two different concepts. The lateral overlap of
the pencil beams is chosen big enough to compensate for position uncertainties and the spacing between
the IESs is chosen sufficiently to obtain a homogeneous dose distribution from the overlapping Bragg
peaks. At the same time the number of IESs is kept as low as possible to reduce the treatment time. The
only passive device used is a ripple-filter (RiFi) behind the exit-window to slightly broaden the Bragg
peak which allows to achieve a homogeneous dose distribution with fewer IESs. The thickness of the
used RiFi is usually 3 mm allowing a satisfying homogeneous longitudinal dose distribution [Web99]. In
Figure 1.9 schematics are shown which illustrate the overlapping of multiple beams in longitudinal and
lateral direction.
Figure 1.9.: Schematic to indicate how the homogeneous target dose in lateral (a) and longitudinal (b)
direction is achieved by overlaying of multiple beams. Figure taken from [Ric12]
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1.1.2.4 Treatment of Moving Tumors
Radiotherapy has improved within the last decades and the number of applications is constantly increas-
ing. While nowadays a good homogeneity and conformity of the dose distribution can be achieved for
static tumors, moving tumors are still challenging for photon as well as particle therapy and remain a
major research topic in the field of radiotherapy.
Different motion types are distinguished and can, in general, be separated into three different cate-
gories:
1. Patient positioning summarizes uncertainties during the positioning process. This can cause tu-
mor deformation as well as changes of the water-equivalent depth of the tumor volume. Positioning
errors can arise due to changes between the planning CT and the treatment positioning and due
to positioning changes between the single therapy fractions. Patient fixation systems and position-
ing protocols are used to avoid systematic errors and minimize uncertainties and thus enabling a
successful treatment.
2. Inter-fractional motion occurs on a time-scale of hours to days and is correlated to anatomical
changes between different fractions. The reasons for inter-fractional motion are manifold. For lung
tumors, shrinkage as well as lung density changes over the course of a treatment can cause severe
overshooting. Additionally, the breathing pattern can change over time [Son08]. The varying filling
of gut and bladder is an important source of uncertainties for prostate cancer patients [Fok04]. To
reduce the effect of inter-fractional motion frequent 3D imaging is necessary to control the changes
between treatments sessions.
3. Intra-fractional motion occurs on a time-scale of seconds to minutes and is mainly correlated
with breathing or the heartbeat. This is the type of motion that is usually counteracted with
motion mitigation techniques during therapy, which are explained in detail in Section 1.1.2.5.
Tumor motion usually causes dose blurring or a deformation of the dose distribution, as the tumor is
partly moving out of the field. This effect is also known from photon therapy, but less critical than for
particle therapy. Density changes have a significant influence on the range of particles and therefore can
cause severe under- and over-dosage. These range changes can significantly increase the dose deposited
in normal tissue and decrease the dose deposited in the targeted volume.
In contrast to photon and passive particle therapy, the delivery time of active particle therapy is in
the order of several minutes so that for breathing and heartbeat movements several motion cycles occur
during the treatment. This can lead to interference effects, so-called interplay effects, between the
target motion and the motion of the scanned pencil beam, causing local over- and under-dosage in the
target volume as well as additional irradiation of normal tissue. The severity of this effects depends
on the motion amplitude of the target volume, the extraction rate of the accelerator and therefore the
scanning speed and the relative direction between target motion and scanning motion [Ber08a,Grö06].
In Figure 1.10 film measurements are shown indicating the consequences of interplay effects in particle
therapy.
In the next Sections different motion mitigation techniques are introduced, which are used to counter
interference effects during the irradiation of moving targets.
16 1. Scientific background
Interplay of motion and scanned particle beams 2259
(a) (b) (c)
Figure 4. The general phenotype of interplay patterns is determined by the motion direction
and the scan path which was line-by-line scanning. In comparison to the stationary reference
(a) up–down target motion in beam’s eye view (b) leads to diagonal patterns because the detector
moves vertically during horizontal beam motion. The slope of these patterns depends on the scan
speed and the motion period (see figure 5). Left–right target motion (c) results in stripe patterns
on the left and right sides of the irradiated area. The extent of these stripes is comparable to the
motion amplitude.
Table 2. Results of the treatment-planning study (one fraction, single field). Besides motion
characteristics of each patient, the statistics (mean, standard deviation, minimum, maximum) of
the volume covered by 95% of the planned dose is listed for each motion amplitude.
Patient GTV Motion (mm) Period (s) Mean (%) SD (%) Min (%) Max (%)
A 3D 6.6 2-6 78.8 17.9 37.0 99.8
LR 1.6 2 79.3 17.7 50.1 98.9
AP 5.6 4 78.6 19.2 37.0 97.8
SI 3.1 6 78.4 17.2 43.9 99.8
B 3D 9.6 2-6 67.1 6.1 55.5 85.2
LR 0.7 2 63.4 3.2 57.6 69.5
AP 0.9 4 67.8 2.3 63.4 71.9
SI 9.5 6 70.1 8.7 55.5 85.2
C 3D 14.1 2-6 69.8 8.0 51.7 90.1
LR 12.2 2 71.1 8.5 58.7 90.1
AP 6.1 4 68.0 7.8 51.7 79.6
SI 3.5 6 70.2 7.6 55.0 80.2
D 3D 11.4 2-6 71.6 15.6 32.4 95.0
LR 3.7 2 71.9 17.0 36.4 94.2
AP 5.0 4 70.0 19.4 32.4 95.0
SI 9.6 6 72.8 8.8 58.3 90.9
E 3D 6.0 2-6 67.7 16.1 25.7 99.5
LR 3.1 2 63.9 12.1 46.3 80.5
AP 3.2 4 69.6 3.9 62.9 78.2
SI 4.0 6 69.6 24.8 25.7 99.5
All 2-6 71.0 14.2 25.7 99.8
2 69.9 14.0 36.4 98.9
4 70.8 13.3 32.4 97.8
6 72.2 15.2 25.7 99.8
phase but with the treatment plan optimized to the ITVR. The treated volume is remarkably
larger because the full extent of tumor motion was included in treatment plan optimization.
Figure 1.10.: Impact of the interplay effect illustrated with a radio-graphic film measure ent. In (a) a
static os distribution s shown. Interplay p tterns caused by a vertical (b) a d horizontal
(c) motion f the films are shown. Th het rogen ity of the optic l density in the films (b)
and (c) is clearly visible and corresponds to over- and under-dosage [Ber08a].
1.1.2.5 Motion Compensation for Moving Tumors
Various different strategies have been developed to counter intra-fractional motion. The following Sec-
tions introduce the ones most important for this work. A full overview of motion mitigation techniques
can be found in [Ber11].
Motion mitigation techniques can be applied either during the treatment planning process or at pa-
tient set-up. For the latter, the motion in the patient is reduced as much as possible, for instance with
abdominal compression or jet ventilation for liver or lung cancer patients, respectively. For the former,
the target volume is enlarged for planning, so that the targeted tumor cannot move outside the irradiated
volume during the treatment.
Apart from considering the motion during the planning and positioning process, additional meth-
ods are known for adapting the treatment itself. The most important ones are rescanning and gating,
which will be explained within this section. An additional possibility is beam tracking, for more details
concerning this approach the reader is referred to [Ber07b,Ber10,Web00].
Rescanning
Motion mitigation via rescanning is only possible for raster or spot scanning. The aim of this approach
is to use statistical averaging to overcome the dose inhomogeneities caused by the interference effects
between target and beam motion. The basic idea is simple: instead of irradiating each raster point
once, multiple rescans are performed, where raster points are irradiated multiple times with a corre-
sponding lower dose. Different versions of rescanning have been proposed. The most common ones are
slice-by-slice and volumetric rescanning. Furthermore, phase-controlled and breath-sampled rescanning
have been proposed [Sec09, Fur07]. They offer an even better motion mitigation at the cost of a more
challenging delivery. The effect of a rescanned irradiation can be seen in Figure 1.11.
The major drawbacks of rescanning are the increased treatment time and the enlarged target volume.
As the target must be covered in all motion states an extended volume needs to be irradiated, which
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Figure 1.11.: Films irradiated with different numbers of rescans. With an increasing number of rescans,
hence with an improved statistical averaging, the interplay pattern becomes homogeneous
indicating the effectiveness of rescanning to compensate motion patterns. Figure taken
from [Ber08b]
increases the dose delivered to normal tissues. The major advantage is the simple delivery, especially for
slice-by-slice and volumetric rescanning. Different kinds of rescanning are already in clinical use [Ros15].
Gating
For gating, a certain part of the motion cycle is selected in which the motion amplitude is small. The beam
is only extracted when the target volume is within this window. The technique needs a sophisticated
motion monitoring and beam extraction system, which can start and stop the beam extraction without a
significant time delay. A drawback of this technique is the prolonged treatment time, as the irradiation
is only possible when the gating window and the accelerator extraction overlap.
For complicated cases a combination of gating and rescanning is possible, where gating is used to
reduce the motion amplitude and rescanning to compensate the residual motion effects [Mor14].
1.1.2.6 Treatment Planning
Nowadays, treatment planning is based on a CT of the corresponding volume. The target as well as the
OARs are delineated by a physician and this structures are then used for the optimization of the treatment
plan. Additionally, positron emmission tomography (PET) and magnetic resonance imaging (MRI) are
used to gain additional information of the tumor, which facilities a more precise contouring.
The tumor region and the OARs have to be defined and different volumes have to be determined
following the International Commission on Radiation Units and Measurements (ICRU) [ICR95, ICR99]:
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• GTV (Gross Tumor Volume) - ’The GTV is the gross palpable or visible extent and location of malignant
growth.’
• CTV (Clinical Target Volume) - ’The CTV is a tissue volume that contains a demonstrable GTV and/or
subclinical microscopic malignant disease, which has to be eliminated. This volume thus has to be
treated adequately in order to achieve the aim of therapy, cure or palliation.’
• PTV (Planning Target Volume) - ’The PTV is a geometrical concept, and it is defined to select an
appropriate beam size and beam arrangements, taking into consideration the net effect of all the
possible geometrical variations, in order to ensure that the prescribed dose is actually absorbed in the
CTV.’
• ITV (Internal Target Volume) - ’This is the margin that must be added to the CTV to compensate
for expected physiological movements and variations in size, shape and position of the CTV during
therapy.’
• OAR (Organ at risk) - ’OARs are normal tissues whose radiation sensitivity may significantly influence
treatment planning and/or prescribed dose.’
During the treatment planning process the beam entry angles and the beam parameters need to be set.
Yet, as major task remains the optimization of the dose distribution. The aim of the TPS is to optimize a
treatment plan satisfying all constraints given by the physician. For heavy ion therapy the RBE as well as
projectile and target fragments need to be taken into account increasing the complexity of the planning
process.
The TPS used throughout the thesis is TRiP4D, a further development of TRiP98, which was developed
at GSI during the pilot project. A detailed description of TRiP98 can be found in [Krä00b,Krä00c,Krä10]
and the upgrade to the 4D version is described in detail in [Ric13].
4D Treatment Planning
Particle therapy, especially actively delivered particle therapy, is very sensitive to target motion. There-
fore a dedicated 4D treatment planning can increase the dose conformity, which allows a higher target
dose while sparing the OARs. TRiP4D [Ric13] was introduced to handle 4D dose calculations as well as
4D dose optimization [Gra13,Gra14].
The basis for 4D treatment planning is representative 4D imaging data gained by a time-resolved
computed tomography (4DCT). The 4DCT was developed in the last decade and is now routinely per-
formed in the clinical workflow. The 4DCT allows adapting a treatment plan to the present motion in
the patient. However, a 4DCT only represents a single motion cycle, which is assumed to be valid dur-
ing the whole treatment. Additional 4D image information can be gained from time-resolved magnetic
resonance imaging (4DMRI) allowing to record several motion cycles.
Typically, one 4DCT is divided in 10 motion phases, either with an amplitude or phased based algo-
rithm. From this phases one is selected as reference phase and all others are registered to it. The image
registration process provides deformation maps between each motion phase and the reference phase.
The resulting deformation maps are required input data for the 4D treatment planning process. The
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image registration needs to be done before the 4D treatment planning process can be started. At GSI
external programs are used for this step, for instance Slicer3D [Fed12].
An image registration can be done between different motion phases in an image modality (intra-
modality registration) or between different image modalities (inter-modality), for instance contrast CT
to native CT or CT to MRI. As mentioned, the result of the image registration is a deformation map,
which specifies the transformation of every voxel in the moving image. In Figure 1.12 a deformation
map is shown and in Figure 1.13 displays the process of registering two images.
Figure 1.12.: Deformation map of a 4DCT of a lung cancer patient in the reference phase (end-exhale).
The vector fields visualize the necessary deformations to convert it to the end-inhale phase.
From left to right axial, coronal and sagittal views are shown [Ric12].
Different registration types are known and can be used for different purposes in treatment planning.
A Rigid registration provides limited degrees of freedom including changes such as translation, rotation
and scaling. Deformable registrations allow arbitrary transformations.
To calculate the 4D dose distribution, the treatment plan is divided into sub-plans corresponding to
the motion phases that are irradiated. To determine the sub-plans a time correlation between the beam
delivery and the present motion phase needs to be available, hence beam delivery sequences need to be
simulated.
Figure 1.13.: Overlay of two different 4DCTs is shown without image registration in (a). In (b) the overlay
of the fixed and the corresponding image after registration is shown. As inverse colors are
used in both CTs perfectly matching areas are displayed in gray [And16a].
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Simulation of Beam Delivery Sequences
A tool was develop at GSI which can use different accelerator settings and simulate the time the irra-
diation of each raster point [Ric12]. Doing this for all raster points yields the timings for the complete
beam delivery, including the timing of the begin and end of each spill, the chosen particle intensity for
each IES or for each raster point, depending on the accelerator, the structure of the beam extraction and
the extraction duration.
1.2 Cardiac Arrhythmia
Cardiac arrhythmia is the general term for any disruption of the cardiac conduction system. It includes
heart rates at rest that are too high (above 100 bpm as resting pulse rate - tachycardia), too low (below 60
bpm - bradycardia) and also all types of irregular beating of the heart. Furthermore, cardiac arrhythmia
can arise from almost any anatomical site of the heart.
The types of cardiac arrhythmia and their corresponding symptoms vary extremely. While several
kinds of arrhythmia are harmless, others can have severe complications like strokes, heart failure and
decreased quality of life or can even cause sudden cardiac death. The risk to develop cardiac arrhythmia
rises with increasing age and they are a serious problem for an aging society.
The effectiveness of the available treatment modalities depends on the type of cardiac arrhythmia and
range from good to very complicated to control. Within this section more details are given for two types
of cardiac arrhythmia: Atrial fibrillation (AF) and ventricular tachycardia (VT). The symptoms, causes
and prevalence is discussed as well as conventional treatment modalities and possible future ones.
1.2.1 Conduction System of the Heart
From a mechanical point of view the heart works like a pump. The control system of the heart is the
heart’s conduction system which takes care that the pumping action occurs regularly and effectively. The
starting point of every healthy heart contraction is the sinoatrial node (SA), in which electrical impulses,
so called action potentials, are created. The action potentials are propagated by specialized cells over
the atria to the atrioventricular node (AVN) and from there over the atrioventricular bundle to the left
and right ventricle. The timing of the propagation of the action potentials is very important to guarantee
an effective heartbeat. The atria beat shortly before the ventricles to allow an effective pumping of
blood through the heart muscle. A scheme of the conduction system and the hearts anatomy is given in
Figure 1.14.
The electrical impulses can be measured on the body surface and are displayed in an electrocardiogram
(ECG), which is used for medical diagnostics. In Figure 1.15, a schematic of the human sinus rhythm
is shown as it can be seen on an ECG. Different wave forms can be distinguished representing different
actions of the heart muscle. The first small wave, the so-called P wave, is formed due to the electrical
impulses causing the atria to contract. The QRS complex, the big spike after the P wave, is created
by the contracting ventricles. The next rising structure, the T wave, measures the release of the action
potentials within the ventricles. For medical diagnostics not only the appearance of the different waves
is important, but also the timing of the ECG. The PQ interval is defined as the elapsing time between
the beginning of the P wave until the beginning of the QRS complex, indicating the necessary time for
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Figure 1.14.: Scheme of the conduction system of a human heart. The figure is taken from [Hea].
the action potentials to propagate from the atria across the AVN to the ventricles. The interval from
the beginning of the QRS complex to the end of the T wave is called QT interval and represents the
stimulation of the ventricle. The ST segment corresponds to the time necessary for the relaxing of the
ventricles.
Figure 1.15.: Scheme of a human sinus rhythm as it can be seen on an ECG of a healthy human [ECG].
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1.2.2 Types of Arrhythmia
The next part focuses on atrial fibrillation as well as ventricular tachycardia, since both are types of
cardiac disorders for which a non-invasive treatment modality was investigated in this work, especially
in Chapter 2. In addition, a short review of conventional treatment modalities for cardiac arrhythmia
as well as an introduction to the current sate of research on radiotherapy as an alternative treatment is
given.
1.2.2.1 Atrial Fibrillation
Atrial fibrillation is the most common cardiac arrhythmia with severe complications [Mun14]. The
number of affected patients is dramatically increasing due to an aging society, especially in developing
countries. The 2010 Global Burden of Disease Study estimated, that 596 out of 100.000 men and 373
out of 100.000 women suffer from atrial fibrillation (AF) [Chu14]. This sums up to a total of 33 million
people worldwide and the global prevalence of AF is expected to double until 2050. The lifetime risk
for people above 40 years is estimated with approximately 25 % and already today about 2 % of the
European population already suffers from AF [Rah14].
AF is not directly life threatening, but can have severe complications like stroke, cardiac infarction
and sudden cardiac death. However, even without severe complications AF decreases the quality of life
significantly. Aside from genetic predisposition, age is the most important risk factor. The AF prevalence
is almost doubling within each decade for people older than 50 years and the average age of patients
suffering from AF in high-income countries is above 65 years. Obesity, hypertension, diabetes, coronary
heart disease and all other conditions related to cardiovascular diseases are risk factors related to AF.
AF is caused by misfunctions of the heart conduction system. During an AF episode additional electrical
impulses are generated by either the entries of the pulmonary veins or some other random cardiacmy-
ocytes. These irregular and erratic signals lead to an irregular beating of the atria, which is marked by a
missing P wave on the ECG. A schematic comparison of a normal sinus rhythm and atrial fibrillation is
given in Figure 1.16.
AF can cause severe symptoms but can also occur silently for the patient, it is assumed that about 20 %
of all strokes are caused by AF. Especially for patients with silent AF, it is often diagnosed after a stroke.
Therefore every stroke patient should be checked for AF [Cam10].
In general several types of AF can be distinguished based on the duration of the attacks and the
presentation:
• Paroxysmal - Attacks last a maximum of 48 hours
• Persistent - Attacks last longer than 7 days or require cardioversion
• Long-standing persistent - Attacks last longer than a year
• Permanent (accepted) - Attacks are not ending anymore and no cardioversion is performed. The
wrong heart rhythm gets accepted.
Usually the different versions of AF develop into each other and the process can only be stopped by an
efficient treatment.
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(a) Schematic of electrical impulse propagation
during a sinus rhythm of the heart on the left and
the corresponding ECG on the right. In normal si-
nus rhythm, the sinus node initiates the electrical
activity that triggers each heartbeat. The elec-
trical impulse travels through the atria, signaling
the muscle to contract. Each atrial contraction
shows on the ECG as a p wave.
(b) Schematic of electrical impulse propagation
during an AF episode on the left and the corre-
sponding ECG on the right. In atrial fibrillation,
the atria’s electrical signals are very rapid and er-
ratic. The atria do not contract and there is no
p wave visible in the ECG. Without a coordinated
signal to guide them, the ventricles contract in an
irregular rhythm.
Figure 1.16.: Schematic comparison of the electrical impulse propagation in the atria between a sinus
rhythm and an AF episode with corresponding ECGs. Both figures are taken from [Fib]
Conventional Treatment Modalities
After AF is diagnosed several treatment options are available. The choice depends mainly on the present
form and duration of the AF, the influence of AF on the quality of life and the cause of AF. The main
aims are either to reset the heart rhythm or to control the heart rate and to avoid the formation of blood
clots. In general, the common treatment options are: Anti-coagulation drugs, drugs for rate and rhythm
control, cardioversion, pulmonary vein isolation and, as a final step, AVN ablation.
The first aim is always to reset the heart to the sinus rhythm. This is why a cardioversion, either with
medication or with an external defibrillator is applied. Even when anti-arrhythmic drugs are effective
the side effects should be considered.
Whether anti-coagulation drugs are necessary and which ones, can be decided with the help of the
CHADS2 score [Cam10], which classifies risk factors and supports the decision pro or against drugs.
Major risk factors which always require antithrombotic therapy are, for instance, a prior stroke, transient
ischemic attack, or thromboembolism and age above 75 years. Clinically relevant but non-major risk
factors are, for instance, heart failure, hypertension or diabetes. In the presence of several non-major
risk factors, anti-coagulation drugs are also recommended.
If controlling the heart rhythm is not possible a rate control of the ventricles is necessary. This can
either be achieved with medication or an ablation of the AVN and the implantation of a pacemaker. The
AVN ablation should always be the last step and is only applied if all other treatment modalities are
unsuccessful.
A cure of AF can be achieved by a radio-frequency catheter ablation of the pulmonary veins. However,
the treatment requires anesthesia, is lengthy and severe side effects can occur. Furthermore, the outcome
is varying and in about 30 % of all patients a recurrence of the symptoms is found [Cap05,Cap10] making
a repetition of the treatment necessary.
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1.2.2.2 Ventricular Tachycardia
Another type of cardiac arrhythmia is ventricular tachycardia (VT), which causes most of the sudden
cardiac deaths in the US. It is a cardiac disorder like AF, but VT is potentially life-threatening as it
is defined as a fast rate of ventricular contractions. These fast contractions are inefficient and slow
down or even interrupt the blood flow, causing an extremely low blood pressure which can develop into
ventricular fibrillation and sudden cardiac death. A schematic of an ECG recorded during a VT attack is
shown in Figure 1.17.
Figure 1.17.: Schematic of the origin of the electrical impulses within the heart on the left and a typical
VT ECG on the right [VT].
During a VT attack an ECG shows 3 or more consecutive QRS complexes at a minimum heart rate of
100 bpm. During VT episodes the heartbeat can easily reach between 160 and 250 bpm. The electrical
impulses do not propagated from the atria through the AVN to the ventricles, instead they originate
directly from the ventricles. Mostly they are caused by an interaction between an arrhythmogenic sub-
strate, for instance the border zone of a scar after a myocardial infarction, and electrophysiological
properties of the heart muscle cells.
Comparable to AF, different kinds of VT can be classified. Important factors to classify VT are the
duration of an attack, the morphology, the hemodynamic characteristics and the underlying mechanism.
A detailed overview of definitions and classifications can be found in [Mit15].
The most common cause of VT is an ischemic heart disease in which scar tissue is created due to
under-supply of the myocardium with oxygen. However, other structural heart diseases can cause VT as,
for instance, cardiomyopathy and surgical incisions in the ventricle. In addition, VT can also occur in the
absence of a structural heart disease and can be triggered by electrolyte deficiencies, digitalis toxicity or
drugs that influence the heartbeat.
Conventional Treatment Modalities
The standard treatment for VT depends on the classification of the VT. While anti-arrhythmic drugs are
successful for patients with idiopathic VT, they are not a stand-alone therapy for patients with structural
heart diseases anymore. For those patients, using an implantable cardioverter-defibrillator (ICD) is the
first treatment choice nowadays. An ICD is able to perform cardioversion, defibrillation and even pacing
and thus reduces the risk of sudden cardiac death and can prolong the lifetime of a patient. However,
ICDs do not offer a cure of ventricular tachycardia and cannot completely avoid sudden cardiac death
[Red07].
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In addition, ICDs are a psychological burden and repeated shocks are challenging. First of all they
are painful for the patient and not well tolerated. Secondly, especially for patients with a heart failure,
repeated shocks can worsen the hemodynamic within the heart and therefore increase the mortality
[Poo08]. To reduce the number of ICD shocks the use of anti-arrhythmic drugs is indicated, even though
they are not well tolerated and can even increase the number of deaths. In patients with severe structural
heart diseases they are even less effective.
Radio-frequency catheter ablations, as a prophylactic measure together with ICD implantation or after
repeated ICD shocks, offer an additional treatment modality. For patients with idiopathic VT, radio-
frequency ablation can even be used as a stand-alone therapy with the aim to cure patients. The success
for radio-frequency catheter ablations is increasing as the technology is developing further. Thus, a study
was carried out to investigate the benefit of radio-frequency ablation for patients. The complication risks
during the procedure were found to be below 5 % and the number of ICD shocks decreased from 53.7 %
in the control group, to 32.7 % in the ablation group. [Bah13]
Radio-frequency catheter ablation is still limited by the thickness of the myocardium as transmural
scars are necessary to control the electrical impulses, as the penetration depth is limited. Hence, for
several patients an additional epicardial ablation is necessary which is correlated with higher risks of
complications and, in addition, only carried out at a very limited number of clinics [Di 12].
1.2.3 Radio-ablation as Catheter-Free Ablation for Atrial Fibrillation and Ventricular Tachycardia
As the conventional treatment of cardiac arrhythmia is not always satisfying or even insufficient for
some patient groups, a potential solution is radiotherapy. It is a non-invasive approach with a sufficient
penetration depth and accuracy. First animal studies were carried out in the last years, showing the
possibility to alter electrical pathways in the heart muscle using ionizing radiation [Sha10b, Bla14].
Trials to isolate pulmonary veins in pigs followed and showed the feasibility to ablate cardiac structures
using photon radiation. However, an improved dose distribution is necessary to avoid radiation related
side effects, especially with conventional linear accelerators.
First patient trials followed that indicated the successful application of photon therapy for cardiac
arrhythmia [Cve14, Loo15]. However, until the method can be used in clinical routine further studies
are necessary. A phase I/II study with more than one patient was carried out at Washington University
St. Louis (USA) irradiating five patients, which showed the feasibility of a fully non-invasive VT ablation
(www.clinicaltrials.gov: NCT02919618). Due to the larger patient number of this study the outcome
could provide more information on advantages, success and side effects of the therapy.
One possibility to further improve the dose distribution and to avoid side-effects reported by [Bod15]
is the use of heavy ions. Therefore a study with Langendorff-perfused porcine hearts was carried out to
investigate the feasibility to ablate cardiac structures using carbon ions [Leh15, Pra15]. In addition, a
treatment planning study for carbon ions of ablating pulmonary veins was published by [Con16,Con14]
to show the feasibility of a carbon treatment for humans. A twin study followed, where the use of
photons and carbon ions for catheter-free ablation was compared. The study was carried out at Mayo
Clinics (Mayo) (Rochester,Minnesota, USA) and GSI (Darmstadt, Germany) [Leh15,Leh16a,Eic15]. The
carbon ion arm of the study and the study’s results are discussed in detail in Chapter 2.
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2 Feasibility Study of Catheter-Free Ablation
using Carbon Ions in Pigs as an Animal Model
Radio-frequency catheter ablation is a widely spread treatment modality for treating cardiac arrhyth-
mia. The aim of catheter ablation is to alter electrical pathways within the heart muscle to prevent
the propagation of action potentials disturbing the normal sinus rhythm of the heart. The procedure
itself is time intensive and requires repetition in about 30 % of all treatments due to a recurrence of
the symptoms [Cap05, Cap10]. Therefore, innovative treatment modalities are highly warranted and
radiotherapy emerges as a promising non-invasive alternative.
First in-vivo studies using photons for cardiac ablations demonstrated the feasibility to alter the elec-
trical conductivity of the heart muscle using radiation [Sha10b, Bla14, Bod15]. In addition, first patient
trials were conducted [Cve14,Loo15]. In none of the two treated patients, radiation induced side effects
were observed, while Bode et al. reported severe side effects in pigs. In one of the patient trials no
treatment effect was found and the patient died 9 months after the treatment due to the underlying dis-
ease [Loo15]. In the other one, no clear connection between the reduced number of ventricular tachy-
cardia (VT) attacks starting 4 weeks after the irradiation and the treatment could be shown [Cve14].
Motivated from these findings a phase I/II clinical trial was initiated at Washington University, St. Louis,
USA (www.clinicaltrials.gov: NCT02919618). The outcome of this study is still pending.
Apart from photon irradiation, the potential of scanned carbon ions beams for non-cancerous dis-
eases was already discussed in 2012 [Ber12]. In 2013, a feasibility study was carried out irradiat-
ing Langendorff-perfused pig hearts with carbon ions [Leh15, Pra15]. In addition, a first treatment
planning study was conducted, proposing the use of carbon ions to ablate pulmonary veins in humans
[Con16, Con14]. The results showed that carbon ions offer an excellent non-invasive alternative with
superior dose distributions compared to photons due to the inverse depth-dose profile. However, carbon
ions are prone to interplay effects and need a careful consideration of breathing as well as heartbeat
motion during the treatment planning process and the irradiation itself. This causes a more complex
treatment compared to photons. Nevertheless, the conformity of the depth dose distribution and the
sparing of the critical structures in close proximity to the target volume is superior.
The following chapter describes the first in-vivo feasibility study on catheter-free ablation using carbon
ions in pigs. Pigs are widely used as an animal model for heart experiments, although anatomical
differences to human hearts are present [Cri98]. The aim of the study was to investigate the potential
of carbon ions as a non-invasive treatment alternative to ablate anatomical structures in the heart. The
study was carried out at GSI Helmholtz Center for Heavy Ion Research (GSI) in Darmstadt (Germany) in
July 2014 in collaboration with Mayo Clinics (Rochester, Minnesota, USA), University Clinic Heidelberg
(Germany) and Helmholtzcenter Dresden Rossendorf (Germany). The focus of this work is the treatment
planning and motion mitigation performed for the experiment. In addition, a summary of the whole
experiment and results is given for completeness. For further details on the experiment the reader is
referred to [Leh16b,Leh15,Gra15,Erb15,Eic15,Hel14,Pra14b].
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2.1 Material and Methods
2.1.1 Patient Cohort and Targets
In total, 22 pigs were included in this study. 16 of them were prepared for irradiation, 3 pigs were kept
as a control group and, in addition, the workflow was tested with 3 pigs prior to the experiment. This
was essential to establish imaging protocols for treatment planning as well as for positioning, to test the
infrastructure at GSI, the transportation to GSI and to investigate the anatomical variability. One of the
pigs prepared for irradiation had to be euthanized prior to the treatment due to a vascular obliteration.
In addition, one of the 15 irradiated pigs suffered from a heart malformation and was thus excluded
from the analysis as the results could not be compared to the healthy pigs. All other pigs were healthy
and did not suffer from any cardiac disorder. At the time of irradiation, all pigs were 10 weeks old and
weighted between 29.0 and 39.1 kg.
For the study, all pigs were randomly separated in three target groups corresponding to three different
target volumes:
• The atrioventricular node (AVN) is part of the electrical conduction system of the heart and
propagates the action potentials from the atria to the ventricles. The ablation of the AVN is used for
patients suffering from permanent atrial fibrillation (AF), which influences the ventricular rhythm.
The AVN was irradiated in order to create a complete AV block preventing any electrical signals to
emerge from the atria to the ventricles. As a complete AV block can be lethal due to slow ventricular
excitation, all pigs in the AVN group were equipped with pacemakers.
• The left ventricular free-wall (LV) was irradiated to create a homogeneous and transmural lesion.
This is a potential treatment for VT, which can occur due to the creation of inhomogeneous scar
tissue in the heart muscle after a myocardial infarction. Ablating the LV is the only possible cure for
patients suffering from VT. The standard treatment, implantation of an implantable cardioverter-
defibrillator (ICD), can only reduce the risk of sudden cardiac death.
• The superior pulmonary vein (SPV) ablation was carried out as an alternative and innovative
treatment for AF. In several cases AF is caused by action potentials that are created in the pul-
monary veins and propagate to the atria. A homogeneous scar at the transition between SPV and
atrium can avoid the propagation of action potentials and, hence, cure AF.
In Table 2.1 an overview of all pigs is given including a numbering system, which is used throughout this
work. In addition, target doses as well as the size of the target volumes are stated.
Selection of Dose Groups
All pigs were irradiated with a single-fraction treatment. The dose groups were selected corresponding
to the findings of previous photon studies [Sha10b, Bla14]. The reported doses necessary to reach a
permanent alteration of the electrical pathways varied between at least 25 Gy [Sha10b] and above
30 Gy [Bla14]. Sharma et al. reported bidirectional cavotricuspid isthmus block after 30 days and a
dose of 40 Gy and an AVN conduction block after 49 days and 70 Gy. Blanck et al. found that the 50 %
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Target Dose [Gy] ID Target Volume [cm3] Treated Volume [cm3] Optimization
AVN
55
1 0.065 1.76
SFUD
2 0.065 1.76
3 0.065 1.74
40
4 0.065 1.73
5 0.065 1.76
6 0.065 1.80
25
7 0.065 1.73
8 0.065 1.73
SPV 40
12 1.30 16.09
IMPT13 0.95 11.11
14 0.96 12.58
LV 40
15 2.11 -
SFUD16 2.28 -
17 2.38 -
Table 2.1.: Overview of the treated animals and the corresponding targets, target doses and target vol-
umes. The stated IDs are used throughout this work. Pigs with ID 9, 10 and 11 were sham-
irradiated control animals. Due to the applied range margins it was not possible to determine
a geometric treated volume for the LV group.
effective dose to induce fibrotic tissue was 31.3 Gy with a follow-up time of 6 months and suggests doses
above 32.5 Gy to ensure a successful treatment.
These findings motivated the use of 25, 40 and 55 Gy for the AVN group to carry out a dose escalation
study within the presented feasibility study. For the pigs with 25 Gy no AV-block was expected, for the
ones with 40 Gy permanent changes were likely and the 55 Gy group was chosen to definitely induce
AV-blocks. For the SPV and LV irradiations only one target dose was applied. Hence, 40 Gy was chosen
to ensure a dose high enough to create fibrotic tissue, while at the same time trying to keep the organ at
risk (OAR) doses as low as possible to avoid radiation induced side effects.
All treatment plans were optimized using physical doses due to insufficient knowledge of the relative
biological effectiveness (RBE). Even though biological effective doses are typically prescribed in carbon
ion therapy, the RBE at such high single-fraction doses is expected to be only slightly above 1 [Fri14a].
2.1.2 Study Outline
Two to three weeks before irradiation all pigs were examined and an electrophysiological mapping of the
heart was performed to collect baseline data as reference for the final analysis. Additionally, skin biopsies
and blood samples were taken. Pigs selected for AVN group underwent a pacemaker implantation to
ensure the survival after a successful treatment. During the experiment and the follow-up time all
animals were kept at the ’Interfakultäre Biomedizinische Forschungseinrichtung’ (IBF) of the University
Clinic Heidelberg (UCHD). All medical examinations of the study were carried out at the IBF. The pigs
were transported to GSI for the catheter-free ablation with an adequately equipped truck.
In total, three follow-ups were carried out 4, 8 and 13 or 24 weeks after the treatment. All follow-
ups consisted of the recording of 12-channel electrocardiograms (ECGs), taking of blood samples and
examination of the skin in the area of the entrance channels to check for side effects. In addition, the
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second and the third follow-up included skin biopsies. During the final follow-up an electrophysiological
cardiac mapping was performed to detect electrical changes in the heart muscle. In-between the follow-
ups regular ECGs were performed for the AVN pigs checking for AV-blocks. After the final follow-up
the pigs were euthanized and heart, lung, trachea, esophagus and phrenic nerve were removed ’en bloc’
with a possibly intact pericardium. Finally, a pathological examination was carried out to assess and
document tissue changes. In Figure 2.1 the complete workflow for each pig is described.
Figure 2.1.: Overview of the workflow carried out for each pig during the feasibility study.
2.1.3 Fixation
A fixation device was constructed to allow a reproducible positioning of the animals during the com-
puted tomography (CT) acquisition at Heidelberg Ion-Beam Therapy Center (HIT) and the catheter-free
ablation at GSI [Pra14b].
Figure 2.2 shows a drawing of a pig positioned in the fixation device. All pigs were fixed in a PMMA
frame containing a vacuum mattress (BlueBAGTM , 750×1025 mm2, ITV Austria) for hip and lower body
as well as a thermoplastic mask for the chest. The vacuum mattress was formed for the first pig and then
reused for all remaining ones. An individual thermoplastic mask was modeled for each pig to ensure a
stable and reproducible positioning of the chest. On each mask the orthogonal laser lines, indicating the
room iso-center, were marked and Beekley spots were placed on the laser intersections. In addition, the
laser intersections and the upper and the lower edge of the thermoplastic mask were tattooed on the
pigs. The marks, especially at the upper edge of the mask, provided a reproducible position of the front
legs avoiding additional tissue in the beam entrance channel.
The fore and hind legs were attached to PMMA bridges, which were connected to the ground plate,
using gauze bandages. Therefore the legs were slightly stretched. A supine position of the pigs was
chosen as this increased the reproducibility, offered a stable positioning of the animals and facilitated the
targeting without additional material in the beam entrance channel. More details on the reproducibility
of the positioning will be published in [Pra].
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Figure 2.2.: Schematic view of a pig positioned in the fixation device. 1) orthogonal laser lines, 2) vacuum
mattress, 3) gauze bandages for the fixation of the legs, 4) thermoplastic mask, 5) Beekley
spots at intersections of laser lines on thermoplastic mask 6) tattoos of the outline of the
thermoplastic mask and laser lines, 7) fixation device. Figure courtesy of Matthias Prall.
2.1.4 CT Acquisition
Cardiac-gated time-resolved computed tomographys (4DCTs) for treatment planning were recorded at
HIT using a multidetector 64 row Siemens Somatom Definition Flash Scanner (Siemens Healthcare,
Forchheim, Germany). The full cardiac cycle was divided into 10 motion phases and a 3DCT was
recorded for each. A reference phase, phase 0, corresponding to the diastole and the onset of the
QRS-complex was selected, as the rising edge in the voltage can easily be detected. The CT was recorded
at end-exhale and a respirator was remotely controlled via a Labview interface (National Instruments,
Austin, TX, USA) to interrupt the ventilation at end-exhale shortly during image acquisition.
A CT protocol was established to generate 4DCTs with Hounsfield units (HUs) comparable to the
planning CTs currently in clinical use for heavy ion treatments at HIT. This was necessary, as the
Hounsfield look-up table, converting photon absorption into water equivalent path length, used for
treatments at HIT was also applied for the treatment planning of the feasibility study. Further investiga-
tions showed that range uncertainties due to the different protocols are negligible as a good agreement
of the Hounsfield units was found [Rica].
Two 4DCTs were recorded for every pig. The first CT was a native cardiac-gated 4DCT and the second
one was a contrast-agent enhanced cardiac-gated 4DCT. This was necessary as several sub-structures of
the heart are not visible in native CT scans. In addition, the correct motion of the cardiac sub-structures
can only be determined in contrast-agent enhanced CT scans [Con14], while treatment planning is
only possible on native imaging data. All CTs were recorded with a field of view of 500 mm to allow
skin-to-skin images, necessary for treatment planning, and with a slice spacing of 1 mm.
For the contrast enhanced CT, 50 cc of a contrast agent (Omnipaque 350 mg, GE Healthcare, USA) was
injected with a rate of 4 cc/s. The scan was recorded 8-10 seconds after the injection of the medication
to ensure a homogeneous distribution of the contrast-agent within the pig.
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2.1.5 Treatment Planning
The treatment planning was carried out using TRiP4D, a treatment planning system (TPS) developed
at GSI for ion therapy [Ric13]. TRiP4D is a treatment planning software capable of calculating 4D
dose distributions and incorporating different motion mitigation techniques in the planning process for
particle therapy (for details see Section 1.1.2.5 or [Ric12]).
In all treatment plans the raster point distance in horizontal and vertical direction was chosen to
be 2 mm with a distance of 3 mm between two iso-energy slices (IESs). A minimum number of 5,000
particles per raster point is needed to obtain a position and intensity feedback from the treatment control
system (TCS) for successful irradiations at GSI. Thus, the absolute minimum particle number during the
optimization was 75,000 as a rescanning scheme with up to 15 rescans was applied. However, as the
speed of the irradiation is mainly determined by the particle intensity, which is fixed for the whole IES
and depends on the raster point with the lowest particle number, the minimal particle number per raster
point was increased until the target coverage started to decrease in order to reduce the irradiation time.
Thus, 125,000 particles were chosen as minimal particle number per raster point for 12 treatment plans.
For two out of the eight AVN pigs, the minimum number of particles had to be reduced to 75,000 in
order to obtain a homogeneous dose distribution in the target volume. For Pig 1 a satisfactory treatment
plan using 200,000 particles as a minimum particle number per raster point was obtained.
To ensure the robustness of the treatment, all irradiations were planned using two opposing horizontal
fields with angles of 90◦ and 270◦. This reduced the sensitivity to slight displacements and deformations
of the heart due to the heartbeat or positioning uncertainties. The treatment plans for the AVN and LV
irradiation were both optimized as single field uniform dose (SFUD). Hence, each field was separately
optimized with half of the planned target dose. This approach increases the robustness of the treatment
plans, as it removes gradients within the overlapping fields. In case of the SPV irradiations, the proximity
of the target volume to several OARs required the usage of intensity-modulated particle therapy (IMPT),
even though this reduced the plans’ robustness. For the optimization of the SPV treatment plans the
AVN was included in the optimization as OAR. The aim was to reduce the maximum point dose in the
AVN below 30 Gy to avoid severe side effects as, for instance, AV-blocks. Hence, for Pig 12 and 14 the
maximum dose allowed in the OAR was set to 70 % and for pig 13 to 80 % of the planned target dose.
The weighting factor for the OAR was chosen to be 0.9 for all SPV pigs.
Prior to the treatment not only standard 3D, but also 4D dose simulations were carried out. All 4D
dose calculations were compared to the 3D simulations, which served as reference for successful motion
mitigation. The motion effect on the delivered dose distribution was estimated to ensure a successful
irradiation in the presence of the heart motion.
In order to calculate 4D dose distributions [Ric12], each phase of the 4DCT had to be registered
to the reference phase and vice versa using a deformable image registration (DIR). Slicer3D (Version
4.3) [Fed12] and Plastimatch (Version 1.15.17) [Sha10a] were used to perform this important process.
The goal of the treatment planning was to reach a median D95 value, greater than 95 % in the target
volume (TV) and ensure that the minimum of the inner quartile range of D95 is above 80 % for all
performed and motion mitigated 4D simulations in the planning target volume (PTV).
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Contouring and Target Definition
Target structures and OARs were contoured prior to the treatment planning by a physician. The contour-
ing process, also important for the risk evaluation, was conducted using Syngo PRT Planning (VC11B,
Siemens AG, Erlangen, Germany) and Eclipse (Varian Medical, Palo Alto, CA, USA) treatment planning
software. Prior to the treatment, only critical structures for the treatment planning were contoured due
to the limited amount of time between image acquisition and irradiation. For a full analysis additional
structures were added retrospectively. For each pig up to 21 OARs were available. For catheter-free
ablation of the AVN a 5 mm sphere contoured in the AV junction was used as TV. For SPV as well as LV
irradiation, targets were defined by polygons in transverse CT slices.
Margins
Safety margins were added to the TV to account for systematic errors and anatomical changes between
treatment planning and the actual treatment. In the first step, isotropic 5 mm margins were added
to the TV for the AVN and SPV target group to contruct the PTV. In the second step a range internal
target volume (ITV) was created using the envelope of the PTV transformed to all motion states. For the
treatment of the LV group margins of 2 mm + 2 % of the beam range in water were added in beam’s eye
view. A range ITV was calculated considering the applied range margins. Further details on the range
ITV can be found in [Gra12]. The differences in the margins chosen for AVN and SPV ablation on the
one side and LV irradiations on the other side can be explained with the different aims of the treatment.
While a precise ablation of anatomical structures was necessary for AVN and SPV, the aim for the LV
irradiation was an induction of a transmural lesion in the free-wall of the left ventricle.
Organs at Risk
The targeted sub-structures in the heart were in close proximity to several OARs. Hence, it was necessary
to determine a certain number of critical structures for each target. The mean and max doses were
investigated for lungs, left coronary artery (LCA), right coronary artery (RCA), myocardium, pericardium
and skin. Depending on the target volume, additional critical structures were analysed. For the AVN
group, aorta and pulmonary artery (PA) were examined. For the SPV group, trachea, esophagus, AVN as
well as superior vena cava (SVC) and for the LV group PA were analyzed.
Dose Volume Limit
OAR Volume Threshold [cm3] Dose Threshold [Gy] Max. Point Dose [Gy]
Aorta 10.0 31.0 37.0
Trachea 4.0 10.5 22.0
Esophagus 5.0 11.9 19.0
Skin 10.0 23.0 26.0
Myocardium 15.0 16.0 22.0
Table 2.2.: Dose-volume and maximal point dose constraints of the most affected OARs [Gri11, Ben10].
In addition to mean and max doses, dose volume constraints were investigated for certain structures,
as recommended by the Radiation Therapy Oncology Group (RTOG) for patients undergoing radio-
surgery. The OAR limits applied throughout this study are listed in Table 2.2. For the maximum point
dose deposited in the LCA and RCA 30 Gy were assumed as acceptable. No data is published on the
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radiation sensitivity of these structures. Therefore the limit is adapted from the known constraints for
great vessels and was approved by the physicians conducting the study.
Motion Mitigation
To avoid overdosage in OARs and underdosage in the TV due to interplay effects, it was necessary to
apply motion mitigation techniques as explained in Section 1.1.2.5. The first motion type that requir-
ing mitigation is the breathing motion. As the pigs had to be anesthetized throughout the procedure
and were externally ventilated using a respirator anyhow, repeated breath-holds were used to suppress
the breathing motion completely. A remotely controlled respirator could be paused up to 120 seconds
allowing consecutive breath-holds at a reproducible lung volume.
The second motion type, which was more difficult to compensate, was the heartbeat. In contrast to
breathing, the heart cannot be stopped during the irradiation. Hence, it was necessary to compensate for
the heartbeat by applying a motion mitigation technique during treatment and treatment planning. A
planning study showed that rescanning is a promising method to account for heart motion while keeping
the technical effort and the irradiation time as small as possible [Con14,Con16]. However, as the amount
of beamtime was limited and the preparation for the pigs, including anesthesia and positioning, was
lengthy, it was important to keep the irradiation time short. Thus, a new, inhomogeneous rescanning
scheme was applied. A schematic of the rescanning strategy is shown in Figure 2.3.
Figure 2.3.: Schematic of the inhomogeneous rescanning scheme used for the irradiation. The numbers
in the IESs indicate the number of rescans for each IES.
In the standard scheme every IES is rescanned a specific number of times, usually between 5 and
20, depending on the present motion amplitude. The new, inhomogeneous scheme assumes that the
proximal slices are already partly rescanned by the irradiation of the distal slices. This allows a reduction
of the number of rescans in the proximal IESs . Hence, an polynomial decay of rescans was applied and
the number of rescans decreased from the distal slice with 15 rescans to the proximal one with only one
rescan following Equation 2.1.
NRescans(i) = NMax −

0.5+

i
NSlices − 1
0.3
· (NMax − NMin)

(2.1)
NMax stands for the maximum, NMin for the minimum number of rescansr and NSlices is the number of
IESs. Furthermore, i corresponds to the chosen IES.
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Simulation Parameters
To investigate the effectiveness of the applied motion mitigation technique, different sets of dose cal-
culations were performed, determining target coverage and doses deposited in several OARs in close
proximity of the target volume. After optimization and calculation of a 3D dose distribution, additional
4D simulations were carried out to estimate the influence of motion effects on the uncompensated and
compensated treatment. Therefore three different sets of 4D simulations were realized:
1. Interplay - 4D Simulations taking into account the motion effects assuming no motion mitigation
technique for the heartbeat is applied.
2. Homogeneous Rescanning - 4D Simulations applying a conventional homogeneous rescanning
scheme with 15 rescans in each IES.
3. Inhomogeneous Rescanning - 4D Simulations applying the inhomogeneous rescanning scheme
developed for the feasibility study.
To investigate the sensitivity of the dose distribution with respect to changes in the motion period and
to ensure the robustness of the treatment plan, all simulations were performed using variations of three
different parameters: heart frequencies, regularity of the heartbeat and spill structure. For all pigs the
heart frequency was simulated using two different motion surrogates, both are shown in Figure 2.4.
Time (s)
(a) Irregular ECG motion. The blue line
correspond to the measured voltage and
the orange line represent the correspond-
ing motion surrogate used for the treat-
ment planning as input data.
Time (s)
(b) Regular sine wave motion surrogate.
Each period of the sine wave corresponds
to one heartbeat.
Figure 2.4.: Scheme of the two different types of motion surrogates.
One was a measured ECG trajectory recorded of an arbitrarily chosen pig at Mayo Clinics (Mayo), the
second one is a regular sinus function. These trajectories were scaled to an average value of 60, 70 and
80 beats per minute, corresponding to heart rates expected during the irradiation. As the timing of the
sinus function is regular, a sinusoidal motion surrogate represents constant heart rate during the full
treatment time. In contrast to this, the measured and scaled ECG trajectory shows an irregular behavior
and, hence, corresponds to a slightly varying heart rate over the time of the treatment.
In addition, the 4D simulations were carried out for 8 different starting phases to investigate the
outcome for different temporal correlations between the beam delivery sequence (BDS) and the target
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motion. One spill structure is a constant particle intensity over the whole extraction time, while the
other one is a Gaussian shaped intensity behavior. Combining all simulation parameters yielded 96
simulations per pig for each of the interplay, inhomogeneous and homogeneous rescanning scenarios.
Hence, in total 14 3D simulations, 1344 interplay and 2688 rescanning simulations were conducted to
ensure plan robustness, a satisfying target coverage and an efficient sparing of the OARs.
Data Analysis
Several parameters were used to verify the quality of a treatment plan. The main aim of the treatment
planning presented in this work was to reach a homogeneous dose distribution avoiding underdosage in
the target volume, while overdosage was seen as less critical. Furthermore, the dose deposited in the
OARs was examined to avoid overdosage. The main parameters for the analysis of the target coverage
are the minimum dose to 95 % of the target volume (D95), the volume that received at least 95 % of the
planned dose (V95) and, finally, D5-D95, as a measure for the dose homogeneity of the target volume. In
addition, the dose to the OARs was assessed as dose volume, maximum point dose and mean dose. The
results for the PTV could only be only determined for the AVN and SPV irradiation. Due to the different
margin approach for the LV, no geometric PTV was defined.
2.1.6 Quality Assurance
Prior to the experiment, quality assurance (QA) was carried out once, validating the focal spot size, beam
position and range, dose homogeneity and selected safety features. In addition, a daily QA was carried
out every morning checking the beam position and dosimetry.
The nights before treatment, treatment plan QA was performed. All treatment plans were irradiated
into a water phantom equipped with 24 pin-point ionization chambers (Type 31009, PTW, Freiburg,
Germany). The pin-points were placed in a plastic holder with a distance of 12 mm in lateral direction
and 10 mm in depth. Furthermore, the 24 pin-point ionization chambers were arranged at three different
heights with a 6 mm distances between each level to avoid shielding of the distal chambers by the
proximal ones. To increase the resolution of the measurement, it was repeated 2 to 3 times on average
with the pin-point holder at different positions allowing a minimal resolution of 4 mm.
The pin-point holder was attached to an industrial robotic arm (Kuka KR5 sixx R850, Augsburg, Ger-
many), which was able to follow the trajectory of the target. The motion trajectories were extracted from
the 4DCT registration and can be found in 2.9. This allowed 4D verification in addition to the standard
3D one. In Figure 2.5 the experimental set-up is shown.
To analyze the recorded verification data, two different tools were used. First of all, a read out software
is available for the MP3 water phantom [Kar99], which allowed online read out and verification. On
the other hand extract+, a command line based program developed at GSI, was used to analyze the
data [Ric12]. This tool includes an optimization algorithm to determine the most probable position of
the pinpoint holder corresponding to the best agreement between measurement and simulation. This
algorithm was used to detect systematic set-up errors during the verification. Hence, a set-up error was
determined in the final analysis for each night.
36 2. Feasibility Study of Catheter-Free Ablation using Carbon Ions in Pigs as an Animal Model
Figure 2.5.: Experimental set-up for 3D and 4D dose verification. 1) robotic arm, 2) ionization chambers,
3) Laser distance sensor, 4) water phantom
For the 3D analysis, an average agreement of all 24 pinpoints was calculated for each plan. In Sec-
tion 2.2.1 the agreement of all plans is presented. For the 4D analysis, the dose at the average position
of the ionization chamber was compared to the result of the calculated dose distribution.
To allow the irradiation of a treatment plan a maximum mean deviation of 5 % was accepted. Higher
deviations for single ionization chambers were allowed due to the high gradients within and the small
size of the fields. However, in case of higher deviations it was always double checked if the corresponding
pinpoint was positioned in a gradient.
2.1.7 Positioning, Preparations and Treatment
After sedation, the animals were transported from the preparation room to the irradiation room. The
respirator and the propofol infusion were connected before positioning the pigs. After a pig was adjusted
to all markers, supporting structures were double checked for the correct vertical and horizontal position
of the hip to avoid contortion of the pig. Immediately before the treatment, the exact position was
controlled using orthogonal X-rays. The recorded images were compared with the projections of the CT
scans used for treatment planning. In Figure 2.6 the whole set-up of the experiment in the irradiation
room is shown.
Data Acquisition during Treatment
Three different data acquisition systems (DAQs) were used during the treatment. The ECG signal and
the BDS were recorded with a real-time data acquisition system, a Beckhoff EtherCAT system (Beckhoff
Automation. Verl, Germany), to provide a time correlation between the BDS and the heart motion for
4D dose reconstruction. In addition, a second Labview based DAQ system (National Instruments, Austin,
TX, USA) was used to redundantly store identical information. Furthermore, the Labview system was
applied as a remote control for the respirator.
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Figure 2.6.: Panoramic view of the treatment room at GSI. 1) DAQs and respirator control, 2) oxygen
and medical air for ventilation, 3) pulsoxymeter and ECG monitor, 4) patient couch, 5) pig
immobilization device, 6) PET cameras, 7) ventilator, 8) horizontal X-ray system, 9) vertical
X-ray system. Figure courtesy of Matthias Prall.
Information about the delivered treatment plans was recorded by the TCS, which stored the actual po-
sition of the pencil beam in horizontal and vertical direction as well as the number of particles delivered
to each raster point.
ECGs
The ECGs recorded during the irradiation were analyzed to investigate the change in the heart rate
during the treatment. Additionally, the analysis was used to check the correct conversion of the recorded
ECG to the motion surrogate used for the 4D dose reconstruction. Therefore the average, minimum
and maximum heart rates were determined for each field and pig during the irradiation. In addition,
the change in the heart rate between field 1 and field 2 and the behavior of the heart rate during the
irradiation was investigated.
2.1.8 Dose Verification Methods
Two different types of dose verification methods, in-room positron emmission tomography (PET) imaging
and 4D dose reconstruction, were applied to gain information on the quality of the treatment. Neverthe-
less, both methods cannot conclusively verify the success of the treatment. While the 4D dose reconstruc-
tion cannot include positioning uncertainties, PET imaging can only display deviations to the planned
dose position, as both techniques rely on the 4DCT used for the treatment planning. Furthermore, the
activity maps obtained from the PET imaging are not proportional to the deposited dose.
In-Room PET Imaging
A two-head in-room PET (CTI PET Systems Inc., Knoxville, TN, USA) was installed in the irradiation
room, which allowed a measurement of the actual beam penetration depth. Therefore reconstructed
activity maps are overlaid with the treatment planning CTs to visualize the position of the deposited
dose. To gain the activity maps radioactive fragments produced due to fragmentation processes during
treatment, emitting β+-activity, are measured. In-room PET can be successfully used as a quality control
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for the irradiation with carbon ions providing valuable information about the actual penetration depth
of the ions [Par07].
The PET images were taken in the spill pauses and after the irradiation under breath-hold. The
measurement time for the PET analysis was between 10 and 39 min. During this time the respiration
of the pigs was frequently stopped and data was taken. The measurement always took place after the
irradiation of the first field. More details can be found in [Hel14,Leh16b].
4D Dose Reconstruction
The ECGs of all pigs were recorded during the treatment. On the one hand, ECGs gave information on
the health status of the pigs. On the other hand, these ECGs were used as motion surrogate for 4D dose
reconstructions to gain information on the actual dose delivered during the treatment. Besides the ECG
also the BDS was recorded providing the temporal correlation between the irradiated raster point and
the corresponding motion phase.
To conduct the 4D dose reconstruction, the data already used for the treatment planning is needed,
including the DIR and the planning CT. This data is combined with the data recorded during irradiation
to calculate the actual delivered 4D dose distribution. These steps could be performed in less than one
hour after the treatment, allowing a first feedback on the quality of the irradiation. Furthermore, a 4D
dose reconstruction using the actual delivered particle number and position of each raster point recorded
by the TCS was performed to also account for uncertainties of the beam delivery.
For the 4D dose reconstruction a graphical user interface (GUI) was developed to facilitate the pro-
cessing of the data and the creation of the files for the treatment planning. A more detailed description
of the general process of a 4D dose reconstruction can be found in [Ric14]. Further details on the GUI
and the reconstruction procedure for this experiment will be published in [Ricb].
2.1.9 Biological Endpoints
The biological endpoints investigated are: fibrosis, cell death to eliminate cardiomyocytes, dysfunctions
of cardiomyocytes, inflammation processes and vascular damage in the irradiated area. For detailed
descriptions of the biological processes the reader is referred to [Pre10,See12,Boe11,Fan12,Sag13].
All of these processes are considered to be meaningful for the interruption of the conductivity of the
targeted structures. Therefore a pathological examination was carried out directly after the withdrawal
of the heart and lung package. To facilitate the identification of the scar tissue within the heart muscle,
a redox indicator (triphenyltetrazolium chloride) was used to improve the visibility of the fibrotic tissue.
For a deeper understanding a histological and a protein analysis was carried out afterward in the lab-
oratories of GSI and UCHD. If possible, two different samples were taken for each anatomical structure.
For preservation, samples for the histological analysis were fixed in 4 % formaldehyde and samples for
the protein analysis were shock frozen with dry ice. The further processing methods of both probes are
described in detail in [Fou04,Sim10].
For the histological analysis the tissue samples were embedded in paraffin and cut in slice. Afterwards
a Hemotoxylin-Eosin as well as Mallorys Trichrome staining was performed. The analysis allowed the
investigation of the amount of bleeding in the tissue and the examination of structural changes in the
2.1. Material and Methods 39
cardiomyocytes. Further details on the techniques used for the histological analysis can be found in
[Sim10].
In addition, a protein analysis was carried out to investigate the presence of apoptosis at two time
points, 3 and 6 months after irradiation. This was done by determining the amount of cleaved caspase
3, which is a common marker for apoptosis, in the protein extractions. The protein expression was vi-
sualized using chemiluminescence (ECL, Amersham Biosciences) and detected on films (ECL-Hyperfilm,
Amersham Biosciences). Further details on the protein analysis in general can be found in [Fou04].
2.2 Results
The following section provides an overview of the experimental results. A detailed analysis is given
for the treatment planning process and the results of all other topics are summarized. Further details
and analysis of the latter sections can be found in [Leh16b, Erb15, Gra14, Eic15] or will be published
in [Pra, Kad, Ricb]. Throughout this chapter all results are either given as mean values with standard
deviation (mean ± standard deviation) or as median values with the range between the 25th and 75th
percentile (median (25 % - 75 %)).
2.2.1 Quality Assurance
The set-up error of the 3D and 4D dose verification were determined to be between 0.3 and 2.5 mm in
depth, 0.6 - 1.4 mm in vertical and 0.0 - 0.8 mm in horizontal direction. The former are relatively large
and were caused by the limited time to set-up the verification equipment.
Figure 2.7.: Deviations of the 3D verification measurements in the water phantom from the planned
dose. For each pig the mean value of both fields including all 24 pinpoint ionization cham-
bers and the standard deviation of the deviations is shown. The different target groups are
indicated with dashed lines. From left to right, the results for AVN, SPV and LV irradiations
are shown.
Verification was carried out for all 14 irradiated pigs. For Pigs 15 and 17, only a 4D QA was performed
due to limited beamtime and promising results of the previous 4D verifications. For the remaining 12
pigs a 3D verification was performed in addition to a 4D verification. After the correction of the system-
atic positioning errors, the overall deviations between measured and planned dose were 1.9 ± 4.6 %
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and 0.8 ± 5.3 % for 3D and 4D dose verification, respectively. The calculated standard deviation was
increasing with decreasing field size due to the high gradients and the poor resolution of the set-up. In
Figure 2.7 the results for the 3D verification for each pig are shown. Detailed results for the 3D verifi-
cation showing the results for each pig and field can be found in Table A.1. All plans were within the
stated limits and therefore accepted for treatment.
2.2.2 ECGs
The average heart rate was found to vary between 50 bpm and 89 bpm during. For all pigs combined
the average heart rate was 65 ± 10 bpm. A detailed overview of heart rates for all pigs and fields can be
found in the Table A.2. An exemplary ECG behavior during irradiation is displayed in Figure 2.8(a). A
similar behavior was found for the majority of the pigs, although not always as pronounced as shown in
the figure. While the heart rate is regular before the treatment starts, it decreases during the breath-holds
and increases again when the respirator is turned on.
The differences in the average heart rate between field 1 (90 degrees) and field 2 (270 degrees) can
be found in Figure 2.8(b). In general, a increase of the heart rate between the irradiation of field one
and field two was found. This can be explained by the reduced impact of the premedication, which is
known to reduce the heart rate [Aza].
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(a) Exemplary time dependent behavior of the
ECG during irradiation. The displayed trajectory
was measured in Pig 13 during the irradiation of
the first field. While in black the heart rate is
visualized, the blue areas correspond to the time
windows when the respirator was switched off.
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(b) Average heartbeat and standard deviation for
each pig and field. Different target groups are in-
dicated with a dashed line. From left to right AVN,
LV and SPV are shown.
Figure 2.8.: Analysis of the measured heart rates during the irradiation.
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2.2.3 Motion of Targeted Substructures
The displacement of the center of mass of the three target areas due to the heartbeat is shown in Fig-
ure 2.9 for all pigs. The absolute value of the motion amplitude vector is plotted as a function of the
motion phase, relative to the reference phase.
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Figure 2.9.: The displacement of the center of mass of the target volume for all motion phases relative to
the reference phase. The figures corresponds to the three different targets, the AVN group
(a), the LV group (b) and the SPV group (c). Each pig is represented by one line. The depicted
uncertainties shown for all motion phases are the calculated standard deviation.
The displacement of all target volumes is chaotic and varies strongly between the different pigs for all
motion directions. In the studied animal cohort, the AVN group showed the biggest motion amplitude
with maximal displacements of 3.8 ± 0.5 mm. For SPV and LV maximal displacements of 3.9 mm and
4.4 mm were determined, respectively. For the AVN, the motion direction with the largest displacement
was found to be anterior-posterior with a mean value of -3.0 ± 0.5 mm. For the LV and the SPV group
it was not possible to determine a major direction of the motion amplitude. The maximal displacement
from the reference phase is stated for each pig and each motion phase in Table A.3. It was found that
the maximal displacement for all target volumes is occurring in motion phase 2 or 3, at 20 % or 30 %
of the cardiac cycle. These motion phases correspond to the ventricular systole, where the maximum
of the ventricular contraction is reached. However, Pig 14 shows a different behavior lacking any clear
maximum motion amplitude.
The presented motion trajectories express the knowledge at the time of the experiment. In Chapter 3
further details are given on the displacement of the targets and the accuracy of the applied DIR used to
determine the displacements of the heart structures.
2.2.4 Treatment Planning
The following section summarizes the results of the treatment planning process for the feasibility study.
All results presented are calculated with the level of the knowledge before and shortly after the experi-
ment. To facilitate the understanding a consistent color scheme is applied throughout this section. In all
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figures orange, green, blue and light blue are used for static, interplay, inhomogeneous and homogeneous
rescanning simulations, respectively.
Target Coverage
Exemplary dose distributions of rescanned 4D simulations for all three targets are shown in Figure 2.10.
Detailed results for the target coverage of the different simulations types are given in the corresponding
subsections.
Figure 2.10.: Exemplary dosecuts for all targets in axial (left), sagittal (middle) and coronal (right) view.
Dose distributions for AVN, LV and SPV are shown in the top, middle and bottom row,
respectively. The targeted area is marked in blue, while the red and pink areas display the
areas with more then 95 % of the planned dose.
Static Simulations
D95 and V95 are greater or equal to 100 % for TV and PTV in all pigs. The homogeneity index D5-D95
varies between 0.06 % and 4.46 % for all pigs. In Figure 2.11 D95, V95 and D5-D95 values are shown for
all static simulations. An overview of the results is given in Table 2.3. Further results can be found in
Figure A.1 and Table A.4.
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(b) Simulation results for the PTV.
Figure 2.11.: The results for V95, D95 and D5-D95 for TV and PTV are shown for static, interplay, in-
homogeneous and homogeneous rescanning simulations. From left to right AVN, LV and
SPV results are shown. Single target groups are separated by solid black lines, single pigs
are separated by dashed gray lines. Static, interplay, inhomogeneous and homogeneous
rescanning results are shown in orange, green, blue and light blue, respectively. The me-
dian value is indicated with a solid line, the boxes represent 25 - 75 % of the data and the
whiskers showing 1.5 times the inner quartile range. Outliers are indicated with dots.
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TV PTV
D95 [%]
AVN 102.8 (101.1 - 102.9) 101.8 (101.7 - 101.8)
SPV 102.9 (102.2 - 103.0) 101.8 (101.8 - 101.8)
LV 101.9 (101.8 - 101.9) -
V95 [%]
AVN 100.0 (100.0 - 100.0) 100.0 (100.0 - 100.0)
SPV 100.0 (100.0 - 100.0) 99.8 (99.3 - 99.9)
LV 100.0 (100.0 - 100.0) -
D5-D95 [%]
AVN 2.0 (1.0 - 3.2) 1.4 (1.3 - 2.0)
SPV 1.6 (1.5 - 2.3) 2.5 (1.8 - 2.7)
LV 1.3 (1.2 - 1.3) -
Table 2.3.: Results showing the target coverage and dose homogeneity of all static simulations. Results
are given as median values with the range between the 25th and 75th percentile.
Interplay Simulations
In Figure 2.11 the results for the interplay simulations are displayed in green. Compared to the static
simulations, the interplay calculations showed reduced values for the median D95 as well and the median
V95 in the TV. In addition, the dose homogeneity values are decreased. The reduction of the median V95
and D95 values as well as the increase of the median D5-D95 is more pronounced for the PTV. Further
details stating the uncertainties of the results of the interplay simulations are listed in Table 2.4.
TV PTV
D95 [%]
AVN 98.1 (94.9 - 101.6) 92.6 (88.6 - 95.2)
SPV 96.4 (94.8 - 98.1) 92.4 (89.4 - 94.8)
LV 97.6 (96.0 - 98.8) -
V95 [%]
AVN 100.0 (88.9 - 100.0) 85.0 (74.0 - 92.9)
SPV 96.2 (91.3 - 99.2) 88.0 (83.1 - 92.4)
LV 98.3 (95.0 - 99.7) -
D5-D95 [%]
AVN 8.8 (6.5 - 11.9) 18.0 (14.4 - 22.6)
SPV 12.0 (9.9 - 15.7) 16.8 (13.2 - 20.2)
LV 10.2 (8.0 - 12.3) -
Table 2.4.: Results showing the target coverage and dose homogeneity of interplay simulations. Results
are given as median values with the range between the 25th and 75th percentile.
In general, no significant differences in the TV and PTV between different combinations of spill struc-
ture and regularity of the heartbeat were found, as it can be seen in Figure 2.12. Nevertheless, the
influence of the BDS and the motion trajectory on 4D dose distributions are visible. In the appendix
detailed results for the interplay simulations are given in Figure A.2, in Table A.5 and in Tabel A.8.
Homogeneous Rescanning Simulations
For the TV the median D95 is 101.1 % , 100.1 % and 100.3 % for AVN, LV and SPV, respectively. The
median values for the PTV are 97.0 % and 94.5 % for AVN and SPV, respectively. A similar behavior can
be seen for the median V95, which is 100 % in the TV for AVN, LV and SPV and decreases to 97.3 % and
93.3 % for the PTV for AVN and SPV, respectively. The median D5-D95 increases from 3.1 % to 8.3 % for
AVN and from 5.5 % to 11.3 % for SPV. The D5-D95 for LV is 4.0 %. A reduction of the PTV coverage was
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Figure 2.12.: Results for D95 for the interplay simulations split by the three different target volumes and
TV and PTV. For all pigs the data is separated into the four possible combinations of the
spill structure and regularity of the the heartbeat. Each boxplot contains 24 4D simulations.
The median value is indicated with a solid line, the boxes represent 25 - 75 % of the data,
whiskers show 1.5 time the inner quartile range. Outliers are indicated by dots.
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found for some pigs. For Pig 6, 8, 12 and 13 median V95 and D95 are below 95 %, indicating underdosing
within the targeted volume.
More detailed results for the homogeneous rescanning simulations can be found in Table 2.5 and in
the appendix in Figure A.3 and Table A.6, stating for V95, D95 and D5-D95 the median values and the first
and third quartile for each pigs.
TV PTV
D95 [%]
AVN 101.1 (99.6 - 102.6) 97.0 (92.9 - 99.3)
SPV 100.3 (99.0 - 101.0) 94.5 (90.1 - 97.5)
LV 100.1 (98.7 - 100.8) -
V95 [%]
AVN 100 (100.0 - 100.0) 97.3 (87.5 - 100.0)
SPV 100.0 (99.7 - 100.0) 93.3 (89.0 - 97.0)
LV 100.0 (99.7 - 100.0) -
D5-D95 [%]
AVN 3.1 (2.1 - 4.5) 8.3 (5.6 - 12.7)
SPV 5.5 (4.0 - 7.6) 11.3 (9.4 - 14.6)
LV 4.0 (3.0 - 7.0) -
Table 2.5.: Results showing the target coverage and dose homogeneity of homogeneous rescanning
simulations. Results are given as median values with the range between the 25th and 75th
percentile.
Inhomogeneous Rescanning Simulations
The target coverage of the inhomogeneous rescanning scheme is reduced compared to the homogeneous
scheme. Mean D95 of the TV was found to be 99.8 % , 99.4 % and 98.7 % for AVN, LV and SPV,
respectively. In the PTV, D95 is 95.4 % (AVN) and 94.0 % (SPV). The TV results show a V95 and D95
above 95 %, the results for the PTV are still above the acceptance level. The same trend can be seen for
the median values of V95, which are 100 % for the TV for AVN and LV and 99.7 % for SPV. For the PTV
V95 decreases to 92.9 % and 92.2 % for AVN and SPV, respectively, which is below the aspired threshold
of 95 %. Compared to the interplay simulations, inhomogeneous rescanning could improve the target
coverage by increasing the median values of the D95 and V95 by 2 % and 3 %, respectively. The dose
homogeneity was improved, indicated by decreasing the median D5-D95 values by a factor of 0.41. The
details can be seen in Figure 2.11, where the overview of the results for all simulations is shown.
TV PTV
D95
AVN 99.8 (97.4 - 102.0) 95.4 (91.8 - 97.7)
SPV 98.7 (97.2 - 99.8) 94.0 (90.3 - 96.9)
LV 99.4 (98.5 - 100.0) -
V95
AVN 100.0 (100.0 - 100.0) 92.9 (83.9 - 98.9)
SPV 99.7 (98.0 - 100.0) 92.2 (88.1 - 96.5)
LV 100.0 (99.7 - 100.0) -
D5-D95
AVN 5.8 (4.2 - 7.8) 12.0 (9.0 - 16.4)
SPV 8.0 (6.7 - 10.1) 12.8 (9.4 - 15.9)
LV 6.2 (5.2 - 7.3) -
Table 2.6.: Results showing the target coverage and dose homogeneity of inhomogeneous rescanning
simulations. Results are given as median values with the range between the 25th and 75th
percentile.
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Figure 2.13.: Results for D95 for the inhomogeneous rescanning simulations split by the three different
target volumes and TV and PTV. For all pigs the data is separated into the four possible
combinations of the spill structure and regularity of the heartbeat. Each boxplot contains
24 4D simulations. The median value is indicated with a solid line, the boxes represent 25
- 75 % of the data and the whiskers show 1.5 times the inner quartile range. Outliers are
indicated by dots.
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None of the combinations of spill structure and heartbeat regularity showed an improved target cov-
erage for all pigs. However, for some pigs slight increases in the target coverage could be found for
one of the combinations, as it can be seen in Figure 2.13. For Pig 13 the combination of a Gaussian
spill structure and a irregular motion shows a dramatic worsening of the results compared to the other
combinations with a significant decrease of median D95. Further details are given in Table 2.6 and in the
appendix, where target coverage and dose homogeneity is shown for each pig in Table A.7. Table A.9
gives more details on the influence of the spill structure and the BDS on the 4D simulations.
Irradiation Times
On average, using the inhomogeneous rescanning scheme, the treatment time could be reduced by
66.7 ± 4.1 % compared to the homogeneous schemes. As the time reduction potential depends on
the size of the target volume, time savings are increasing with increasing field size. In Figure 2.14 the
differences for the irradiation times for homogeneous and inhomogeneous rescanning are shown as well
as the treatment time reduction for each pig. In Table A.10 an overview of the time savings achieved by
using the inhomogeneous rescanning scheme is given.
The results shown in Figure 2.14 are pure irradiation times from 4D simulations. In the experiment
the times necessary for the respiration of the pigs have to be added too. The average treatment time
for the irradiation including the respiration time was found to be 10.7 ± 3.6 min, 23.9 ± 8.6 min and
36.2 ± 11.9 min for AVN, LV and SPV, respectively. A detailed analysis of the irradiation times per field
and per pig can be found in A.11.
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Figure 2.14.: Differences in the treatment time between homogeneous and inhomogeneous rescanning.
Organs at Risk
For all pigs with an irradiation of the AVN and LV, the maximum dose deposited in the LCA and RCA
could be kept below 30 Gy. The maximum point dose in the Aorta and, in general, the maximum point
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doses in the substructures of the heart were in the region of the target dose due to their anatomical
proximity to the targeted area. However, the mean doses in all investigated structures were below the
target dose. In addition, dose volume constraints were analyzed for certain OARs. It was shown that for
all structures stated in Table 2.2 the dose volume constraints could be kept. Figures A.5, A.7 and A.6
illustrate the excellent sparing of the critical structures due to the use of carbon ions.
Furthermore, several critical structure as, for instance, the trachea and the esophagus could be com-
pletely spared for the AVN and the LV irradiation. Respective doses for the SPV treatments were far
below the limits. An overview of the maximum and mean doses in the most important OARs is given in
Figure 2.15, where the expected doses deposited in the OARs are given for static as well as rescanning
simulations.
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Figure 2.15.: Mean and max dose deposited in the OARs during rescanned 4D treatments (blue) and ideal
static treatments (orange). The results are shown for AVN, SPV and LV from left to right.
The static boxes summarize the results for all pigs of the corresponding target groups, while
the blue boxes include all results of the 96 4D simulations for all pigs of the corresponding
target group. The median value is indicated with a solid line, the boxes represent 25 - 75 %
of the data, whiskers show 1.5 times the inner quartile range. The ascending aorta and
myocardium are abbreviated as AscAorta and Myo, respectively.
The doses deposited in the OARs vary only slightly. While for some structures a dose reduction is
found in the 4D simulations, for instance, for the AVN during the treatment of the SPV pigs, slight dose
increases could be found for the LCA and RCA for the AVN target group. However, no severe overdosage
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was found due to the used motion mitigation technique. A detailed overview of the doses deposited in
all OARs for static and 4D simulations is given in Tables A.12 and A.18.
2.2.5 In-room PET
The in-room PET was successfully used for online verification of the beam range. A 3D measurement
was performed for one field of 12 pigs. Figure 2.16 shows exemplary activity distributions for all three
target volumes.
Figure 2.16.: Activity maps for all three target volumes. The activity is given in arbitrary units and is
increasing from blue to red. From left to right a LV, an AVN and a SPV example is shown.
The activity map is overlaid with the contrast enhanced CT used for contouring and DIR. For
the first two targets the beam entrance is on the left side of the CT, while the beam enters
the pig from the right side for the SPV irradiation. Figure adapted from [Hel14]
The activity maps were overlaid with the planning CT for all measured fields. Good correlations
between the activity hot spots corresponding to the Bragg peak region and the targeted structures,
marked with red contours, can be seen. The high activity in the chest indicates the entrance channel of
the beam. The reduced activity in the targeted structure compared to the entrance channel is due to the
strong blood flow causing a biological washout of the radioactive fragments in the heart. This effect has
the biggest influence on the PET images of the SPV pigs.
2.2.6 4D Dose Reconstruction
A successful 4D reconstruction was possible for 11 pigs. The reconstruction of the remaining pigs failed
due to technical problems with the DAQ. First preliminary results were available 30 min after the
irradiation. Final results were calculated offline. An overview of the results for the target coverage in TV
and PTV is given in Figure 2.17.
Apart from Pig 8, where D95 is 89.55 %, the D95 was found to be greater 95 % for the TV. The reduced
TV coverage for Pig 8 can be explained by technical problems with the DAQ and the accelerator during
the irradiation. The target coverage in the PTV is generally lower, especially for pigs 2 and 6. The small
D95 value for Pig 8 in the PTV reconstruction is a direct consequence of the result in the TV reconstruction
and it is founded in the same technical problems.
For the OARs, all dose volume constraints stated in Table 2.2 could be kept and were comparable
to the 4D simulations shown above. This is also the case for the maximum and the mean dose de-
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posited in the critical structures. In general, no significant deviation between the simulations and the 4D
reconstructions was found for the target coverage as well as for the doses deposited in the OARs.
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Figure 2.17.: Results of 4D dose reconstruction for TV and PTV. The blue bar represents the median value
of all 96 inhomogeneous rescanning simulations for the corresponding pig. The gray bar
shows the results for the 4D dose reconstruction. A critical target coverage reduction be-
tween TV and PTV was found for pigs 2, 6 and 8. Figure courtesy of Daniel Richter.
2.2.7 Biological and Medical Study Outcome
After the experiment, the animals were kept for up to 24 weeks. During the follow-up, three animals (3,
5 and 6) died due to inflammation around the pacemaker electrodes. For Pig 1 and 4, complete AV-blocks
were found 17 weeks after the irradiation. While the AV-block was permanent for Pig 1 and could be still
recorded during the final follow-up examination 24 weeks after the irradiation, the complete AV-block
vanished for Pig 4 and only a persistent slowing of the conduction could be found during the final follow
up.
Skin toxicity was investigated during the first 9 weeks of the follow up. No changes of the skin within
the entrance channels were found. Critical structures like esophagus, trachea and coronary arteries were
carefully examined during the final follow-up. No radiation related side effects were observed during
the whole study.
While for Pig 13 and 14 only sporadic fibrotic tissue could be found within the targeted volume, Pig
12 showed an almost complete isolation of the SPV. However, the electrophysiological examinations of
Pig 13 and 14 showed statistically significant decreases in the conductivity.
For all LV animals, changes in the electrical conductivity of the left ventricle were found. Even though
the histological analysis showed structural changes in the cardiomyocytes within the whole thickness of
the heart muscle, epi- and endocardial fibrosis was only found in parts of the targeted area. The extent
of fibrotic tissue varied between pigs, ranging from tiny fibrotic spots in pig 17 to clear fibrotic areas in
pig 14 with epi- and endocardial scars.
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Different biological endpoints were investigated by specialists, in the following a short summary will
be given for completeness.
Pathological Results
For all targets it was possible to identify macroscopic lesions within the targeted area in the heart muscle.
No additional lesions were created in the surrounding critical structures for any pig, except Pig 12, where
fibrotic tissue was found throughout the left atrium. In Figure 2.18 an exemplary result is shown for each
target volume.
(a) Lesions (marked with dashed lines) after irradi-
ation of the AVN.
(b) Lesion after the SPV irradiation,
showing fibrosis and bleeding.
(c) Epi- and endocardial lesion after the irradiation
of the left ventricle. Targeted area marked with
dashed lines.
Figure 2.18.: Pathological analysis for all three target groups 6 month after the irradiation. Important
anatomical structures are marked. In (a) and (c) lesions are indicated with dashed lines.
Figure adapted from [Leh16b].
Histological Results
For all animals with macroscopically visible lesions, fibrotic tissue and persistent bleeding was found
in the target area, as is can be seen in Figure 2.19b. The amount of hemorrhage was reduced after 6
months compared to the findings after 3 months. The amount of scar tissue was increased after 6 month
compared to 3 month indicated by the reduced number of pink and the increased number of blue areas
between Figure 2.19 b and c, as the blue color corresponds to an increased amount of collagen indicating
fibrosis.
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Figure 2.19.: Histological results showing the outcome of a Mallory Trichrome staining. Figure adapted
from [Leh16b].
Protein Analysis
Western blots from the protein analysis are shown in Figure 2.20. Three months after the irradiation
apoptosis was found in tissues samples of the irradiated animals. However, no apoptosis could be found
in the control animals and the apoptosis peak was already over in the animals euthanized 6 months after
the treatment. These findings indicate that the process of apoptosis finished between 3 and 6 months
after irradiation.
Figure 2.20.: Results of Western blotting. The left Western blot shows the results for an irradiated pig,
while the right one shows the results for the same analysis for a sham irradiated pig. Figure
adapted from [Leh16b].
The dose dependence is shown in Figure 2.19d-f were tissue slices for AVN targets are shown for all
three dose groups. Effects in the organization of the cardiomyocytes and apoptosis can be seen for all
dose groups. However, the findings are more pronounced for 40 and 55 Gy, where a strong fibrotic
response is visible, while only minor changes could be found for 25 Gy.
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2.3 Summary and Discussion
This is the first in-vivo study showing the potential of carbon ions to alter electrical pathways in the
heart muscle. The study was carried out at GSI irradiating 15 pigs in total. The successful application
of 4D treatment planning was demonstrated, including the feasibility to conduct such a treatment with
the standard equipment available in heavy ion centers. The presented data suggests a homogeneous
dose deposition to the targeted structures and shows an excellent sparing of the OARs, which was also
confirmed by the examination of the removed heart and lung of the euthanized animals. In addition, the
used motion mitigation techniques, repeated breath-holds and rescanning, could successfully account
for the interplay effect for the majority of the pigs. Overall, the study showed that carbon ion therapy is
a reasonable alternative to radio-frequency catheter ablation. It allows to induce persistent changes of
the cardiomyocyte conductivity using doses of 40 Gy and higher.
Motion Mitigation - Homogeneous Rescanning vs. Inhomogeneous Rescanning Simulations
As it is necessary for carbon ion irradiations to account for the motion caused by the heartbeat, rescan-
ning was selected as the most promising motion mitigation technique. It combines an easy to implement
approach with an effective reduction of interplay effects. Nevertheless, all this comes at the cost of
an increased target volume and prolonged treatment times. Other motion mitigation alternatives, such
as, cardiac gating, could reduce the treated volume as already investigated in [Con14, Con16]. How-
ever, rescanning is simpler and less prone to technical problems whereas the drawback of an increased
treatment time is known for both approaches. In addition, due to the short spill durations at GSI, the
treatment time prolongation is more pronounced for cardiac gating than for rescanning. Even though a
standard homogeneous slice-by-slice rescanning scheme significantly improves the target coverage and
dose homogeneity, simulations of the BDS showed that it was not fast enough to irradiate all pigs during
the available beamtime. Therefore, a new inhomogeneous rescanning scheme was to the number of
rescans from the distal to the proximal slice. This shortened the treatment time to approximately one
third and allowed the irradiation of 15 pigs during 5 days including quality assurance, positioning and
PET imaging.
A slight reduction of the target coverage could not be avoided due to the use of the inhomogeneous
rescanning scheme compared to a homogeneous one, increasing the susceptibility of the treatment plans
to motion effects. However, no significant changes in the success rate of the study are expected due to
the use of the inhomogeneous scheme. In TV and PTV the found reduction in the median D95 and V95
values of the single pigs were below 2.5 % and 5.3 %, respectively. The largest reduction in the target
coverage is seen in Pig 2 and 7. In contrast to this, for Pig 13, the use of the inhomogeneous rescanning
scheme even seems advantageous, showing a slight increase in the median D95 as well as in V95 and
a reduced inner quartile range for the 4D simulations. Even though this can occur due to a temporal
correlation between the target motion and the scanning motion of the beam, it is a surprising finding.
However, it is unlikely to appear during a real treatment as several additional random fluctuations, such
as, the fluctuations of the particle flux and the irradiation breaks due to the repeated breath-holds,
influence the irradiation. Using the inhomogeneous rescanning enabled a successful irradiation of all 15
pigs within the limited beamtime. However, the target coverage is varying for some pigs, for instance,
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Pig 6, indicating residual motion effects. The drawbacks of the inhomogeneous rescanning scheme, a
higher sensitivity to motion effects, slightly reduced target coverage and higher variations within the
4D simulation, were accepted with the goal to irradiate as many pigs as possible for a reliable study
outcome.
Treatment Planning
The applied margin strategy differed from the ones used in the studies of [Sha10b] and [Bla14]. During
the irradiation at GSI, reproducible repeated breath-holds were applied, which allowed to neglect the
breathing motion during the treatment planning. In previous studies, either a CyberKnife was used,
which can follow the breathing motion [Sha10b], or the breathing motion was considered in an ITV
margin approach for the study using a linear accelerator [Bla14]. However, for both photon studies it
was not necessary to compensate the heart motion as photon treatments are much more robust against
inter-fractional motion. This was an additional challenge for the treatment with carbon ions. The applied
margins in the presented study were relatively small to avoid radiation related side effects, as they were
later reported for the ITV margin approach in [Bod15]. This can be explained by the high amount of
OARs in close proximity to the target.
For all pigs, the mean doses deposited to the OARs were extremely low and well within the published
dose volume constraints [Gri11, Ben10]. The maximum point doses allowed were only exceeded for
structures close to the targeted volume or even within the applied margins. For instance, the maximum
point dose in the aorta was as high as the planned target dose or even higher. For the RCA it was
also not possible to stay below the self-imposed maximum point dose of 30 Gy for Pig 12 targeting
the SPV. In the 4D simulations for this pig, doses deposited in RCA were up to 20 % higher than the
allowed maximum point dose. However, no structural changes in the OARs were found during the follow-
up and pathological examination. Furthermore, it was possible to successfully spare critical structures
during the irradiation due to the inverse depth dose profile of carbon ions compared to photons as, for
instance, the esophagus [Con14]. In contrast to previous findings [Zac97, Ham00], the skin did not
show any reactions. A dose volume effect is discussed, as the targeted areas were small with a maximum
diameter of approximately 5 cm for the SPV and LV group and 3 cm for the AVN group. Alternatively, the
radio-sensitivity of the used pig breed might be lower compared to the breed used in previous studies.
However, the success rate of this study is low, especially when comparing the results with a twin study
using photons carried out at Mayo [Leh16a]. In the present study only 2 out of 6 animals of the AVN
group, that were irradiated with doses likely high enough to induce AV-blocks, showed a persistent AV-
block or extensive slowing in the signal conduction. While 3 animals out of this group died because of a
pacemaker infection, Pig 2 irradiated with 55 Gy did not show any incidence for a successful irradiation.
The reasons are likely to be found in the positioning, treatment planning or a combination of both. In
addition, dose volume effects could have an impact on the irradiation outcome due to the sharp dose
gradients compared to photon irradiations. A general problem in the AVN target group during the imag-
ing, treatment planning and treatment were the image artifacts caused by the implanted pacemakers,
although the image artifacts were reduced as much as possible by the use of the thinnest available pace-
maker leads (7 fr). Prior to the irradiation, dose calculations were carried out for an electrode placed in a
water phantom, which showed that the employed margins should be sufficient to compensate for poten-
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tial range changes due to the varying position of the electrodes in the heart. However, as the position of
the leads during the irradiation is unknown, a displacement of the leads in combination with positioning
uncertainties could significantly alter the treatment outcome and can, in the worst case, cause a com-
plete target miss. Even though all pigs of the LV and SPV group received the same dose, the results for
the LV and SPV group are heterogeneous. Especially the LV pigs did not show homogeneous transmural
fibrotic tissue on a macroscopic scale and even the amount of patchy fibrotic tissue was highly varying.
This is most likely caused due to registration problems underestimating the thickening of the left ven-
tricular wall during the heart contraction. The low success rates for the SPV pigs can be explained more
easily. Pig 14 was irradiated with a reduced target dose of 30 Gy as the dose deposited in the trachea
was otherwise exceeding the limitations. Therefore, the physicians decided to reduce the target dose to
not risk severe radiation induced side effects. In addition, for Pig 13 the irradiation was aborted due to
technical problems of the accelerator causing a reduction of the target dose.
Another reason for the low success rate of the study could be the relative low results for D95 and
especially V95 in the PTV of some pigs. Pig 2, contrary to the expectations showing no AV-block, is
one of the animals with significantly reduced target coverage in the PTV with median D95 and V95
values of 94.1 % and 89.0 %, respectively. In addition, the low D95 result in the PTV was confirmed
by the 4D dose reconstruction with a D95 of only 84.6 %. As the number of surviving pigs is limited,
it cannot be completely ensured that the result of the 4D dose reconstruction allows a prediction of a
successful treatment. However, comparing the results of the 4D dose reconstruction combined with the
final outcome of Pig 1 and 2 indicates a connection between both. This would support the findings
of [Ric14] that a 4D dose reconstruction is extremely valuable and can give information on the dose
deposited in targeted structures. Nevertheless, the PTV coverage is important in 4D dose reconstruction
as the approach relies on the treatment planning CT and cannot take positioning uncertainties into
account.
In general, the reduced target coverage in TV and PTV indicates a lacking robustness of the treatment
plans. However, due to the use of a rescanning scheme with 15 rescans the low robustness is unexpected,
as the applied motion mitigation strategy should be sufficient to compensate any present interplay effects
[Ber08b]. One possibility could be, that the found reduction in the target coverage is only a simulation
artifact. During further analysis of the experiment problems with the image registration were detected,
especially for the inverse consistency, which could cause a insufficient propagation of the dose from each
motion phase to the reference phase. To verify this, the AVN position was marked by a physician in
each motion phase and the dose of all motion phases was accumulated to check if the target coverage is
satisfying over the full motion cycle. This topic is discussed in more detail in Chapter 3.
Furthermore, treatments using carbon ions are always prone to range deviations, due to anatomical
changes of the patient between the recording of the treatment planning CT and the irradiation. Especially
the position and the volume of the heart can cause uncertainties throughout the presented study. Further
studies are necessary to determine the reproducibility of the heart volume and position over a longer
time frame and for more then 3 pigs, as it was done during the preparation of this experiment. Another
problem for this experiment could be the growth and the weight changes of the pigs due to the young
age. In-between the planning CT and the treatment the highest weight changes were 13 % and -11 %
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for Pig 3 and Pig 8, respectively. While the weight gain is due to the growth of the pigs the weight loss
is due to the stress of the baseline examinations and pacemaker implantation.
One method to check for range changes is in-room PET [Par07, Bau13], which was applied during
the presented study. Other possibilities to determine range uncertainties during the irradiation can
be the detection of prompt gammas or prompt particles emitted during the irradiation [Pie14, Pri15].
Increasing the robustness would also be possible by improving the imaging modalities at the treatment
location. Instead of the use of orthogonal x-rays, either installing a CT on rails or using cone beam CTs
to gain a 3D position feedback would significantly increase the outcome. In addition, 3D imaging at
the treatment position would enable an improved outcome prediction using the 4D dose reconstruction
approach.
A step further is the consideration of all possible uncertainties during the treatment planning. In the
case of the presented study it is likely that the chosen margins were too small and could not account
for all possible error sources. A possibility to overcome this problem and to introduce margins cover-
ing all situations, also taking into account range changes, is the use of a robust optimization. Robust
optimization allows an incorporation of potential range changes and positioning uncertainties in the
treatment optimization. Several approaches are available to use robust optimization in proton ther-
apy [Pfl08, Fre11, Liu12]. The integration of robust optimization in TRiP4D is under development and
will offer new possibilities for carbon ion treatment planning in the future [Wol16].
Another possible uncertainty is the RBE. Carbon ions are known to have an increased biological
effectiveness compared to photons [Kra00a]. However, the knowledge of the RBE for high single-fraction
doses and the irradiation of cardiomyocytes is extremely limited since no reliable data is available so far.
Therefore, the whole treatment planning process was performed using physically optimized treatment
plans. The RBE for such high doses is expected to be only slightly above 1, allowing the treatment
planning with physical dose.
Use of Carbon Ions - Promising Non-Invasive Alternative?
The use of carbon ions for catheter-free ablations of cardiac substructures offers great perspectives.
Carbon ions are an extremely effective tool for radiotherapy due to their inverse depth-dose profile and
the low lateral scattering in the entrance channel. This offers high precision and allows to successfully
spare critical structures, which are a potential show stopper for comparable photon treatments.
However, the success rate of the presented study was not sufficient to directly transfer the treatment
into clinical routine. Further animal experiments are necessary to investigate new margin and optimiza-
tion strategies, such as, robust optimization, 4D optimization or a combination of both. In addition, it
would be important to investigate the change of the heart volume of the pigs over several weeks and
to investigate the corresponding positioning reproducibility over a longer time frame. For further treat-
ments without 3D imaging in the treatment location larger margins should be useful to increase the
success rate. In general, the use of 3D imaging at the treatment room is highly recommended. Further-
more, it would be beneficial to critically examine the possibility to increase the margins considering the
doses deposited in the OARs.
For further experiments, alternative approaches without additional metal artifacts during imaging and
irradiation should be carefully investigated. However, metal artifacts are a highly critical problem for
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the translation of catheter-free ablation to clinical routine, as patients suffering from severe cardiac
disorders most likely have ICDs or pacemakers implanted. Therefore more research is needed to reduce
metal artifacts within the planning CT and to determine the position of the leads prior to the treatment
[Jäk07].
Comparing both methods, photon and carbon ion irradiation, photons are advantageous in the robust-
ness against breathing and heart motion. Necessary compensation strategies for interplay effects make
the application of carbon ions more challenging compared to photons. Before a clinical application is
possible more animal experiments are necessary, to further understand the biological reactions of the
high doses delivered in a single fraction to a small volume. To finally reach the aim of a non-invasive
treatment modality also the beam delivery needs to be modified to combine, for instance, gating for the
breathing motion and rescanning or gating for the cardiac motion. To date, no carbon ion facility is able
to perform motion mitigation for both motion types without anesthesia. In general, it is not possible to
apply radiotherapy as a stand-alone therapy for people suffering from severe cardiac arrhythmia. Re-
garding the findings of all published animal studies, the time until an effect is expected lies somewhere
between 3 and 6 months. Hence, radiotherapy always needs to be applied in combination with an ICD.
In summary, catheter-free ablation using carbon ions can be a possible alternative to radio-frequency
catheter ablations in the future. The presented study demonstrates the feasibility and shows possibilities
to overcome the heart and breathing motion. A first and important step is done and now further research
is needed to apply the presented techniques in clinical routine. In addition, no radiation induced side
effects were observed over the whole follow-up time of 6 months. The success rates can be increased
using 3D imaging in the treatment room and applying new margin strategies or treatment plan opti-
mization methods such as 4D optimization [Gra14,Gra13] or robust optimization [Liu16]. Nevertheless,
a first in-vivo study was conducted and the success of carbon ion therapy in cancer treatment could be
continued in treatment of cardiac arrhythmia.
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3 Deformable Image Registration for Beating
Hearts and Influence on the In-Vivo
Feasibility Study
Image registration is a widely used tool in clinical routine nowadays. As it is necessary to compare the
outcomes of different image modalities, such as magnetic resonance imaging (MRI), positron emmission
tomography (PET), computed tomography (CT) and cone-beam CT (CBCT) or of image data taken at
different time points, commercial treatment planning software provides registration algorithms able to
match the imaging data. In radiotherapy deformable image registration (DIR) opens a wide field of
opportunities and new fields of applications are already described in literature, such as 4D optimization
[Tro05], 4D dose calculation [Fla06] and contour propagation [Lu06]. Several years ago, 4D dose
calculations became available for protons [Pag05] as well as for carbon ions [Ber07a]. Even though these
methods are sensitive to uncertainties in DIR, they are a powerful tool to determine dose distributions
of moving targets.
In TRiP4D the calculation of 4D dose distributions works as follows. A temporal correlation between
the raster points and the corresponding motion phase is determined using a beam delivery sequence
(BDS) and the dose contributions of all raster points to each CT voxel. For this step, the voxel position of
the reference phase is modified according to the DIR, considering the Hounsfield unit (HU) of the actual
motion phase. The overall physical dose is calculated as a summation of all dose contributions from all
motion states projected onto the reference phase. For biological dose calculations the particle spectra
initial and secondary particles are accumulated over all motion phases projected onto reference phase.
Furthermore, contour propagation can be carried out transforming the contours from the reference phase
to any arbitrary motion phase. For further details the reader is referred to [Ric12].
The transformation from reference to each motion phase and vice versa is carried out separately to
avoid uncertainties due to a simple inversion. Thus, a lacking inverse consistency of the registration
is possible and points to a poor DIR outcome. Large inverse consistency error (ICE) can cause severe
deviations between reality and 4D simulations such as under- and overdosage within the target volume
and the organs at risk (OARs). Thus, the inverse consistency of DIR should be checked for all motion
phases to gain important information about DIR quality.
For the application in lung and liver cancer therapy, DIR has already been in use for several years
[Ric14, And16b]. To carry out catheter-free ablations, DIR is essential to mimic the complex motion
of the heart allowing 4D dose simulations and even 4D dose optimization in future. In a previous
treatment planning study, a DIR approach was established for the registration of human and pig hearts
[Con14,Con16] using Plastimatch [Sha10a]. A similar approach was used for the in-vivo feasibility study
presented in Chapter 2. However, a detailed retrospective analysis showed insufficiencies of B-spline
DIR for beating hearts. The registration of the heart motion is incorrect and especially lacking inverse
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Figure 3.1.: Diastole and systole of the contrast enhanced 4DCT of Pig 16. The thickness of the left ventric-
ular free-wall is clearly increasing. Even though the deformation of the heart muscle occurs
in 3D, the strong influence of the heart contraction on its anatomy is clearly visible in the 2D
slice.
consistency [And16a]. The problems are among others, the complex motion with an extreme contraction
of the left ventricle as shown in Figure 3.1, imaging artifacts present due to the irregular flow of the
contrast agent, the fast contraction of the heart and the implanted pacemakers in the atrioventricular
node (AVN) pigs.
Therefore, the following chapter will present the result of two approaches trying to increase the quality
of DIR using Plastimatch. In the first approach the registration parameters are varied and in the second
one a stepwise registration is tested. In addition, an estimation of the effect of the DIR uncertainties on
the feasibility study presented in Chapter 2 is given. Finally, further approaches to increase DIR quality
are discussed.
3.1 Material and Methods
3.1.1 Registration method
The registration process was carried out using Plastimatch [Sha10a] included in Slicer3D [Fed12]. Plas-
timatch is an open-source commandline based software, often used in medical research. It is included in
a Slicer3D plugin, called SlicerRT [Pin12], that offers fast parameter adaption and prompt visual feed-
back. SlicerRT was used to carry out the original DIRs for the feasibility study as well as for the new
approaches presented in this chapter trying to improve the DIR for beating hearts.
Registration parameters and nomenclature
A short summary of the nomenclature for the different images created during a registration process is
given in the following:
• Reference Image: As the name already states, this image is used as a reference for the registration
process.
• Moving Image: The image that needs to be transformed to the reference image.
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• Warped Image: After the registration, the warped image is the transformed moving image which
should resemble the reference image as close as possible.
• Forward Registration: Registration of each moving phase to the reference phase.
• Backward Registration: Registration of the reference phase to all moving phases.
In all cases, the original registration was performed as a two-step process using the registration parame-
ters stated in Table 3.1. A detailed descriptions of the parameters can be found in [Pla].
Parameter Stage 1 Stage 2
Resolution 4,4,2 2,2,1
Grid Size 50 15
Regularization Lambda 0.005 0.005
Iterations 200 100
Table 3.1.: Parameters used for the deformable image registration for the pig study.
3.1.2 Quality Assurance of a Deformable Image Registration
After acquisition of the 4DCTs, a time frame of several days was available to perform registration, regis-
tration quality assurance, contouring, treatment planning and 4D dose simulations to prepare the irra-
diation of all 15 pigs. Due to the limited time and large amount of data, automated processes were used
for registration, registration quality checks, treatment planning and 4D dose simulations. In addition,
the registration quality checks were performed only on one motion phase to reduce the workload as pre-
viously reported in [Con14]. For each pig an overlaid image of reference and warped image was created
using inverse colors. Furthermore, a square shaped region of interest (ROI) around the body was deter-
mined manually. Within this region the mean value of the absolute difference, the Jacobian determinant
and the ICE were calculated. In the following paragraphs the quantities used for the deformable image
registration quality assurance (DIRQA) are explained in detail.
To estimate the agreement of reference and warped image it is useful to apply an inverse color code
to both images. The differences are usually small between reference and warped image and the gray
scale of the recorded CTs makes it difficult to determine slight deviations. Overlaying both images with
inverse color codes, as, for instance, red and cyan, facilitates to recognize deviations. After the overlaying
process, matching areas will be displayed in gray and non matching ones in red and cyan. This allows a
fast visual quality check of the registration.
In addition, the absolute difference is a measure to determine the agreement of two images quan-
titatively. The difference of the Hounsfield units is calculated for each voxel and can then be used to
calculate the mean, standard, minimum and maximum deviation in the selected ROI across all voxels.
For an ideal registration the results would be 0. As a registration is typically used for single motion
phases and minimizes the mean square error, the absolute difference indicates if an image registration
was carried out successfully.
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Besides analytical and visual checking of the reference and warped image, an analysis of the deter-
mined vector fields is necessary. One important quantity is the Jacobian determinant to validate the
physical properties of the registration process [Leo07]. The Jacobian determinant is defined as
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where u is the calculated vector field, which assigns each voxel in the reference image a new voxel in
the moving image. The Jacobian determinant should be greater than 0 for all voxels, as values below
correspond to mirroring voxels within the patient, which is impossible [Rey99,Che08]. Values above or
below 1 correspond to an expansion or contraction of the volume, respectively. For an analysis, mean,
standard deviation, minimum and maximum of the Jacobian determinants can be calculated similar to
the approach for the absolute difference. Hence, the minimum value of all Jacobian determinants gives
a quick overview whether the registration outcome is realistic.
Another important quantity of the vector field is the inverse consistency error. The ICE checks if the
forward and backward transformation, which are carried out independently, are defined consistently.
Therefore an arbitrary starting point of the reference image x is transformed to the moving image using
the vector uAB leading to x
′. After that x ′ is transformed to the reference image using the vector uBA
leading to x ′′. The distance between x and x ′′ gives the ICE. In other words, the ICE is defined as the
Euclidean norm between x and x ′′. This process is performed for all voxels of the CT and again a mean,
standard deviation, minimum and maximum can be calculated.
In general, it is important not to focus solely on the mean results. Instead, increased attention should
be given to the minimum and maximum values. The extreme values are able to point out certain areas
within the total ROI which need further investigation.
3.1.3 In-Vivo Feasibility Study
A detailed retrospective analysis of the DIR calculated prior to the pig study can be found in [And16a].
In summary, the analysis showed that the registration was not able to reproduce the complex motion of
the heart contraction. The minimization of the absolute difference, which is the goal of the optimizer
in the applied B-Spline registration, was satisfying. However, this is not a clear indication for a good
registration as organ folding and maximum ICE values greater than 20 mm were found for some pigs. In
addition, the DIR was not able to reproduce the thickening of the left ventricular free-wall (LV) and the
opening and closing of the valves. In Figure 3.2 the false color image of systole and diastole is shown,
indicating the complexity of the heart motion. In Figure 3.3 false color images after DIR, according
warped images and vector fields are shown.
The DIRQA prior to the in-vivo study was not sufficient and, in general, an improved registration of all
pigs is necessary to gain reliable results from the 4D dose calculation. Hence, two different registration
approaches were carried out to improve the DIR and to reach satisfying results for the absolute difference,
the Jacobian, the ICE as well as for the inverse color images.
64 3. Deformable Image Registration for Beating Hearts and Influence on the In-Vivo Feasibility Study
Figure 3.2.: False color image of the motion phases 3 and 0 before registration representing the two
extreme phases of systole and diastole.
Different parameter combinations were investigated for the two-step DIR used prior to the experiment.
The grid size was reduced twice, first a rough resolution was chosen with grid sizes of 30 and 10 mm
in stage 1 and 2, respectively. After that a finer resolution was chosen, with grid sizes of 20 and 5 mm.
Besides the original value of 0.005, the regularization lambda was changed to 0.0005, 0.001, 0.050,
0.010 and 0.015.
In addition, it was investigated if the registration outcome of complex motion types, such as the
heartbeat, is increased when applying a stepwise registration approach. Thus, neighboring phases were
Figure 3.3.: Results of the forward and backward DIR of diastole and systole are presented corresponding
to reference phase and motion phase 3, respectively. In a) the false color image overlaying
phase 3 (systole) with the warped image of the reference phase (diastole) is shown. The
corresponding vector field overlaid on the warped image of phase 0 is shown in c). In b)
and d) the same images are shown for the forward registration. It can be seen that the
deformation of the left ventricle is extreme and that motion amplitudes of the forward and
the backward registration differ.
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registered onto each other and, in the end, adding the transformation vector fields for each registration
to obtain the transformation from each motion phase to the reference phase and vice versa. Instead of
registering each motion phase directly to the reference phase, as it is usually done in a standard DIR.
To improve the results of the DIR, different approaches were tested. These studies were carried out
for Pig 16, which was part of the LV group. The latter was selected due to the good quality of the
4DCT without pacemaker and reconstruction artifacts. Furthermore, a homogeneous contrast agent
distribution was available. It was assumed that a successful registration of all 4DCTs is only possible, if
an approach for the 4DCT of Pig 16 is found. In addition, for all pigs of the AVN group the position of
the AVN was manually determined in each motion phase of the 4DCT to estimate the influence of the
inexact DIR. The manual contouring was carried out by a physician blinding the study outcome. This
study was necessary to investigate if the inhomogeneous results throughout the target and dose groups
can be correlated with the applied DIR. Two important examples for this examination were Pig 1 and
Pig 2. Both pigs were irradiated with 55 Gy, while Pig 1 developed a complete AV-block, Pig 2 did not
even show a slowing of the conductivity of the AVN.
3.1.4 Perfect Rescanning
Idealized 4D treatment simulation neglecting the influence of interplay effects are possible using perfect
rescanning (PRSC) [Bre15]. In a PRSC simulation the deposited dose is equally distributed to all motion
states of the treatment planning 4DCT. This allows to simulate a treatment without interplay effects and
yields the maximum target coverage possible in a 4D simulation. A PRSC simulation is independent of
the BDS and does not need a motion surrogate.
Throughout this chapter PRSC was applied to clarify if the reduced target coverage found in Chapter 2
is due to residual interplay effects or the underlying registration. If the motion was mitigated sufficiently,
the median values found from the rescanning simulations should be comparable to the results of the
PRSC simulation. However, if the target coverage is reduced in PRSC simulations as well, the reason
lies in the insufficient registration quality, specifically a lacking inverse consistency, and not in residual
interplay effects.
Therefore a PRSC simulation was performed for each of the 14 investigated pigs. From the simulations
D95, V95 and D5-D95 values were determined and compared to the corresponding median values for
homogeneous and inhomogeneous rescanning presented in Chapter 2.
3.1.5 Target Coverage for Manual AVN Contours
To investigate the influence of the found registration uncertainties on the 4D dose calculations the AVN
position was determined by a physician in each motion phase. The manual contouring was carried out
blinding the study results. Afterwards a sphere of 5 mm diameter was created around the determined
location, comparable to the target volume (TV) used throughout Chapter 2. As the uncertainties for
determining the correct position within each single motion phase are in the order of several millimeters,
the target coverage was calculated only for the TV.
A static dose distribution depositing 10 % of the target dose in each motion phase of the 4DCT was
calculated. The target coverage and dose homogeneity in the TV was analyzed determining V95, D95
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and D5-D95 values. To estimate the target coverage in a 4D dose simulation without uncertainties due
to the DIR, the values of V95, D95 and D5-D95 over all motion phases were determined using a rigid
transformation of the target sphere. This procedure cannot replace a full 4D simulation, especially
considering the dose deposited within the OARs. However, it allows a rough statement about the actual
target coverage as well as an estimation if the DIR uncertainties caused a poor target coverage due to a
wrong internal target volume (ITV).
3.2 Results
The following sections present the results of two new registration approaches and an estimation of the
influence of the DIR uncertainties on the study outcome. Throughout this chapter results are either given
as mean values with standard deviation (mean ± stdev) or as median values with the range between the
25th and 75th percentile (median (25 % - 75 %)).
3.2.1 New Registration Approaches
Parameter Variation
The parameter variation showed a clear influence on the registration outcome. In general, the calcula-
tions indicate that a small grid can cause negative Jacobians and large ICEs. However, when investigating
absolute differences between the warped and the reference image, a small grid seems to be the optimal
choice. For the two larger grids the results showed comparable outcome for all used regularization lamb-
das, but the results of the absolute difference were poor. For all parameter combinations the resulting
minimum Jacobian, maximum ICE and absolute difference are displayed in Figure 3.4.
Even though the results of the vector field analysis look satisfying for certain parameter combinations,
the corresponding inverse color images displayed in Figure 3.5 cannot confirm the good results of the
vector field analysis. Compared to the inverse color image of phase 0 and 3 without registration (see
Figure 3.2) it can be seen that the deviations at the outer contours of the heart muscle are reduced.
However, none of the parameter combinations were able to model the thickening of the left ventricle and
the deformation of the heart at the superior edge satisfyingly. In addition, the deviations are tremendous
in the area of the right atria, where the contrast agent is flooding the heart muscle.
Stepwise Registration
Based on the findings of the parameter variation the stepwise registration approach was tested for two
parameter combinations. Grid sizes of 30 mm in the first and 10 mm in the second stage and 20 mm in
the first and 5 mm in the second stage were combined with regularization lambdas of 0.015 and 0.00005,
respectively. Even though the vector field quality of both was not satisfying due to large maximum ICE
and negative Jacobians, both parameter combinations showed the most promising false color images,
indicated by a reduction of the absolute difference.
In Table 3.2 the quantitative analysis of the stepwise registration is shown. The homogeneity of the
vector field was increased using the stepwise approach and the inverse consistency benefited from this
approach as well. For the combination with the small grid also the absolute difference benefited for
the stepwise registration approach. However, comparing the results of the false color images for both
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Figure 3.4.: Results of the parameter variation approach. The maximum ICE, the minimum Jacobian, the
absolute difference and the standard deviation of the absolute difference are plotted over 6
different values for the regularization lambda and for 3 different grid sizes.
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Figure 3.5.: Overview of the false color images gained with all different combinations of regularization
lambda and grid sizes. All images show an overlay of sagittal cuts from phase 0 and 3 from
forward registration.
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Grid: 20mm, 5mm Grid: 30mm, 10mm
Regularization λ: 0.0005 Regularization λ: 0.015
One Step Stepwise One Step Stepwise
Mean Absolute Difference [HU] 25.91 14.76 26.65 27.54
Standard Deviation Absolute Difference [HU] 37.92 24.42 40.15 45.07
Maximum Inverse Consistency Error [mm] 9.56 3.06 6.07 1.98
Minimum Jacobian -0.02 0.39 0.21 0.25
Table 3.2.: Results comparing the one step and the stepwise registration approach.
registration approaches in Figure 3.6, it can be seen that the overall outcome is not satisfying. The step-
wise registration is able to avoid negative Jacobians and to reduce the ICE. Nevertheless, the stepwise
registration approach could not sufficiently improve the transformation from moving phase to reference
phase and vice versa. Especially the changes of the heart anatomy due to the opening and closing of the
valves and the thickening of the left ventricle cannot be represented.
Figure 3.6.: Overview of the false color images for the stepwise and the original registration approach
gained with two different combinations of regularization lambda and grid size.
3.2.2 Perfect Rescanning
The simulations carried out with PRSC are in good agreement with median values of the inhomogeneous
and homogeneous rescanning simulations presented in Chapter 2. In Figure 3.7 the results are compared.
The target coverage expressed by the D95 and V95 as well as the dose homogeneity show reduced
values for the same pigs. Nevertheless, for some pigs, for instance Pig 1, 3 and 4, the dose homogeneity
is better for the perfect rescanning simulations. Furthermore, for some pigs, for instance, Pig 6, a larger
variance in the results for the target coverage was found, which cannot be explained by the results of
the perfect rescanning simulations and indicate residual interplay effects for these animals. The 4D
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Figure 3.7.: V95, D95, D5-D95 results of the PTV. Comparison for the results of the perfect, inhomogeneous
and homogeneous rescanning simulations. For inhomogeneous and homogeneous rescan-
ning simulations the box represents the 25 to 75 % of the data of 96 simulations including
different motions and beam delivery sequences. The median is given by a solid line and the
whiskers represent 1.5 times the inner quartile range.
rescanning simulations presented in Chapter 2 could successfully compensate the motion for most of the
pigs and the found reductions in the target coverage are due to registration problems.
3.2.3 Influence of Deformable Image Registration on Study Outcome
The analysis of the manually drawn contours showed a good target coverage for all AVN pigs in all motion
phases. Single outliers were found for some pigs, which could be identified calculating the motion vector
showing unnatural changes between single motion phases.
The overall target coverage in all motion phases was determined by shifting the target point for each
motion phase. The results were satisfying, showing D95 values above 94 % without corrections for
identified outliers. Especially, when considering the contouring uncertainties of several millimeters, a
good target coverage was reached indicating a correct treatment planning process for the AVN group.
In Table 3.3 the D95 values are shown for each pig of the AVN group using the manual contours in all
motion phases.
Pig 1 2 3 4 6 7 8
D95 [%] 94 98 95 101 98 103 101
Table 3.3.: Results for D95 values for the hand drawn contours.
In addition, dose cuts of the reference phase and the motion phase with the largest contraction were
visually analyzed for the LV group. This allowed to check for the transmural dose coverage of the left
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ventricular free-wall during the motion phase with the largest contraction. The analysis incorporates 3D
images of the static dose distribution for each phase. In Figure 3.8 the dose distribution is shown for
Pig 15 in the reference motion phase and in motion phase 3, corresponding to the ventricular systole.
The dose cuts show that full dose coverage of the entire thickness of the left ventricular free-wall in the
motion phases with extreme contractions was not achieved. Hence, a reduced target dose within the TV
is likely.
Figure 3.8.: Axial, sagittal and coronal views of the dose distribution of Pig 15 in diastole (top) and systole
(bottom). The corresponding propagated contours are marked in blue. The arrows indicate
that during systole the contour is not large enough to cover the full myocardium. Thus, it is
likely that it was not possible to deposit the full target dose in a transmural region.
3.3 Summary and Discussion
To overcome the DIR problems reported in [And16a], two new registration strategies were tested. An
approach with adapted parameter combinations was applied as well as a stepwise registration. None of
theses approaches could significantly improve the registration outcome. The DIR quality is still too low
to be used as suitable input data for 4D simulations.
However, the results of PRSC simulations showed that the reduced target coverage in the 4D simu-
lations, reported in Chapter 2, is due to the low quality of the registration’s inverse consistency. This
finding was especially pronounced within the planning target volume (PTV). Even though the interplay
effects are mitigated by the applied rescanning strategy for the majority of the pigs, large variations
within the target coverage indicate residual motion effects for specific pigs.
For the AVN group no impact on the study outcome is expected due to DIR uncertainties. This was
investigated using manually drawn contours in all phases. Although it was not possible to contour each
motion phase for the superior pulmonary vein (SPV) group, equal findings are expected due to the
comparable deformation of the targeted volume. In contrast, the registration uncertainties likely had an
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influence on the LV group irradiation, as the thickening of the myocardium during the systole was not
correctly modeled. Hence, target doses below the planned dose of 40 Gy are likely.
CT Quality
The in-vivo feasibility study presented in Chapter 2 was the first in-vivo study performing 4D treatment
planning on cardiac gated contrast enhanced 4DCTs. In a retrospective analysis of the CT data, several
irregularities were found within the 4DCTs used in treatment planning and DIR.
For almost all contrast enhanced 4DCTs the contrast agent was not homogeneously distributed, es-
pecially within the right atrium, see Figure 3.9. In addition, the concentration of the contrast agent
was changing over time. Thus, the different rotations of the CT detectors resulted in different HU for
the same anatomic structure. Furthermore, the reconstruction of the 4DCTs did not work reliably in
all cases, hence, imaging artifacts are visible in different motion phases of certain pigs. These motion
artifacts can be identified as edges in the CT and are caused by a fast and irregular motion of the imaged
structure [Che04].
(a) Pig 2
(b) Pig 17
Figure 3.9.: Axial, sagittal and coronal view of the reference phase of two 4DCT are shown. All stated un-
certainties in the 4DCT recording can be seen in this cuts. In both figures the inhomogeneous
contrast agent distribution is visible, while in (a) the pacemaker and in (b) the strip artifacts
can be seen.
Two additional problems occurred in the 4DCTs of the AVN group. First of all, the tip of the heart
was not recorded for these pigs. Even though this was not critical for the DIR process carried out
prior to the feasibility study, the missing heart tip could increase the difficulty to solve the DIR problem
for the AVN group when applying motion models. In addition, metal artifacts due to the implanted
pacemakers reduced the quality of the 4DCTs further and, hence, could alter the treatment planning
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outcome [Jäk07]. Especially for Pigs 2, 6 and 8 the metal artifacts could cause problems during DIR as
well as irradiation, as they are in close proximity to the target volume.
The determination of necessary improvements of the CT protocol is essential to be able to develop a
reliable DIR algorithm. As the 4DCTs are used as base data for DIR, a low quality of the 4DCTs is strongly
connected to uncertainties of the DIR outcome. A first necessary step is a CT protocol that guarantees
a homogeneously distributed contrast agent throughout the whole heart. Secondly, the use of a metal
artifact reduction during the reconstruction of the CT is highly recommended [Abd16]. And finally, to
overcome the motion artifacts, a heart rate reduction combined with an increased regularity of the heart
beat by the use of drugs should be studied [Kal16]. Alternatively, the employment of an advanced and
iterative CT reconstruction algorithm [Hah16] or the use of a CT scanner with 320 detector rows [Coo09]
could increase the imaging quality and at the same time avoid image artifacts.
Deformable Image Registration
Catheter-free ablation is the first application of DIR in beating hearts for 4D treatment planning in par-
ticle therapy. Prior to the feasibility study presented in Chapter 2, no in-vivo experiment was carried out
using deformation vector fields of cardiac-gated 4DCTs as input data for 4D treatment planning. Espe-
cially as innovative approaches are susceptible to uncertainties, careful consideration of error sources
is necessary to allow a fast transition to clinical routine and enable a consequent improvement of the
applied methods. Even though the presented study underestimated the complexity of the heart motion
and overestimated the power of a B-Spline DIR, it is important to point out the uncertainties found in
the retrospective analysis for the CT as well as the DIR data to support a prompt improvement of the
described methods.
Considering the procedure of a DIR, trying to reduce the absolute difference between the reference
and moving image, unsolvable challenges for the algorithm were found during the retrospective analy-
sis. Extreme differences between the HUs, especially in the right atrium where the contrast agent was
flooding the heart, as well as distinct changes of the anatomical structure, such as opening and clos-
ing of valves, cannot be correctly modeled by the applied DIR. One possibility to improve the outcome
could be a segmentation of the contrast agent and afterwards a replacement with a constant HU value.
This might increase the registration results, as strong gradients would vanish. Furthermore, a correct
registration requires knowledge about deformable and non deformable areas of the CT. Especially the
sternum and the spine should not be affected by the registration of the heart motion, as the 4DCT was
recorded under breath-hold. To solve this problem, a segmentation of the heart should be considered for
future simulations.
To estimate the effect of the DIR uncertainties on the treatment planning, contours of the AVN were
manually created in each motion phase for all pigs of the AVN group blinded to the study outcome. Even
though the precision of the target location is only within several millimeters, this approach allows an
estimation of the actually deposited dose in the targeted area. The D95 values were above 94 % using
the manual contours indicating that the reduced target coverage for some pigs in Chapter 2 is due to
the poor inverse consistency of the registration and not due to residual motion effects. However, due to
the described uncertainties in the target location of several millimeters in all three dimensions, manual
contouring did not allow to calculate motion trajectories of the AVN throughout all motion phases.
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Nevertheless, the manual contours can be used as an indication for new DIR algorithms to validate the
contour propagation.
For the development of a DIR algorithm suitable for cardiac motion, incorporating biomechanical heart
models should be considered. Several models for the heart motion are available. However, most of them
are focusing on specific properties and anatomical structures of the heart due to the high complexity
of the motion. The high complexity is caused by the contractions of atria and ventricles, which occur
slightly shifted in time and moving the atrioventricular plane up- and downwards, as well as the complex
interaction of myocardium and pericardium [Fri14b]. A review of different models is given in [Ker06].
One model of the atrioventricular plane motion was published in [Mak15], describing the atrioven-
tricular plane as a piston unit. In addition, models of the left ventricular motion are published, but due
to the high workload to develop them the number of models is still low. To overcome the extreme work-
load, MRI and diffusion tensor MRI approaches were proposed as a new class of anatomically accurate
electromechanical models [Gur11]. Even though all these models are species dependent, left ventricular
motion models are available for humans, canine as well as pigs [Ste03, Gur11]. Realistic ventricular
models are more complex, as it is necessary to consider the interaction of atria and ventricles as well as
the interaction of both with the pericardium. A first cardiac model for the full heart including the impact
of the pericardium is published in [Fri14b]. In addition, first approaches for patient specific models, al-
lowing an improved personalized treatment are available [Kri13]. These heart models are important and
could provide support to overcome the registration problem for the heart motion discussed throughout
this chapter. An integration of a biomechanical model, ideally a patient-specific biomechanical model,
into a new DIR strategy should be tested in future, although this is a challenging approach.
Furthermore, the development of reliable DIRQA should be continued. While it is possible to check
the success of contour propagation visually, a reliable quality assurance (QA) of the vector field outcome
needs a dedicated software and a good understanding of the calculated results as it is not always obvious
to distinguish between successful and unsuccessful vector field outcomes. In addition, it is useful to not
only determine all quantities in the whole ROI, but also in the target volume and the entrance channel.
This improves the knowledge of the vector field within the actual irradiated region. The mean values of
the total body ROI can be influenced by the good results of the non deformable structures such as the
chest wall and the spine.
For clinical transition, it is important to improve the knowledge of cardiac motion. One method
could be ultrasound measures of AV plane displacement [Slø04]. In addition, ultrasound guidance
[Sch14,Pra14a] could be an option for future experiments to gain baseline data as well as for real-time
motion monitoring. As since 2015 MRI compatible implantable cardioverter-defibrillators (ICDs) are
available [Med], MRI could be a powerful tool for the determination of scar tissue within the heart
muscle for baseline data and treatment planning as well as for success control of the treatment [Ips14].
Reliability of the 4D simulations
During the manual contouring of the AVN position within all motion phases, it was found that Pig 5 had
a malformation of the heart. Due to a defect in the myocardium, the pacemaker electrode was positioned
in the left ventricle instead of the right one. This caused an inappropriate pacemaker electorde position
in close proximity to the AVN. Furthermore, the timing of the contrast-agent enhanced 4DCT was lacking
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and, hence, the amount of contrast agent was reduced causing a poor quality of the vector field with
underestimated motion amplitudes. This small vector amplitudes explain the superior target coverage
for Pig 5 compared to all other pigs shown in Chapter 2.
The results of the PRSC simulations are comparable to the median values of the 4D simulations carried
out in Chapter 2. Reduced values for the target coverage within the PRSC simulations indicate problems
of the inverse consistency of the applied DIR, as the general idea of the perfect rescanning approach
is performing 4D simulations neglecting interplay effects. Thus, the results should yield a good target
coverage. However, a realistic 4D simulation considering a motion surrogate and a BDS should give
comparable results on average. Based on the results of the PRSC simulations, it was not possible to
achieve a satisfying target coverage for several pigs due to the poor inverse consistency. Thus, all results
should be analyzed relative to the PRSC results. Within these limitations, the observed target coverage
in TV and PTV indicates a successful interplay mitigation in most pigs. However, for some pigs large
variations were found that are due to residual motion effects. Nevertheless, the DIR uncertainties do not
allow a correct 4D simulation for the in-vivo experiment presented in Chapter 2.
Influence on Study Outcome
Even though the poor inverse consistency diminishes the value of 4D simulations, the repeated manual
contouring indicates that the treatment planning for the AVN group was correct. The area of the AVN
was fully irradiated within all motion phases taking the location uncertainties into account. Hence,
the heterogeneous study results are not necessarily correlated with the registration problems. However,
several other possible reasons are known. One of the main reasons might be missing 3D imaging at
the treatment location. This did not allow to determine a position of the pacemaker leads during the
irradiation. Furthermore, anatomical changes, such as the heart or lung volume, are not exactly known.
The situation is assumed to be comparable for the irradiation of the SPV group. However, due to the
complex contouring process for the SPV irradiation, it was not possible to carry out contouring for each
phase.
The effect of the low quality DIR on the outcome of the LV group is different. As shown in Figure 3.8,
the DIR does not successfully model the thickening of the left ventricular free-wall, which caused too
small ITVs and, hence, did not allow a transmural irradiation within all motion phases. Especially during
the systole the spread-out Bragg was not deep enough to penetrate the whole myocardium. However, in
this case it was not possible to determine the actual target coverage as carried out for the AVN group.
Due to the strong contraction and deformation of the myocardium it was not possible to follow the
arbitrarily determined target volume over the full cardiac cycle. This would be different for patients, as
in a real case, an already existing scar, visible in MRI and ultrasound, would be irradiated. This would
allow a correct contouring in all motion phases.
In summary, more advanced DIR methods are necessary. Existing strategies from other fields, especially
image fusion and biomechanical motion modeling, can be adapted. In clinical routine, irradiation can be
carried out if all phases of a 4DCT are contoured, but 4D dose simulations would strongly benefit from
better DIR approaches.
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4 Fast Rescanning Strategies for
Hypofractionated Ion Beam Therapy
The trend in radiotherapy is moving from fractionated treatments to hypofractionated or even single-
fraction treatments also known as radiosurgery [Whe08, Whe10, Fri16]. In addition, the use of radio-
therapy is spreading to treatments of non-cancerous disease, such as cardiac arrhythmia, trigeminal
neuralgia, arterial aneurism and arteriovenous malformations [Ber12]. In recent years, this trend is
supported by technical developments, allowing a treatment with an increased conformity of the dose
distribution [Bra00, Sal12]. Furthermore, especially in scanned particle therapy, the treatment of mov-
ing targets is becoming more common. Besides handling range changes, this frequently requires the use
of motion mitigation techniques to avoid interplay effects due to an interference of the scanned ion beam
and the target motion. One possible motion mitigation approach in particle therapy is rescanning. It can
be applied easily with just minor technical changes and it is more robust compared to gating or tracking.
However, both, the increased doses due to hypofractionated treatments as well as the use of rescanning
prolongs the treatment time. As longer treatment times decrease the number of patients treated per day
and their comfort, for economical reasons as well as for more efficient and comfortable treatments new
approaches are warranted to allow a faster irradiation.
In particle therapy, the main factor determining the treatment duration is the intensity of the particle
beam. In an ideal system the allowed intensity for each iso-energy slice (IES) and raster point is the
maximum intensity available at the accelerator. However, the several conditions are necessary to perform
a controlled and high-quality treatment can cause an intensity reduction. The main source for the latter is
the requirement to perform two beam position measurements during the irradiation of each raster point.
Other reasons are a high loss of particles in the beam transition between two raster points or the limited
measurement range of the ionization chambers which is fixed for each IES. All limitations need to be
considered to guarantee the deposition of the correct amount of particles at the predetermined position.
Further details can be found in [Sch15]. As particle numbers can vary between 5·103 and 1·106 within
each IES, the previously stated limitations are necessary to guarantee a high quality treatment. Different
attempts to overcome intensity limitations and to reduce the treatment time are already known. While
the Paul Scherrer Institut (PSI) and the National Institute of Radiological Sciences (NIRS) reduced the
time necessary for energy changes significantly [Ped01, Miz14] and implemented a dynamic intensity
control (DIC), Heidelberg Ion-Beam Therapy Center (HIT) implemented only a DIC. The latter allows to
adjust the particle intensity during each spill.
The following chapter presents new approaches to conduct faster rescanning irradiations by applying
a scan path optimization (SPO) to overcome intensity limitations. Therefore, IESs are split according
to the particle number of each raster point. In addition, the influence of the SPO as well as the DIC
implemented at HIT on 4D dose distributions is investigated. Therefore the SPO as well as the DIC was
implemented in a designated beam delivery sequence simulation (DSim) software to carry out realistic
4D simulations using TRiP4D [Ric12].
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4.1 Material and Methods
4.1.1 Fixed Intensity
At facilities operating with a fixed intensity over the whole extraction time predetermined intensity levels
are available for the irradiation. The standard procedure for determining the maximum possible intensity
level for each IES is to identify the raster point with the lowest particle number. The particle flux is then
scaled down until the intensity level is reached that allows the treatment control system (TCS) to perform
a beam position measurement twice within the irradiation time of this raster point. After that, other
intensity limitations, like the dose lost in transition between two raster points and the measurement
range of the ionization chambers, are checked. If necessary, the intensity is further reduced until all
constraints are fulfilled. As the intensity is kept constant for the whole IES, a long irradiation time for
the whole IES can be caused by a single low intensity raster point. In this case most of the time is
spent irradiating raster points with an unsuitable low intensity. These varying irradiation times cause an
irregular motion of the beam over the targeted volume. The behavior of the beam intensity over time
is schematically shown in Figure 4.1(a). This irregular time behavior has no effect on the treatment of
static tumors other than prolonged irradiation time. Its effect on moving targets is investigated within
this chapter.
(a) Schematic behavior of the intensity over time
for an irradiation carried out with a constant in-
tensity.
(b) Schematic behavior of the intensity over time
for an irradiation carried out with a dynamic inten-
sity control.
Figure 4.1.: Comparison of the variation in time of raster points irradiated with a fixed and a dynamic
intensity. R1 to R4 correspond to 4 raster points. Adapted from [Pan14].
4.1.2 Dynamic Intensity Control
A DIC allows altering of the beam intensity during the irradiation of a single IES and applies the highest
possible intensity for each raster point [Fur07, Sch15]. The aim of DIC is to increase the efficiency and
78 4. Fast Rescanning Strategies for Hypofractionated Ion Beam Therapy
the stability of the accelerator and, hence, to reduce the treatment time. Prior to the treatment, the
TCS needs to determine the maximum possible intensity for each raster point to be able to request the
varying intensities from the accelerator. This allows a constant irradiation time for each raster point
corresponding to the shortest treatment time possible with the used system. The intensity behavior over
the treatment time for a system with a DIC is schematically shown in Figure 4.1(b) The DIC influences
the beam delivery sequence (BDS) of a treatment plan and can therefore have an effect on the 4D
dose distribution for moving tumors. Compared to a constant intensity, a more regular motion of the
beam across the targeted volume is present applying a DIC. If this is more prone to interplay effects, is
investigated throughout this chapter.
The technical implementation requires a feedback loop connected to the accelerator to automatically
adjust and control the intensity. For the work of this chapter the model of the DIC at HIT is used. The
simulated system is not able to use the maximum intensity allowed for each raster point, as increasing
and decreasing the intensity cannot be done instantaneously. The treatment times are thus prolonged
compared to an ideal case. In addition, comparable to the fixed intensity, several conditions need to be
fulfilled to irradiate the IES with the highest possible intensity. Especially, if the particle numbers of the
raster points are heterogeneous, the maximum allowed intensity can be reduced due to the dose lost
in transition or the restricted measurement range of the ionization chambers. In general, two types of
intensity fluctuations are always present and have to be considered. The feedback loop of the DIC needs
milliseconds to adjust the intensity, hence, only intensity fluctuations on this time scale can be influenced.
Fluctuation on the scale of microseconds are always present due to statistical variations and cannot be
avoided by the use of a DIC as implemented at HIT. Further details about the described DIC can be found
in [Sch11, Pan14, Sch15]. For more information about DIC in general and the implementation at the
Heavy Ion Medical Accelerator in Chiba (HIMAC) the reader is referred to [Fur04,Fur05,Fur07,Sat07].
4.1.3 Scan-Path Optimization
To deliver a carbon ion treatment, the single raster points of an arbitrary IES are connected via a scan
path determining the order of their irradiation. However, due to technical limitations of the raster
scanning system, the gaps between two raster point must be smaller than a facility specific threshold, for
instance, 2.2 times the FWHM of the beam at HIT, in the following called scanner limit. The standard
scan path implemented in TRiP98 tries to connect all points using a meander path across the IES avoiding
to change the x and the y coordinate of the position at the same time, an example is given Figure 4.2(a).
The algorithm is divided into three steps. In the first one the algorithms starts at the top of the IES and
determines lines of raster points. The latter are then connected with each other as long as the distance
between two following raster points is smaller than allowed by the system. In case of a too large distance
the algorithm starts searching for ’subpaths’. The final ’subpath’ is the one which can connect the highest
number of raster points. In the second step the algorithm tries to extend the previously found path with
the residual points, which could not be included in the first step. Therefore it is checked if neighboring
points, not included in the scan path yet but within the scanner limit, can be added to the path. If it is
not possible to connect all raster points, the IES is subdivided into two separate slices. In the last step
small subgroups of the path are permuted to smooth the path [Web]. An ideal scan path is as short as
possible, avoids larger gaps to reduce the number of particles lost between two raster points and does
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not have any crossings [Kan07]. As the inhomogeneity of treatment plans is increasing, especially when
using intensity-modulated particle therapy (IMPT), alternatives to the meander path are warranted.
An alternative method to optimize the scan path is to cast it as a traveling salesman problem trying
to minimize the path length while neglecting the amount of direction changes, an example is given in
Figure 4.2(b). The distance between the raster points can be determined by
di =
Æ
(x i − x i+1)2 + (yi − yi+1)2. (4.1)
Thus, the objective function which needs to be minimized is given by
f =
∑N−1
i=1
di. (4.2)
In Figure 4.2 the two different scan path optimization methods are compared. A SPO as a traveling
salesman problem is a NP-hard problem. It needs high computational power to be solved exactly for
a non-trivial sample size. Several different polynomial-time algorithms can be found in the literature
for approximating the optimal solution [Rei94]. Sengoku et al. and Dias et al. proposed the use of a
genetic algorithm with heuristics [Sen98, Dia12, Dia15]. A genetic algorithm is a metaheuristic, which
is inspired by the survival of the fittest, the process of natural selection, and belongs to the large group
of evolutionary algorithms [Raw91]. For this work a genetic algorithm is combined with a mutation and
a crossover method [Sen98, Dia12, Dia15]. This combination allows to perform an efficient calculation
of a scan path with minimized length. The use of a genetic algorithms allows to overcome a locally
found minimum and approach the global minimum. In comparison to the traditionally used meander
algorithm, the genetic algorithm provides better optimization especially for inhomogeneous raster point
distributions. The traveling salesman algorithm manages to optimize a connected scan path in cases
where the meander algorithm fails. During the work of this thesis a genetic algorithm was implemented
in the DSim software.
(a) Meander algorithm (b) Traveling salesman algorithm
Figure 4.2.: Comparison of the two scan path optimization methods, showing that a traveling salesman
algorithm produces shorter scan paths’ than the meander algorithm.
Generally, the following steps have to be performed to minimize a scan path with a genetic algorithm:
1. Determination of a starting population P0 with a certain number (N0) of random paths.
2. Determination of the fitness value of all paths (e.g. the path length) and removing a certain fraction,
pd×N0, of the paths with the worst fitness values. This yields a new path population P1.
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3. From the path population P1 a predetermined percentage, pc, is selected for the greedy-subtour
crossover. The newly created paths are added to P1 to obtain again N0 paths in total.
4. For the mutation, a predetermined percentage, pm, of the population P1 is selected. The modified
paths replace the selected ones in P1.
5. Finally, the whole process is repeated from step two using P1 instead of P0. The loop ends when
either the maximum number of iterations is reached or no improvement is found within a certain
number of iterations.
For the mutation the 2-opt method [Cro58] was chosen and for the crossover the greedy-subtour
crossover was selected, proposed in [Sen98].
2-Opt method
The 2-opt method was proposed by Croes in 1958 to solve the traveling salesman problem (TSP) [Cro58].
The approach is able to create paths without intersections, but it cannot consider global optimization
goals. To reduce the path length intersections are identified and removed. Equation 4.3 can be used to
identify an intersection comparing the distance between two pairs of neighboring points. If exchanging
the partners of the pairs reduces the sum of the distances the exchange is kept.
Wi+rWi+r+1 +WiWi+1 >Wi+rWi +Wi+r+1Wi+1 (4.3)
This approach neglects all optimizations that take into account more than the exchange of two subparts.
In addition, the runtime is rather long, as the algorithms need to calculate the distances between all
raster points yielding a O(n2) complexity. The algorithm needs to run several times as new crossings can
be induced by the 2-opt method. A scheme of the application of the 2-Opt method is given in Figure 4.3,
where the exchange of neighboring pairs is illustrated.
Figure 4.3.: Schematic of the 2-Opt method. Adapted from [Dia12]
Greedy-Subtour Crossover
The greedy-subtour crossover was proposed in [Sen98] to add new paths to the existing path popula-
tion. While the 2-Opt method can only perform local optimizations, the greedy-subtour crossover allows
to combine two paths, changing their global structure, to approach the optimal solution. A schematic
of the method is shown in Figure 4.4. Performing the greedy-subtour crossover involves the following
steps:
1. Two random parent paths are selected.
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2. A random entry of the first parent is chosen, the position is stored (x1) and the entry is added to
the child path.
3. The position of the same entry in the seconds parent path is searched(x2).
4. x1 is changed to x1-1 and x2 to x2+1. The entry of x1 is placed on the left of the existing entry in
the child path and x2 is placed on the right.
5. The previous procedure (step 4) is continued until one entry is already part of the child path.
6. In case the child path is still shorter than the parent paths, the remaining entries are added in
random order to the end of the child path.
1 3 5 9 0 6 2 4 7 8
9 5 6 3 7 1 8 2 4
9 0 6 3 7
2 1 4 5 8
0
Add residual spots 
in random order
child path
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Figure 4.4.: Schematic of the greedy-subtour crossover method. The red boxes indicate the positions x1
and x2. Figure adapted from [Sen98]
4.1.4 Separate Iso-Energy Slices
As pointed out in the previous sections, the irradiation time is prolonged by the large differences in
particle numbers of the raster points in a single IES. In the case of a fixed intensity, time is lost irradiating
raster points with an unsuitable low intensity. In the presence of DIC, the perpetual increasing and
decreasing of the intensity is responsible for a prolonged treatment times due to the finite intensity
gradient. Both problems can be handled by categorizing the raster points of a single IES into sets of
small and large points, which have a small or high particle number, respectively. With a fixed intensity
irradiation, these two sets are placed on two different slices, from here on called SPO I. Using DIC both
sets can be irradiated within one slice, but due to the new scan path considerably less intensity ramping
is needed. This approach is named SPO II in the following. However, when applying a SPO it must
be ensured that the adapted scan path can be irradiated. For instance, the distance between two raster
points that are irradiated in succession must not be greater than the limit given by the scanning magnets.
In the following the SPO developed during this thesis is explained. A schematic of the SPO algorithm
is given in Figure 4.5. In addition, the outcome of SPO I and SPO II is shown in Figure 4.6(a) and
Figure 4.6(b), respectively.
At the beginning the raster points are separated by a threshold, which is proportional to the mean
particle number of the raster points within the IES. To exploit the potential of the algorithm the threshold
is slightly increased until the maximum particle number of the chosen intensity level is reached. If the
separation of the raster points does not lead to a shortened irradiation time, the IES is irradiated in the
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Figure 4.5.: Scheme of the SPO.
original form. This is only the case, if all raster points in the original IES can be irradiated with the same
intensity level.
Subsequently, the algorithm tries to find and optimize a scan path for the large raster points. If a scan
path can be constructed, the algorithm proceeds with the next step. If it is not possible to optimize a
new scan path due to gaps, the intensity threshold is reduced to the next intensity level provided by the
accelerator and the optimization is started again. This procedure is repeated until a scan path is found
for a subset with an increased intensity. Otherwise the IES is irradiated with the original scan path and
intensity.
If the algorithm is successful, it continues with the optimization of the scan path of the small raster
point set. The number of small points is usually significantly lower than the number of large raster points,
hence, gaps are more likely. For the set of small points gaps can be closed by creating additional raster
points. The additional raster points are generated by splitting some of the large raster points. During
this process it must be ensured that the number of particles for any of the large points is higher than the
minimum number allowed by the current intensity level. Hence, a subset of large raster points with a
sufficiently high particle number to deduct new beam spots is identified. Then the A*-algorithm [Har68]
is used to bridge every gap in the small points by using the subset of the large points. If no path is
found for one of the gaps, the whole separation of the IES is canceled. Otherwise, the points used by the
A* algorithm are added to the set of small points and the corresponding particle number is subtracted
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(a) Example for SPO I. On the left (red) the original IES
is shown with the meander scan path. In the middle (or-
ange) the raster points with the low number of particles
are shown with the corresponding scan path and on the
right (blue) the same is shown for the large raster points.
This SPO can be applied with a constant intensity as well as
using ac DIC
(b) Example for called SPO II. On the
left (red) the original scan path is shown,
while on the right the combination of the
scan paths of the small (orange) and large
(blue) raster points is displayed.
Figure 4.6.: Examples for the outcome of the SPO algorithm.
from the corresponding large point, yielding a successful separation of the IES. The plan can now be
irradiated, either within one slice for a DIC or in two separated ones applying a constant intensity.
4.1.5 Simulation Software
To simulate treatment time and intensity, the software DSim, developed at GSI Helmholtz Center for
Heavy Ion Research (GSI), was used and extended. The software allows the simulation of a beam
delivery taking into account the different parameters for different accelerators. Up to now simulations
for HIT and GSI are possible and an extension for Marburg Ion-Beam Therapy Center (MIT) is planned.
The DSim is a necessary step for 4D simulations carried out with TRiP4D.
DSim can simulate different modes like static, rescanning and 4D optimized irradiations and can com-
bine all modes with gating. The software is command line based and written in C++. It was originally
developed by Daniel Richter and Peter Steidl [Ric12,Ste12]. A modularization was carried out by Sebas-
tian Hild in 2014. The latter allows the fast implementation of additional features such as DIC and SPO,
which are independent of the optimization of a treatment plan but are reordering the raster points.
The aim of the DSim is to predict the speed and timing of an irradiation. Correct treatment simulations
are especially important for irradiations of moving targets to gain a correct temporal correlation between
the irradiation and the target motion. Thus, 4D dose distributions can be calculated and the possible
interplay effects as well as the efficiency of the motion mitigation techniques can be assessed. Therefore
DSim processes all IESs and corresponding raster points and determines the intensities and irradiation
times per raster point. The list of intensities and treatment times is merged with the spill structure
of the accelerator, providing a full temporal simulation of a specific accelerator. To allow the correct
determination of the accelerator settings and corresponding irradiation times, libraries representing the
different available accelerator parameters are included. In addition, the tool is able to correlate the
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irradiation timepoints of the beam spots and a motion surrogate to simulate 4D optimized and gated
treatments.
For the results described in this chapter, the irradiation time was determined using DSim. The raster
point order was modified by applying the previously described SPO. The particle number per raster
point was kept constant to not change the static dose deposition optimized by the treatment planning
system (TPS).
4.1.6 Patient Data
The use and influence of the fast rescanning strategies presented within this chapter was investigated
using three different data sets. First of all, the algorithm was applied to the data set of the pig feasibility
study presented in Chapter 2, consisting of 14 pigs, divided in three different target and dose groups.
Further details can be found in section 2.1.1.
In addition, a data set of five patients for the catheter-free ablation of the pulmonary veins in humans
was used. A corresponding treatment planning study was published in [Con14,Con16]. As the irradiation
times of the published data are long, the benefit of the approaches described above was investigated.
However, to successfully apply the SPO, the spacing between the raster points had to be increased from
1 mm to 2 mm to gain a more homogeneous grid of raster points.
To show the efficiency of the approaches not only for catheter-free ablations, the use of the proposed
techniques for hypofractionated cancer treatments was investigated. Hence, five lung cancer patients
were used out of the patient group of a study published in [And16b]. Finally, the SPO efficiency is
investigated during experiments using three clinical plans for liver and one clinical plan for pancreas
treatments provided by HIT.
4.1.7 Experimental Set-up
To measure the exact timing and to benchmark DSim for further simulations studies, an experiment
was carried out in the quality assurance cave at HIT. Two different experimental set-ups were used,
see Figure 4.7. For the first one, called 2D-setup, a prototype of the Octavius SRS1000 (PTW, Freiburg,
Germany) capable of proton dosimetry recorded the dose of single IESs in shoot-through measurement.
In addition, a Beckhoff system and the machine beam records provided information on the timing of the
accelerator [Ric12]. The Octavius SRS1000 was mounted on top of a sliding table to be able to perform
4D measurements. The motion amplitude in horizontal direction was 2 cm and the motion period was
chosen to be approximately 5 seconds to investigate the effect of DIC on 4D dose distributions. In
second set-up, called 3D-setup, the Octavius SRS1000 detector was replaced with a water phantom
(PTW, Freiburg, Germany) and 24 pinpoint ionization chambers to measure the accuracy of 3D dose
distributions. As in the first set-up, the Beckhoff system and the machine beam records were used to
gain the timing information.
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(a) The experimental set-up of the 2D measure-
ments is shown. The Octavius SRS1000 (1) was
mounted on top of a sliding table (2) to be able
to perform 4D measurements and reconstructions.
The set-up was positioned up stream of the beam
exit window (3) without additional material in-
between.
(b) An experimental set-up comparable to the one
used for the 3D measurements is shown, including
the 24 pinpoint ionization chambers and the wa-
ter phantom, both manufactured by PTW. Figure
taken from [Kad11].
Figure 4.7.: Experimental set-up of both parts of the experiment in the QA-room at HIT.
4.1.8 Data Analysis
The data analysis carried out for the 4D simulations as well as for the measurements is described within
this section. For an easier understanding the used methods are split in two parts. First the data analysis
of the simulations will be explained followed by the analysis of the measurements.
Simulations
For all patient cohorts, treatment plans were optimized using TRiP4D [Ric13]. The resulting treatment
plans were then modified using the SPO and corresponding BDS were determined using the DSim soft-
ware to create the necessary input data for 4D dose calculations. Afterwards a set of interplay and
rescanning simulations was carried out for each patient cohort.
In the pig cohort, for each animal simulations were performed combining three different heart rates
with 60, 70 and 80 bpm, 8 different starting phases (0◦, 45◦, 90◦, 135◦, 180◦, 225◦, 270◦, 315◦) and a
regular and irregular heartbeat. All described options were simulated for a constant and a dynamic inten-
sity for rescanning as well as for interplay irradiations. For the rescanning simulations, also calculations
for the SPO were carried out for both intensity patterns, yielding in total 2688 simulations for the pig
cohort. For the human patient cohort interplay and rescanning simulations for two different heartbeats
with 60 and 86 bpm and 4 different starting phases (0◦, 90◦, 180◦, 270◦) were conducted, comparable
to the simulations performed in [Con14, Con16]. In total, 240 simulations were carried out for a con-
stant and a dynamic intensity for rescanning as well as for interplay irradiations. For the rescanning
simulations, also calculations for the SPO were carried out for both intensity patterns. Also two motions
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of 17 and 12 breathing cycles per minute were used for the lung cancer data combined with 4 different
starting phases (0◦, 90◦, 180◦, 270◦), comparable to the simulation performed in [And16a, And16b].
The total number of simulations was 240, as for the catheter-free ablation in humans.
For all simulations, the expected irradiation times for the different scan paths were extracted from
the logfiles of the DSim. The resulting irradiation time of the simulation without DIC and without SPO
was treated as a reference. All time savings were calculated relative to this reference time, if not stated
differently. In addition, for all different simulation types and patient cohorts a two-sided paired T-test
was carried out.
V95, D95 and D5-D95 were calculated for all simulations comparable to chapter 2, to determine changes
in the target coverage and dose homogeneity. The found results were compared for the different ap-
proaches using SPO, applying DIC and combining both approaches.
Measurements
For the readout of the Octavius SRS1000, the software delivered by the manufacturer (BeamAdjust 1.9,
PTW Freiburg, Germany) was used, while for the pin-point ionization chambers a software written by
C. Karger was applied [Kar99], providing a graphical feedback. The differences between measured and
simulated irradiation times were determined using the machine beam records and the log files of the
DSim. To compare the deviations for the simulated and measured treatment time for each raster point,
the root-mean-square error (RMSE) was determined for each treatment plan. For the measurements
with the water phantom and the pinpoint ionization chambers, the mean and the standard deviation
of all pinpoints for each measurement was determined. The results for the original plans without SPO
were taken as reference. For all irradiated 2D and 3D plans the actual time savings of DIC and SPO was
determined.
To compare the outcome of the static measurements with the Octavius 1000SRS, the measured doses
of 60 plans were analyzed. The similarity of the measured dose distributions was investigated by de-
termining the γ index [Low03, Low98]. For each plan the γ-index was calculated to compare DIC and
constant intensity measurements, measured dose distributions with and without rescans as well as SPO I
and SPO II dose distributions. In addition, the measured dose was plotted for all irradiated plan types
to visually compare the results. For γ-indices smaller than 0.95 (2mm/2 %) the total deviation of the
measured doses was determined.
For the 3D dose measurements the deviations in each pinpoint were analyzed and deviations for each
field, pinpoint and patient were determined. In total 35 measurements were carried out investigating
treatment plans of 5 different patients. However, due to technical problems, such as, interlocks and
aborted measurements, only 30 measurements could be analyzed.
For the 2D measurements 7 single IESs of liver cancer and cardiac ablation plans in pigs were used.
For the 3D measurement one pancreas plan, two liver plans (Liver1, Liver2) and both fields of a cardiac
ablation plan in pigs was measured. In total 270 measurements were carried out during the experiment.
4.2 Results
In the following chapter results of simulations as well as measurements investigating the influence of DIC
and SPO on 4D dose distributions are presented. In addition, possible time savings for both speed-up
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techniques are analyzed. Throughout this chapter results are either given as mean values with standard
deviation (mean ± stdev) or as median values with the range between the 25th and 75th percentile
(median (25 % - 75 %)).
4.2.1 Simulations
Simulated time savings
For all patient cohorts combined, average time savings of 50 ± 10 %, 55 ± 7 %, 51 ± 11 % and 59 ± 8 %
were found for the use of a DIC, SPO I, SPO II and for SPO I with DIC, respectively. Applying SPO II for
a plan delivered with DIC could further reduce the treatment time by 5 ± 2 %, 8 ± 1 % and 1 ± 1 % for
the pig feasibility study, human pulmonary vein ablations and lung cancer treatments, respectively. In
addition, the time reduction was increased using DIC and SPO I, as originally proposed for facilities with
constant intensity. In this case additional time savings of 27 ± 7 %, 3 ± 1 % and 18 ± 3 % were found
compared to a irradiation without SPO for the pig feasibility study, human pulmonary vein ablations and
lung cancer treatments, respectively, were found. An overview of the time savings separated for each
patient cohort is given in Table 4.1.
DIC SPOI SPOII + DIC SPOI + DIC
Cardiac Ablation - Pigs 51 ± 5 % 45 ± 6 % 49 ± 5 % 38 ± 7 %
Cardiac Ablation - Humans 33 ± 2 % 39 ± 2 % 30 ± 2 % 32 ± 2 %
Lung Cancer Patients 58 ± 8 % 50 ± 8 % 58 ± 9 % 48 ± 8 %
Table 4.1.: Simulated relative irradiation times compared to rescanned irradiation with constant intensity
for each IES
Target Coverage
The target coverage for all simulation types of the pig feasibility study are shown in Figure B.1. While for
some pigs, for instance, 4, 6 and 8, deviations in the interplay pattern can be seen between a delivery with
constant intensity and one with DIC, no differences can be found for the different rescanning simulations.
Comparing the results to the simulations with constant intensity and traditional scan path, no clinical
relevant reduction in the target coverage and dose homogeneity was found, neither for applying the
SPO nor using a DIC or a combination of both. However, for all simulation types statistical significant
deviations (p < 0.05) were found, especially for the planning target volume (PTV) coverage. Detailed
results are listed in Table B.3.
As for the pig study, also the human heart cohort showed differences in the interplay pattern between
a delivery with and without varying intensity. The rescanning results are comparable for both kinds of
accelerator specifications and the different applied SPOs. In Figure B.2 detailed results for the 4D sim-
ulations of the pulmonary vein isolation in humans can be found. In Table B.5 the p-values, comparing
the target coverage and dose homogeneity for all different simulation types are given. Even though all
deviations are not clinically relevant, statistically significant (p < 0.05) changes were found in D95 and
D5-D95 values.
The interplay patterns for the lung cancer patients vary between simulations with constant intensity
and with DIC, especially for Patient 1, 3 and 4. There was no relevant difference in the target coverage
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for the different types of rescanning simulations. In summary, the changes in the BDS have no relevant
influence on the outcome of the motion compensated 4D simulations. For a detailed analysis of the 4D
simulations the reader is referred to Figure B.3. Statistically significant changes (p < 0.05) were found
for all simulations types in the V95 results. However, none of the deviations are clinically relevant.
4.2.2 Measurements
In the following sections the results of the measurements at HIT are presented, showing the actual time
savings and validating the DSim. In addition, comparisons of the measured doses are performed in 2D as
well as in 3D to verify the comparable dose distribution for different scan paths and delivery intensities.
In total 270 plans were irradiated, 235 2D and 35 3D plans.
Validation of DSim
The agreement between measured and simulated irradiation times is good, showing average deviations
below 5 %. However, the deviations are larger for the short single IES plans measured with the Octavius
set-up. In this measurements deviations above 4 seconds were found, neglecting interlocks during the
irradiation. This can be traced back to the number of spill pauses, as they differed between the simulation
and the measurements. The extraction time varied between 4.4 and 5.1 seconds deviating from the
expected and simulated extraction time of 5 seconds.
Median [%]
3D 4 (1 - 7)
Static -1 (-6 - 4)
Rescanning -1 -6 - 2)
NewPath 0 (-2 - 1)
Large Points -14 (-21 - -4)
Small Points -17 (-62 - -6)
All 2D Plans -4 (-18 - 1)
Table 4.2.: Temporal agreement between simulated and measured irradiation time of the complete treat-
ment plan including spill pauses but neglecting interlocks. Negative values correspond to an
underestimation of the treatment time in the simulations. In column 2 median values are
given with the correspond 25th and 75th percentile given in brackets.
An overall agreement of 4% (1% - 7%) and of -4% (-18% -1%) was found for the total treatment
times for 2D and 3D plans, respectively, neglecting irradiation with interlocks. Detailed results separated
according to the different plan properties are shown in Table 4.2.
For all plans the RMSE of the simulated and measured treatment times was determined, quantifying
the agreement of simulations and measurements. For all following calculations, all raster points influ-
enced by spill pauses were ignored due to a varying duration of the latter. In addition, the data was fitted
with a line through the origin to determine systematic deviations between simulation and measurement.
It was found that for the 2D measurements a significant deviation of 3 % and 4 % is present for DIC
and constant intensity, respectively, whereas the simulated treatment time is always overestimating the
actually necessary time. For the 3D measurements delivered with DIC a deviation of 3 % was found as
well. In Table 4.3 the RMSE is given for all plan types and for DIC as well as for a constant intensity.
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Constant Intensity Dynamic Intensity
RMSE [ms] Incline RMSEcor [ms] RMSE [ms] Incline RMSEcor [ms]
3D - - - 1.43 0.97 1.43
Static 2.34 0.96 0.91 3.44 0.99 3.41
Rescanning 1.74 0.96 0.70 1.24 0.97 1.13
NewPath - - - 1.03 0.96 0.87
Large Points 0.51 0.95 0.39 0.58 0.96 0.53
Small Points 0.67 0.95 0.53 1.00 0.98 0.99
All 2D Plans 1.56 0.96 0.67 1.25 0.97 1.17
Table 4.3.: RMSE for the temporal agreement between simulated and measured treatment times splitted
by constant and dynamic intensity for the 2D measurements. The first column states the RMSE
comparing the simulated and the measured values. The second column states the incline of
a fitted line through the origin and the third column states the corrected RMSE considering
the fit as truth. All results neglect the raster points influenced by the varying spill pause
timepoints. Incline smaller 1 corresponds to an overestimation of the treatment time by the
simulations.
Furthermore, the incline of the fit is stated to indicate the systematic deviations. The uncertainty of the
incline was below 0.001. The largest deviations are found for heterogeneous treatment plans irradiated
with high intensities (static). Furthermore, the RMSE for DIC is higher compared to deliveries with a
constant intensities.
(a) Irradiation times for each raster point displayed for
4 different measurements using a fixed intensity and the
simulation.
(b) Simulated irradiation time of each raster
point plotted over the corresponding mea-
sured irradiation time. Data points appear
almost as line through origin. Strips for the
simulations appear due to fixed possible irra-
diation times.
Figure 4.8.: Comparison of the simulated and measured irradiation times for each raster point.
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Differences between constant intensity and DIC are caused on the one hand by larger RMSE errors of
the dynamic intensity due to the time necessary for DIC to adjust the intensity, which is in the order of
10 ms [Sch15]. On the other hand, a slight systematic overestimation of the irradiation times for raster
points with irradiation times greater 100 ms is present. Both deviations can be seen in Figure 4.8(b).
The agreement between simulations and measurement are good and the DIC at HIT works stable and
reproducible. In Figure 4.8 the agreement between measured and simulated irradiation times is shown.
Measured Time Savings due to SPO and DIC
The time savings of the measured treatment plans were determined for DIC, SPO I, DIC+SPO I and
DIC+SPO II. The results show significant time savings as expected from the simulations. For the 2D
plans the total time saving due to DIC was determined to be 34 ± 26 %. For the 2D plans the use of
the separated SPO saves 59 ± 6 % of the treatment time, while with combined path saves 15 ± 9 %
for DIC. For a constant intensity, SPO I was able to save 79 ± 10 % of the treatment time. For the 3D
plans applying SPO I saves 28 ± 13 % of the treatment time compared to 13 ± 5 % for using SPO II on
average.
Dose Comparison in 2D
A good agreement between the measurments was found for the high dose IES taken from pig 12 and
pig 14. For this plans all calculated γ-indices were 0.99 or 1.00. However, deviations were found for
the IESs taken from a treatment plan of a liver cancer. Here γ-indices below 0.7 were found for the
rescanned plans with constant intensity compared to the rescanned plan with DIC and compared to the
non-rescanned plan with constant intensity. The deviations were determined to vary between 9 and 17
% depending on the measured plan. All calculated γ-indices and determined deviations can be found in
Table B.1 and B.2. In Figure 4.9 the measured doses of pig 12 are displayed for all situations.
Dose Comparison in 3D
The found deviations of the pinpoint measurements were in average smaller than 2 percent, except for
one patient. The exact values can be found in table 4.4. For Liver 2, a dose error due to path crossings
in the new scan path cannot be completely excluded. However, due to results of the other plans and the
good agreement of all other measurement of Liver 2, a technical problem is more likely.
Plan Deviations [%]
Pancreas 0.1 ± 0.0
Liver 1 1.0 ± 0.8
Liver 2 -9.2 ± 0.0
Pig 14 - Field 1 0.5 ± 0.4
Pig 14 - Field 2 -0.2 ± 0.9
Table 4.4.: Deviations of the measurement for all 5 irradiated treatment plans.
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Figure 4.9.: Comparison of measured doses with different delivery methods, showing results for a con-
stant intensity on the left and for DIC on the right. All different modalities to delivery the
dose are shown including the standard path with and without rescans, the modified one,
the delivery with raster points split in large and small particle number and, finally, the sum of
the large an the small dose. Apart from the top row all plans were delivered with 15 rescans.
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4.3 Summary and Discussion
In this chapter, new developments for faster rescanning techniques in ion beam therapy were presented.
It was shown that a significant reduction of the treatment time is possible without reducing the the target
coverage by using DIC, SPO or a combination of both. Even though changes in the BDS are present and
have influence on the interplay patterns, the same motion mitigation strategies could be applied for all
approaches. In addition, the software DSim used throughout this chapter was successfully validated for
irradiations at the accelerator at HIT allowing realistic 3D and 4D simulations, which can serve as a
platform to develop new treatment and motion mitigation strategies.
Agreement between Measured and Simulated Treatment Times
The deviations of the number of spill pauses between simulations and measurements had a significant
influence on the treatment time for short 2D plans, as irradiation times for the single IES measurements
were in the order of one spill duration. The reason for the extraction time variation is not clear yet and
further investigations are necessary. For reliable 4D simulations a correct prediction of the spill pause is
important to correctly correlate the irradiated raster point with the actual motion phase. Deviations in
the correlation can have severe influence on the final dose distribution, as one unexpected spill pause is
sufficient to change the temporal correlation of all following raster points of one IES. Some increased
understanding of the accelerator behavior is necessary to fully adapt the DSim to the HIT accelerator.
Nevertheless, it is possible to conduct realistic simulations of the irradiation time as well as the delivered
dose with the current version of the DSim. The behavior of the HIT accelerator is well reproducible and
stable. Irradiation time predictions of an arbitrary raster point are possible with median RMSE of 1.56
ms, 1.25 ms and 1.43 ms for 2D constant intensity, 2D DIC and 3D measurements, respectively. Especially
for motion mitigated simulations, different starting phases can be used to verify that the irradiation is
independent of slight changes in the temporal correlation.
Dose Comparison in 2D and 3D
Good agreements were found in the 2D dose distributions for Pig 12 and 14 between all application
methods, indicated by γ-indices of 1.0. However, for the single IES measurements of the liver plan
deviations were found in a certain plan. Especially, the measurement for the rescanned plan delivered
with constant intensity shows deviations from the rescanned plan delivered with DIC and non rescanned
plan delivered with constant intensity. Even though the shape of the recorded dose distribution were
equal, deviations in the absolute values of around 10 % were found as already stated in Section 4.2.2.
A possible explanation for such deviations was the different particle flux between the measurements.
All measurements showing a good agreement between all different modalities were irradiated with a flux
of 1·107 particles per second and higher, whereas all measurements showing deviations were irradiated
with a particle flux of 5·106 particles per second. The used detector is a prototype manufactured by PTW
(Freiburg, Germany). At the German Cancer Research Center (DKFZ) in Heidelberg a study showed that,
for smaller intensities measuring a homogeneous field without rescans, the measured dose deviates by
about 1 % from the expected outcome on average [Dol]. Further investigations are necessary to ensure
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that the measured deviations for the 2D dose distributions are not correlated with the use of DIC or SPO
and only occur due to detector properties.
For the 3D dose measurements the relative agreement between different scan paths was calculated
and did not show deviations between different modalities except for one plan. For a pancreas plan, a
deviation was found between the original and all modified plans. As all other plans showed a good
agreement, it is assumed that something went wrong with the data acquisition for the reference plan.
However, to completely ensure that the new scan paths or the application of a homogeneous rescanning
scheme did not alter the results, a repetition of the measurement should clarify the situation.
Potential Time Savings
Both methods described throughout this chapter offer excellent time savings. The described SPO pro-
vides an opportunity for facilities without DIC to reach treatment times that were only possible by using
DIC before. In addition, facilities already using DIC can further reduce the time necessary for irra-
diation. Furthermore, the possible time savings are comparable to the ones reached by applying the
inhomogeneous rescanning scheme. While time savings of 58 ± 8% were possible for an irradiation of
the inhomogeneous rescanning plans at HIT accepting a slightly reduced target coverage (see Chapter
2), SPO allows a time reduction of 55 ± 5% with target coverage comparable to the original plan.
However, the presented SPO works only when small intensity levels are used and the variation of the
particle number between the raster points is large. All this is typically avoided in the clinical routine,
where, especially for static tumors, the dose delivered per fraction is low and the minimum particle num-
ber per plan can be increased until the maximum intensity is allowed for each IES without any influence
on the target coverage. Even though increasing the minimum particle number works for static cases with
a normal fractionation scheme and also for hypofractionated ones, this approach is not possible anymore
when it comes to rescanned treatments. Rescanning reduces the minimum particle numbers significantly.
In addition, it is typically not possible to irradiate rescanned plans with particle numbers high enough to
allow the maximum available intensity without a significant influence on the target coverage and dose
homogeneity. To overcome the intensity limitations DICs were implemented in different particle facili-
ties [Fur07, Sch15]. However, it is shown in this chapter that the presented SPO can be effective even
in the presence of DIC. If SPO I or SPO II is more effective depends on the implementation of DIC and
is therefore facility specific. In case of the DIC implemented at HIT increased time savings are possible
using SPO I due to the chosen settings of the ionization chambers. To ensure a correct beam position
measurement for all raster points independent of the particle number, a sensitive setting of the ioniza-
tion chambers is chosen which does not allow the DIC to use the full range of available intensities. This
causes the superior time savings of SPO I combined with DIC compared to SPO II. Hence, it would be
interesting to perform comparable measurements at facilities with different DIC algorithms and compare
the found time savings.
The time savings found for DIC in combination with hypofractionated treatment plans are in the
order of 60 % for rescanned treatment plans and, hence, significantly higher as the possible reduction
of approximately 10 % described in [Sch11, Pan14]. However, the time savings are expected to be
less prominent in clinical routine. Especially for the liver and pancreas treatment plans, which were
optimized for a static irradiation but then delivered with 4 rescans. Thus, the minimum particle number
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was extremely heterogeneous. For more valid time saving results, clinical treatment plans optimized for
rescanned irradiations should be investigated.
The results for the 2D measurements show that time savings depend strongly on the structure of the
treatment plan. Potential time savings are limited for plans with high intensities, but are very prominent
for plans with mixed intensities. These plans can benefit from DIC as well as SPO.
Outlook
Due to the excellent time savings and unchanged target coverage the use of SPO and, if possible, DIC to
overcome intensity limitations is highly recommended. Depending on the facility and the characteristics
of a present DIC, additional time savings could be possible by further separating and optimizing the
scan path. An ideal scan path is facility dependent and tries to sort the raster points in a way that the
irradiation time is minimized. Thereby an automatic choice between SPO I and SPO II depending on
the IES properties would be beneficial. For a clinical transition further tests are necessary to ensure the
comparable dose distribution in more experiments. Furthermore, the implementation of the SPO in a
commercial treatment planning system is required.
In addition, the presented DSim offers great opportunities investigating new possibilities to overcome
interplay effects, to further reduce the treatment time using new techniques and to carry out realistic
4D simulations. A possible step for future developments is to combine simulated 4D optimized treat-
ments [Gra14] with the presented SPO. This would further improve the treatment options and hence
improve the treatment outcome of carbon ion therapy. In future, the extension and validation of the
DSim software is planned for more ion beam therapy centers. To compare different implementations of
DICs, comparable experiments as presented in this chapter should be carried out at the Marburg Ion-
Beam Therapy Center, at the Shanghai Proton and Heavy Ion Center as well as at Centro Nazionale di
Adroterapia Oncologica.
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5 Discussion and Outlook
A first in-vivo study treating cardiac arrhythmia with scanned carbon ions was successfully conducted at
GSI Helmholtz Center for Heavy Ion Research (GSI) in July 2014. This was not only the first study using
particle therapy, but also the first one employing a full 4D treatment planning approach based on cardiac
time-resolved computed tomographys (4DCTs) as well as a respiratory gating strategy. Fibrosis and
tissue modifications were induced at predetermined locations showing the potential of scanned carbon
ions as a non-invasive treatment modality for cardiac disorders. Electrical pathways were altered in the
heart muscle without observing radiation induced side effects. Due to the inverse depth-dose profile
of carbon ions and the raster scanning technique, highly conformal dose distributions were delivered
successfully, sparing critical structures.
Nevertheless, the use of 4D treatment planning and dose calculations was necessary to ensure a correct
mitigation of interplay effects. As carbon ions delivered by an active scanning system are prone to motion
effects, repeated breath-holds were combined with rescanning to account for breathing and heart motion,
respectively. A new, inhomogeneous rescanning scheme was applied to reduce the necessary treatment
time, allowing the irradiation of all pigs within a limited time frame. However, the inhomogeneous
rescanning approach came with the drawback of a reduced target coverage.
Even though a large effort was invested to achieve comparable treatments of all pigs, the study results
were heterogeneous and differed between animals of identical target and dose groups [Leh16b]. As
shown in Chapter 3, retrospective analysis showed that the quality of the recorded 4DCTs was poor
and that the applied B-spline deformable image registration (DIR) was not sufficient to correctly model
the heart motion. Thus, the target volume of the left ventricular free-wall (LV) group was likely not
irradiated with the full planned target dose. For the atrioventricular node (AVN) group, manual re-
contouring blinded to the study outcome was done for each motion phase to study the effects of DIR on
the treatment planning. In this scenario, it was shown that the treatment planning for the AVN group was
correct. The same result is expected for the superior pulmonary vein (SPV) group, although a validation
study was not possible as the contours were too complex and could not be reliably transformed to each
motion phase manually.
The poor quality of the DIR is also the reason for a reduced median target coverage in the 4D simu-
lations. The reduced median target coverage in the planning target volume (PTV) found in Chapter 2 is
mainly not due to residual motion effects. Instead, the uncertainties of the DIR, especially the large er-
rors of the inverse consistency, shown in [And16b], did not allow realistic 4D simulations. However, the
large variation in the target coverage for single pigs, for instance, Pig 6 shows that the used rescanning
scheme was not sufficient to completely mitigate interplay effects. Future treatment planning studies
should carry out perfect rescanning (PRSC) simulations first, before 4D simulations using beam deliv-
ery sequences (BDSs) and motion surrogates are performed. This allows to calculate the ideal 4D dose
distribution not influenced by motion effects. In case of a poor target coverage for PRSC simulations,
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problems of the DIR are likely and a careful consideration of the DIR is necessary prior to the conduction
of full 4D simulations.
In addition, new and faster delivery methods were developed and implemented in the beam delivery
sequence simulation (DSim) software. The treatment time was a critical quantity during the feasibility
study as the beam time was limited and, hence, fast application of each plan was necessary. The same
problem occurs during clinical routine in particle therapy. In the clinics the treatment time of each
individual patient should be as short as possible, not only to increase the number of patients treated per
day, but also to increase the patients’ comfort. Furthermore, baseline drifts and other irregular motion
effects are known to increase with treatment time, deteriorating the treatment outcome [Wöl14]. Hence,
a scan path optimization was developed to reduce the treatment time. The scan path optimization as
well as the dynamic intensity control (DIC), developed at Heidelberg Ion-Beam Therapy Center (HIT),
was implemented in the DSim software to enable reliable 4D simulations using TRiP4D [Ric13].
The scan path optimization allows a reduction of the treatment time, comparable to the inhomoge-
neous rescanning scheme used during the feasibility study, while target coverage and dose homogeneity
are not altered on a clinically relevant level. The DSim software was also validated in experiments at HIT
and can be the base for future developments for the irradiation of moving targets. The DSim validation
showed a good agreement between measured and simulated irradiation times of each raster point. Only
the timing of the spill pauses needs some further investigation to allow correct prediction of the BDS.
5.1 Possible Improvements for Future Studies
The feasibility study was successful and new approaches were developed to further reduce the treatment
time in following in-vivo studies. Even though the reported study could induce tissue modifications
in the targeted areas, the heterogeneous results suggest the need for further experiments in animal
models. Image acquisition, DIR and treatment planning should be appropriately adapted considering
the knowledge gained from the reported study. Furthermore, the schedule of a following study should
be adapted. The time span between each irradiation should be prolonged to allow an iterative approach
increasing the knowledge from pig to pig. The first in-vivo study was carried out with several boundary
conditions. The available beam time was limited, the positioning equipment not state-of-the-art and
the infrastructure too complex and labor intensive. Additionally, an iterative approach would allow
to shorten the time between recording of the treatment planning computed tomography (CT) and the
irradiation. This reduces the possibility of anatomical changes in the still growing animals. Hence,
several improvements are possible and necessary for future in-vivo studies as well as for a fast transition
of catheter-free ablations into clinical routine.
Image Guidance
The first and most important aim for a following study must be an enhanced image guidance, through-
out the whole workflow from recording of the treatment planning CTs to real-time imaging during the
irradiation. For an improved outcome new protocols for the 4DCTs recording are necessary, as they are
the base for a correct DIR. The timing of the contrast agent, the 4D reconstruction and the suppression
of metal artifacts must be improved. Furthermore, a reliable DIR for cardiac-gated 4DCTs needs to be
developed. A correct DIR is essential to carry out 4D dose calculations and 4D treatment planning using
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vector fields connecting the single motion phases. However, a reliable DIR can be only determined on
the basis of high quality 4DCTs. While for abdominal and lung cancer treatments B-Spline algorithms
provided by Plastimatch [Sha10a] are sufficient, more advanced strategies are necessary to model the
complex motion of the heart, especially the thickening of the left ventricular free-wall during the ven-
tricular systole. To gain a correct description of the heart motion incorporating a biomechanical model
is necessary. Several heart models are known, however, most of them display only a certain area of the
heart due to the complex interaction of atria and ventricles. The first model considering all chambers
and the pericardium was published in [Fri14b]. The model is also able to consider patient specific data,
such as voltage maps from electrophysiological mapping examinations, which would be necessary for in-
dividual radiotherapy treatment planning. In addition, it would be necessary to develop a DIR algorithm
which can include the information of a biomechanical model.
Furthermore, it is not only necessary to understand and model the heart motion of the 4DCT recorded
for treatment planning. A deeper understanding of anatomical changes between data sets recorded at
different time points - such as the treatment planning CT, the actual treatment as well as possible changes
during the treatment - would be important for a reliable 4D treatment planning and 4D simulations. The
time between treatment planning and irradiation was several days for the feasibility study, which is also
the case for cancer treatments, as a certain amount of time to plan and approve the treatment plans
is necessary. However, it was found that within this time the heart volume can change causing range
errors [Pra14b]. In addition, it was found that the heart frequency varied during the treatment. The
heart frequency was increased between field 1 and field 2 due to a decreasing impact of the premedi-
cation. Furthermore, variations during each breath-hold were found. Hence, a study should be carried
out investigating how a changing heart rate or a changed heart volume influence the heart motion. This
could be investigated by magnetic resonance imaging (MRI) in healthy volunteers and patients. Alter-
natively, ultrasound imaging could be used, especially for patients with MR incompatible implantable
cardioverter-defibrillators (ICDs). The found data could then be included in a patient-specific heart
model.
The positioning is another crucial point, where image guidance plays an important role and needs to
be improved for future studies, especially for an extremely range sensitive treatment, such as carbon ion
therapy. For the presented feasibility study only orthogonal x-rays could be used due to the available
infrastructure. The use of a CT on rails or a cone-beam CT (CBCT) would increase the positioning
accuracy significantly [Ben15]. In addition, it would allow to recognize changes of the anatomy prior to
the irradiation, especially the position of pacemaker electrodes and the heart volume. This information
could be either used to re-plan and postpone the treatment or, in case of smaller changes, to gain a
more meaningful feedback from 4D dose reconstruction. Volumetric imaging at the treatment location
would enable dose calculations using the actual treated patient anatomy. Retrospective dose calculations
would be possible, without any further work, using a CT on rails. The use of CBCTs would require more
effort, but several different strategies are already published calculating particle dose distributions on
CBCTs [Lan15,Par15].
Finally, the application of image guidance as real-time monitoring of the motion would be another
important improvement. Ultrasound could be used as a possible motion control, since it is a powerful
tool to visualize heart motion and was already used in cancer therapy to track intra-fractional changes
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[Sch14,Pra14a]. However, the delays are still in the order of 200 ms and, hence, too large for a 4D beam
delivery. Thus, for motion guidance, it would be necessary to have a prediction model forecasting the
actual position of the target volume [Pra14a].
Treatment Planning and Delivery
Besides an improved image guidance also the treatment planning process as well as the beam delivery
could be improved. One possible option would be the use of 4D optimization strategies as proposed
in [Gra13, Gra14]. This approach determines individual treatment plans for each motion phase, allow-
ing a more conformal dose distribution further reducing doses deposited in the organs at risk (OARs).
However, 4D optimization, especially 4D rescanning [Gra14], requires an exact knowledge of the ac-
tual motion phase and a specialized treatment control system (TCS). Therefore, a real-time motion
surrogate would be necessary for the delivery of a 4D optimized treatment plan, showing again the im-
portance of improved image guidance. A further option to improve the treatment would be the use of
a robust 4D optimization. Robust optimization was proposed in [Unk04] for photons and in [Unk07]
first approaches for protons were published. Robust optimization allows to incorporate different scenar-
ios in the optimization, such as range changes and positioning errors. The number of scenarios can be
adapted to further uncertainties, which are, for example, extracted from the new DIR approach. Differ-
ent types of robust optimization algorithms are known [Liu12,Cha06]. An algorithm using the worst case
optimization approach proposed in [Pfl08,Liu12,Liu16] is under development for carbon ions [Wol16].
So far, all the stated improvements are concerning the treatment planning process and online imaging.
However, also the beam delivery is susceptible to errors and several improvements are possible. To fur-
ther reduce the treatment time and increase the target coverage, the developed scan path optimization
could be used, as shown in Chapter 4. Especially the combination of the scan path optimization and DIC
offers excellent possibilities to carry out the treatment in a reasonable time frame of below 15 minutes.
The extended and validated DSim software is capable to carry out realistic 4D simulations. Possible
future delivery techniques can easily be tested and simulated extending DSim. One possibility would be
the combination of a 4D optimized treatment, such as 4D rescanning [Gra14] and the scan path opti-
mization. For this task the determination of the optimal scan path has to be possible within milliseconds,
connecting the different phases without scanner jumps and ordering the raster points according to the
necessary intensities at the same time.
5.2 Clinical Transition
The goal of the described feasibility study is the transition of catheter-free ablation using carbon ions
into clinical routine. While the feasibility of this approach was shown, further research is still needed
to achieve this goal. Considering the results of the described animal study, the outcome is too heteroge-
neous to directly move from the reported in-vivo study to patient trials. Especially the irradiation of the
LV, as the target offering the highest potential gain for the patients, still comes with several challenges
and shows the most puzzling results of all three irradiated targets. Patients suffering from ventricular
tachycardia (VT) cannot be cured with the available treatments nowadays, as the penetration depth of
radio-frequency catheters is not high enough. Episodes of VT are interrupted by ICD shocks, but this
significantly reduces quality of life. In severe cases, including the so-called electrical storm with more
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than 3 events per day, mortality is markedly increased in spite of the ICD. However, in none of the
irradiated pigs out of the LV group a homogeneous transmural scar was observed, in contrast to the
original aim. As the fibrotic tissue induced in the LV is patchy for carbon ion as well as photon ir-
radiation [Leh16b, Leh16a], also experiments investigating the biological processes occurring after the
irradiation of cardiomyocytes are needed. Several other functional changes were observed besides fi-
brosis, which led, for instance, to a full AV-block. These changes might also be sufficient to eliminate
the causes of VT in inhomogeneous infarct scars. Further studies are needed to confirm this hypothesis,
preferably in an animal model of myocardial infarction or otherwise induced VT [Tao16]. In the animals
in this study, a homogeneous section of the LV was targeted. In actual patient cases, scars or other sub-
strates would be the target offering a visible contrast in both MR and ultrasound imaging. Contouring
and following this scar in all motion phases would be considerably easier, simplifying the task of both
physician and the DIR algorithm. Nevertheless, this requires reliable 4D imaging prior to the treatment,
combining CT, ultrasound and MRI data. These data also have to be fused using DIR, which poses new
challenges, though these are often already solved in clinical routine. However, one limitation is that MRI
is only possible for a subgroup of patients, as ICDs are a necessary step in the treatment of VT, but only
a limited number of MR compatible ICDs are in the market [Med]. Even though the goal is to introduce
radiotherapy as a non-invasive treatment for VT, due to the time needed to induce the scar tissue, the
use of an ICD cannot be avoided in most cases.
Furthermore, the use of radiotherapy would be extremely useful for patients who cannot undergo
surgery. For this patient group it would be advantageous to provide a non-invasive treatment without
anesthesia. Hence, it would be necessary to actively account for heart and breathing motion at the same
time. The approach used during the feasibility study relied on anesthesia as this was necessary in an
animal study anyway. An alternative, a combination of respiratory as well as cardiac gating was already
proposed in [Con14, Con16]. In photon radiotherapy, irradiation in deep-inspiration breath-hold is not
uncommon [BH16], also combined with patient coaching and visual feedback to stabilize the inspiration
endpoint. Even though this would reduce the stress of the patient, the technical complexity would be
increased even further.
5.3 Conclusions
In conclusion, this work reported the first in-vivo study showing the feasibility of carbon ions to change
electrical path ways in the mycoardium using pigs as an animal model. Catheter-free ablation using
carbon ions could induce an AV-block, an almost full isolation of the SPV and significant slowing of
the conduction. Furthermore, fibrosis as well as tissue modifications were created in the myocardium.
However, retrospectively uncertainties within the DIR were found and the influence on 4D treatment
planning and simulations was determined. The AVN and, according to the available data, also the SPV
group treatment planning was correct, although uncertainties in DIR were present. In contrast to this,
the treatment planning of the LV group likely could not achieve a transmural irradiation of the left
ventricular free-wall during all motion phases. Hence, for the LV group DIR uncertainties might have
caused a reduced target coverage.
A new inhomogeneous rescanning scheme was applied reducing the treatment time by more than
60 % while slightly reducing target coverage. As a clinically more acceptable and more robust alter-
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native, a scan path optimization was developed to similarly reduce the treatment time, while keeping
target coverage. This method can also be highly useful for single-fraction and hypofractionated cancer
treatments. The scan path optimization, as well as a DIC developed at HIT, were implemented in a
DSim software to carry out realistic 4D simulations. In addition, the DSim software was validated in
experiments throughout this thesis.
4D treatment planning as well as 4D dose calculations are important for a successful treatment of
moving targets. However, it was demonstrated throughout this work that 4D simulations rely heavily
on DIR and are thus are highly sensitive to errors in the DIR. As DIR is prone to errors, especially for
complex motion types such as the heartbeat, a careful investigation of each DIR on all motion phases is
necessary prior to treatment planning and dose simulations steps.
A future repetition of the pig study is necessary to bring catheter-free ablations using carbon ions
into clinical routine. For realistic 4D simulations and treatments, a reliable DIR is necessary and a new
registration algorithm needs to be developed based on a biomechanical model of the heart motion,
incorporating patient-specific information, such as ultrasound and MRI data.
From a physics point of view more in-vivo experiments are necessary to establish a reliable 4D treat-
ment planning approach especially for the LV patients. Major steps forward were done by conducting
the feasibility study presented in this work, developing the scan path optimization and extending and
validating DSim. The specific challenges of cardiac DIR became apparent for the first time in this unique
study setting. Even though they could not be solved completely during this work, their characterization
will enable future researchers to contribute to a successful clinical transition.
Radiotherapy, especially using carbon ions, is a promising non-invasive alternative which has the po-
tential to become a routinely used tool for the treatment of cardiac arrhythmia, opening new opportuni-
ties for patients who cannot be cured with radio-frequency catheter ablation. The remaining challenges,
described in detail in this work, can be overcome within the next years to make catheter-free ablation of
cardiac substructures using carbon ions as successful as carbon ion cancer therapy.
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Table A.1.: Mean values and standard deviation is given in [%] for the 3D verification. Results are given
for all pigs and fields as well as for the combination of both fields.
ID both fields 90◦ 270◦
1 0.30 ± 3.84 0.80 ± 3.91 1.90 ± 3.78
2 2.06 ± 4.30 2.43 ± 4.28 1.68 ± 4.32
3 2.38 ± 4.21 2.64 ± 4.20 2.13 ± 4.22
4 2.44 ± 4.36 1.82 ± 4.16 3.05 ± 4.55
5 0.54 ± 4.36 0.09 ± 3.94 0.99 ± 4.73
6 2.31 ± 4.62 2.02 ± 4.12 2.49 ± 4.93
7 1.36 ± 7.69 2.32 ± 4.98 -0.08 ± 12.40
8 2.86 ± 4.18 3.21 ± 4.04 2.16 ± 4.45
12 0.10 ± 3.27 -0.42 ± 2.80 0.62 ± 3.68
13 0.00 ± 2.95 -0.51 ± 2.49 0.52 ± 3.35
14 1.87 ± 2.97 1.87 ± 2.97 -
16 1.10 ± 3.05 0.54 ±3.30 1.95 ± 3.56
Table A.2.: Mean, max and min heart rate for all pigs during the irradiation for both fields.
ID
90◦ field 270◦ field
Mean BPM Max BPM Min BPM Mean BPM Max BPM Min BPM
1 86.68 94.64 80.86 88.61 95.69 82.64
2 49.51 59.464 44.09 51.18 58.14 45.98
3 81.14 86.33 76.34 78.90 83.68 76.24
4 67.28 81.41 62.96 66.18 73.44 61.92
5 63.28 68.97 58.14 62.73 66.52 58.48
6 52.79 61.29 47.51 66.41 73.35 59.88
7 58.08 63.90 53.43 65.96 73.08 60.42
8 66.83 71.94 61.79 74.83 79.47 70.59
12 65.54 76.24 58.31 75.27 96.00 63.56
13 52.80 60.12 47.58 - - -
14 52.04 60.98 45.35 53.69 61.73 47.96
15 64.16 78.43 56.55 67.39 76.82 60.30
16 57.43 63.16 52.17 62.05 68.89 58.25
17 59.53 70.92 51.72 66.01 78.74 56.71
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Table A.3.: Maximum motion amplitudes and corresponding motion phases of all pigs.
ID Max. Amplitude [mm] Motion Phase
AVN
1 3.58 2
2 4.54 2
3 3.48 3
4 4.33 2
5 2.25 2
6 4.74 3
7 3.08 2
8 4.05 3
SPV
12 3.15 3
13 3.87 3
14 1.82 1
LV
15 4.41 3
16 1.83 3
17 2.05 3
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Figure A.1.: Results of the static simulations for TV (a)and PTV (b). For all three target volumes (AVN, LV,
SPV) the values for V95, D95 and D5-D95 are given.
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Table A.4.: Results of the static simulations for V95, D95 and D5-D95.
ID V95[%] D95[%] D5-D95[%]
TV
AVN
1 103.0 100.0 0.1
2 102.9 100.0 2.1
3 103.0 100.0 0.1
4 101.1 100.0 3.6
5 102.8 100.0 1.3
6 101.0 100.0 3.8
7 102.9 100.0 1.8
8 101.1 100.0 3.0
SPV
12 101.5 100.0 3.1
13 103.0 100.0 1.3
14 102.9 100.0 1.6
LV
15 101.8 100.0 1.3
16 102.0 100.0 1.1
17 101.9 100.0 1.3
PTV
AVN
1 101.5 100.0 1.7
2 101.7 100.0 3.1
3 101.6 100.0 1.5
4 101.8 100.0 3.0
5 101.8 100.0 1.2
6 101.8 100.0 1.3
7 101.7 100.0 1.3
8 101.8 100.0 1.2
SPV
12 101.7 100.0 2.8
13 101.8 99.8 2.5
14 101.9 98.8 1.1
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Figure A.2.: Results of the interplay simulations for TV (a) and PTV (b). For all pigs the values for V95, D95
and D5-D95 are given. Each box includes 96 simulations per pig, including different motion
patterns, regularity of the heartbeat and spill structures.
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(a) Results of the interplay simulations of the TV
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(b) Results of the interplay simulations of the PTV
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Table A.5.: Results for the interplay simulations for V95, D95 and D5-D95. For all pigs and volumes the
median values for all 96 simulations are given and in brackets the 25th -75th percentiles are
shown.
ID V95[%] D95[%] D5-D95[%]
TV
AVN
1 100.0 (84.6-100.0) 98.7 (93.2-102.5) 8.4 (6.2-11.9)
2 100.0 (88.8-100.0) 97.6 (94.7-101.1) 10.1 (7.2-14.0)
3 100.0 (92.8-100.0) 98.8 (95.6-101.7) 8.1 (6.4-10.8)
4 100.0 (84.9-100.0) 98.2 (94.3-101.8) 9.3 (7.0-11.2)
5 100.0 (100.0-100.0) 99.6 (97.6-102.0) 6.0 (4.8-7.8)
6 99.0 (75.5-100.0) 97.0 (92.6-99.9) 11.7 (9.4-15.2)
7 100.0 (80.1-100.0) 98.4 (94.3-101.6) 9.6 (7.5-12.4)
8 98.9 (87.5-100.0) 97.6 (95.1-100.6) 8.6 (6.1-11.3)
SPV
12 96.8 (93.3-99.2) 96.9 (95.2-98.5) 11.8 (9.8-14.9)
13 93.8 (89.3-97.6) 95.7 (93.7-97.1) 14.0 (11.7-16.2)
14 98.4 (91.4-99.6) 97.2 (95.1-98.6) 10.7 (9.0-14.4)
LV
15 96.5 (92.8-98.3) 96.3 (95.3-97.7) 12.0 (10.7-13.2)
16 99.8 (98.9-100.0) 98.7 (97.7-99.6) 7.7 (6.6-8.8)
17 97.9 (93.4-99.2) 97.5 (95.8-98.6) 10.7 (8.8-13.0)
PTV
AVN
1 88.5 (76.9-95.9) 94.4 (90.1-96.6) 17.1 (14.2-23.8)
2 81.8 (73.4-87.7) 92.0 (89.7-93.4) 18.2 (15.0-23.2)
3 92.1 (82.6-95.2) 94.6 (92.1-96.1) 15.8 (13.1-19.4)
4 86.1 (74.1-91.8) 93.2 (90.9-94.6) 18.5 (16.7-22.0)
5 96.7 (90.4-98.7) 96.6 (94.7-98.0) 11.3 (9.1-13.7)
6 72.3 (62.8-80.0) 87.5 (83.9-90.4) 25.2 (20.8-29.5)
7 88.0 (77.6-92.2) 93.3 (91.2-95.0) 16.9 (14.9-20.0)
8 76.1 (69.5-81.8) 86.6 (84.4-88.7) 21.4 (18.5-25.4)
SPV
12 89.9 (86.7-91.6) 93.3 (92.1-94.4) 15.0 (13.1-17.6)
13 82.2 (78.6-84.3) 88.6 (87.0-89.5) 20.8 (18.9-22.9)
14 93.5 (89.2-95.5) 95.4 (93.5-96.1) 13.3 (11.6-17.1)
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Figure A.3.: Results of the homogeneous rescanning simulations for TV (a) and PTV (b). For all pigs the
values for V95, D95 and D5-D95 are given. Each box includes 96 simulations per pig, including
different motion patterns, regularity of the heartbeat and spill structures.
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(a) Results of the homogeneous rescanning simulations of the TV
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(b) Results of the homogeneous rescanning simulations of the PTV
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Table A.6.: Results for the homogeneous rescanning simulations for V95, D95 and D5-D95. For all pigs
and volumes the median values for all 96 simulations are given and in brackets the 25th -75th
percentiles are shown.
ID V95[%] D95[%] D5-D95[%]
TV
AVN
1 100.0 (100.0-100.0) 101.6 (100.0-103.1) 2.8 (2.1-3.9)
2 100.0 (100.0-100.0) 100.9 (99.5-102.6) 3.0 (1.6-4.7)
3 100.0 (100.0-100.0) 101.3 (99.7-102.4) 3.8 (2.3-5.0)
4 100.0 (100.0-100.0) 101.2 (99.8-102.0) 2.8 (1.6-3.7)
5 100.0 (100.0-100.0) 101.7 (100.9-102.7) 2.7 (1.6-3.6)
6 100.0 (100.0-100.0) 100.1 (97.6-102.9) 4.7 (3.2-6.9)
7 100.0 (100.0-100.0) 101.6 (100.7-102.9) 2.8 (1.5-4.0)
8 100.0 (100.0-100.0) 99.7 (98.5-101.6) 3.5 (2.5-5.0)
SPV
12 100.0 (99.8-100.0) 100.4 (99.4-100.9) 4.9 (4.0-5.8)
13 99.2 (87.8-100.0) 98.2 (92.5-99.9) 8.0 (5.6-14.8)
14 100.0 (100.0-100.0) 101.0 (100.4-101.8) 5.3 (3.2-6.9)
LV
15 99.8 (98.5-100.0) 99.4 (97.9-100.6) 4.6 (3.1-7.2)
16 100.0 (100.0-100.0) 100.3 (99.7-100.7) 4.3 (2.8-7.4)
17 100.0 (99.7-100.0) 100.0 (98.8-100.9) 4.4 (3.0-6.5)
PTV
AVN
1 100.0 (99.8-100.0) 99.2 (98.4-100.0) 6.2 (4.8-7.8)
2 94.2 (90.6-96.0) 95.5 (94.3-96.5) 9.7 (7.7-11.2)
3 99.2 (91.4-100.0) 97.6 (95.6-99.6) 8.4 (5.6-11.0)
4 99.0 (95.1-99.9) 98.1 (96.0-99.0) 7.2 (5.6-8.7)
5 100.0 (100.0-100.0) 100.2 (99.4-100.8) 4.4 (3.6-5.1)
6 84.5 (73.1-88.9) 91.1 (88.8-92.9) 14.2 (11.6-17.9)
7 98.2 (96.7-99.2) 97.9 (96.9-98.8) 7.2 (5.7-9.1)
8 82.4 (78.3-84.9) 87.0 (85.7-88.3) 17.3 (16.2-19.1)
SPV
12 93.3 (91.1-94.2) 94.5 (92.7-95.4) 10.6 (9.5-12.3)
13 86.7 (74.8-89.0) 88.4 (78.6-90.3) 17.8 (14.9-30.0)
14 97.8 (97.0-98.4) 98.6 (97.5-99.7) 8.8 (4.8-11.0)
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Figure A.4.: Results of the inhomogeneous rescanning simulations for TV (a) and PTV (b). For all pigs the
values for V95, D95 and D5-D95 are given. Each box includes 96 simulations per pig, including
different motion patterns, regularity of the heartbeat and spill structures.
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(a) Results of the inhomogeneous rescanning simulations of the TV
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(b) Results of the inhomogeneous rescanning simulations of the PTV
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Table A.7.: Results for the inhomogeneous rescanning simulations for V95, D95 and D5-D95. For all pigs
and volumes the median values for all 96 simulations are given and in brackets the 25th -75th
percentiles are shown.
ID V95[%] D95[%] D5-D95[%]
TV
AVN
1 100.0 (98.7-100.0) 100.1 (96.8-103.0) 5.9 (4.4-7.7)
2 100.0 (100.0-100.0) 99.6 (97.3-101.8) 6.7 (4.7-8.8)
3 100.0 (100.0-100.0) 100.2 (98.3-102.5) 4.2 (3.2-6.0)
4 100.0 (100.0-100.0) 99.7 (97.6-102.7) 5.7 (4.4-7.8)
5 100.0 (100.0-100.0) 100.4 (99.2-101.8) 5.1 (3.8-6.5)
6 100.0 (86.1-100.0) 98.4 (95.0-103.1) 7.0 (5.8-8.8)
7 100.0 (100.0-100.0) 99.5 (97.1-102.1) 6.8 (5.0-9.2)
8 100.0 (98.9-100.0) 99.4 (97.3-101.8) 5.0 (4.1-7.4)
SPV
12 99.4 (97.6-99.9) 98.7 (97.1-99.7) 8.7 (7.2-10.6)
13 98.7 (95.3-99.7) 97.8 (96.0-98.9) 8.9 (7.4-11.5)
14 100.0 (99.8-100.0) 99.4 (98.7-100.1) 6.8 (5.7-7.9)
LV
15 100.0 (99.7-100.0) 99.4 (98.7-99.9) 6.4 (5.2-7.5)
16 100.0 (99.9-100.0) 99.6 (99.0-100.4) 5.6 (4.9-6.4)
17 99.9 (99.2-100.0) 98.9 (98.1-99.8) 6.8 (5.7-8.0)
PTV
AVN
1 96.7 (90.1-99.8) 96.6 (94.9-98.6) 10.6 (8.4-13.5)
2 89.0 (82.3-93.3) 94.1 (92.6-95.6) 13.1 (10.7-16.1)
3 99.0 (95.4-99.7) 98.0 (96.4-99.0) 9.0 (7.4-10.9)
4 94.7 (89.8-97.9) 95.9 (94.3-97.1) 11.9 (10.7-14.4)
5 99.8 (99.3-99.9) 98.6 (97.8-99.3) 7.0 (5.9-8.4)
6 79.4 (61.2-88.0) 90.7 (87.8-92.7) 17.0 (13.3-20.8)
7 92.9 (89.2-97.2) 95.4 (93.7-97.0) 12.6 (10.1-15.0)
8 82.5 (74.5-86.5) 87.0 (85.2-89.4) 19.0 (16.4-22.1)
SPV
12 92.2 (90.7-93.4) 94.0 (93.3-94.9) 12.8 (11.3-14.1)
13 87.0 (84.1-88.5) 89.2 (87.5-90.4) 17.3 (15.4-20.2)
14 97.4 (96.5-97.8) 97.7 (97.0-98.5) 8.5 (7.4-9.4)
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Table A.10.: Simulated irradiation times for homogeneous and inhomogeneous rescanning neglecting
necessary time for breath holds. The results show the values for each field as well as the
total time for the combination of both fields.
Target ID
homogeneous rescanning inhomogeneous rescanning
90◦ [min] 270◦ [min] total [min] 90◦ [min] 270◦ [min] total [min]
AVN
1 6.98 6.06 13.04 2.40 2.31 4.72
2 10.71 9.15 19.86 3.14 3.15 3.28
3 10.57 11.60 22.17 3.52 3.87 7.39
4 8.07 10.30 18.37 2.75 2.57 5.32
5 5.82 5.02 10.84 2.37 1.72 4.09
6 5.84 6.97 12.81 1.86 2.02 3.89
7 5.23 5.94 11.16 2.23 2.41 4.64
8 9.35 9.34 18.69 3.12 3.26 6.39
SPV
12 30.11 36.43 66.54 8.21 8.83 17.04
13 23.26 31.05 54.31 7.06 9.30 16.36
14 20.92 20.93 41.85 7.27 6.01 13.27
LV
15 18.23 7.09 25.32 5.78 2.29 8.04
16 12.77 10.29 23.06 4.59 3.54 8.13
17 18.28 7.09 25.32 5.98 2.83 8.80
Table A.11.: Total irradiation times during the experiment including the time needed for the repeated
breathholds.
Target ID
90◦ 270◦
total [min] total [min]
AVN
1 4.82 4.01
2 5.63 5.10
3 5.71 7.18
4 6.78 -
5 4.50 3.39
6 3.32 3.32
7 5.55 12.06
8 6.08 7.76
SPV
12 16.28 17.15
13 13.51 38.47*
14 13.22 9.97
LV
15 12.91 4.99
16 10.42 7.35
17 15.98 20.16
115
Table A.12.: Doses deposited in the OARs for the static simulations of the AVN patient cohort. Corre-
sponding dose volume limits are given in Table 2.2.
OAR Pig 1 Pig 2 Pig 3 Pig 4 Pig 5 Pig 6 Pig 7 Pig 8
Aorta
Dmean [Gy] 3.69 1.82 2.36 2.56 2.04 1.88 1.15 2.55
Dmax [Gy] 56.82 56.48 56.43 41.76 41.20 41.64 25.67 25.97
DoseVolume [Gy] 10.94 8.55 10.48 7.27 11.49 11.28 10.35 16.42
Skin
Dmean [Gy] 0.17 0.28 0.22 0.16 0.12 0.16 0.10 0.15
Dmax [Gy] 17.44 17.49 17.55 13.88 11.88 12.36 7.45 9.88
DoseVolume [Gy] 3.40 3.36 3.30 3.53 3.11 3.41 3.21 3.69
Myo
Dmean [Gy] 2.86 2.75 2.86 1.64 1.44 2.20 1.08 1.58
Dmax [Gy] 56.87 57.25 56.87 41.52 41.68 41.60 25.85 26.00
DoseVolume [Gy] 8.06 6.60 5.68 6.41 5.68 6.51 6.19 6.98
AscAorta
Dmean [Gy] 6.16 3.52 4.95 4.52 4.60 3.32 2.05 4.95
Dmax [Gy] 56.82 56.48 56.43 41.76 41.20 41.64 25.67 25.97
Lungs
Dmean [Gy] 0.00 0.11 0.17 0.00 0.04 0.04 0.05 0.10
Dmax [Gy] 18.81 20.13 20.24 16.36 13.40 14.00 8.18 22.18
PA
Dmean [Gy] 0.00 0.06 0.11 0.00 0.04 0.04 0.00 0.05
Dmax [Gy] 0.22 6.05 8.80 1.72 3.04 3.52 0.65 4.85
LCA
Dmean [Gy] 6.05 10.95 9.79 5.84 4.00 8.04 3.40 5.00
Dmax [Gy] 20.63 20.85 19.58 15.52 12.92 13.56 8.03 18.35
RCA
Dmean [Gy] 1.71 9.02 6.44 2.28 9.72 4.80 5.95 4.75
Dmax [Gy] 19.31 19.80 24.70 15.84 13.88 14.44 8.40 11.13
Pericard
Dmean [Gy] 1.10 0.88 1.05 0.64 0.48 0.68 0.38 0.58
Dmax [Gy] 20.29 20.68 20.68 16.16 13.76 14.44 8.45 23.00
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Table A.13.: Doses deposited in the OARs for the static simulations of the SPV patient cohort. Corre-
sponding dose volume limits are given in Table 2.2.
OAR Pig 12 Pig 13 Pig 14
Skin
Dmean [Gy] 0.48 0.48 0.44
Dmax [Gy] 21.16 20.40 20.40
DoseVolume [Gy] 6.80 6.18 5.77
Myo
Dmean [Gy] 2.60 2.72 3.48
Dmax [Gy] 42.60 42.16 41.80
DoseVolume [Gy] 9.84 8.63 10.89
Trachea
Dmean [Gy] 0.80 1.36 4.32
Dmax [Gy] 23.96 31.36 32.28
DoseVolume [Gy] 1.07 1.25 2.26
Esophagus
Dmean [Gy] 0.00 0.00 0.04
Dmax [Gy] 0.00 0.04 1.28
DoseVolume [Gy] 0.00 0.00 0.00
Lungs
Dmean [Gy] 0.72 0.64 0.96
Dmax [Gy] 23.20 23.80 28.00
LCA
Dmean [Gy] 3.88 4.44 4.08
Dmax [Gy] 40.72 26.12 29.68
RCA
Dmean [Gy] 6.16 6.68 7.56
Dmax [Gy] 19.60 20.36 19.00
AVN
Dmean [Gy] 9.72 5.84 1.00
Dmax [Gy] 42.72 37.72 4.00
Pericard
Dmean [Gy] 3.04 2.48 3.56
Dmax [Gy] 42.24 41.88 41.84
SVC
Dmean [Gy] 1.76 0.00 0.08
Dmax [Gy] 14.24 0.00 1.40
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Table A.14.: Doses deposited in the OARs for the static simulations of the LV patient cohort. Correspond-
ing dose volume limits are given in Table 2.2.
OAR Pig 15 Pig 16 Pig 17
Skin
Dmean [Gy] 0.24 0.24 0.28
Dmax [Gy] 15.36 16.68 16.68
DoseVolume [Gy] 3.99 3.83 4.12
Myo
Dmean [Gy] 3.80 2.88 3.92
Dmax [Gy] 41.80 41.60 41.48
DoseVolume [Gy] 10.04 9.56 10.26
Lungs
Dmean [Gy] 0.72 0.36 0.56
Dmax [Gy] 41.76 41.12 41.80
PA
Dmean [Gy] 0.00 0.00 0.00
Dmax [Gy] 0.00 0.00 0.00
LCA
Dmean [Gy] 0.40 2.12 2.52
Dmax [Gy] 9.84 17.68 17.04
RCA
Dmean [Gy] 0.00 0.00 0.00
Dmax [Gy] 0.00 0.00 0.00
Pericard
Dmean [Gy] 2.64 2.08 2.52
Dmax [Gy] 41.36 41.36 41.76
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Table A.17.: Doses deposited in the OARs for the inhomogeneous rescanning simulations of the SPV pa-
tient cohort. Corresponding dose volume limits are given in Table 2.2.
OAR Pig 12 Pig 13 Pig 14
Skin
Dmean [Gy] 0.48 (0.48 - 0.48) 0.48 (0.48 - 0.48) 0.44 (0.44 - 0.44)
Dmax [Gy] 21.12 (21.11 - 21.12) 20.40 (20.36 - 20.40) 20.44 (20.40 - 20.44)
DoseVolume [Gy] 6.67 (6.67 - 6.67) 6.18 (6.18 - 6.18) 5.77 (5.77 - 5.77)
Myo
Dmean [Gy] 2.48 (2.48 - 2.48) 2.60 (2.59 - 2.60) 3.28 (3.28 - 3.28)
Dmax [Gy] 44.56 (44.16 - 45.90) 44.18 (43.75 - 45.24) 43.70 (43.45 - 44.11)
DoseVolume [Gy] 9.49 (9.48 - 9.50) 8.24 (8.20 - 8.25) 10.41 (10.39 - 10.41)
Trachea
Dmean [Gy] 0.76 (0.76 - 0.76) 1.38 (1.36 - 1.40) 4.54 (4.52 - 4.56)
Dmax [Gy] 22.72 (22.38 - 23.48) 32.68 (32.32 - 33.09) 33.80 (33.26 - 34.33)
DoseVolume [Gy] 1.00 (1.00 - 1.01) 1.26 (1.26 - 1.27) 2.37 (2.35 - 2.37)
Esophagus
Dmean [Gy] 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.04 (0.04 - 0.04)
Dmax [Gy] 0.04 (0.04 - 0.04) 0.04 (0.04 - 0.04) 1.60 (1.56 - 1.64)
DoseVolume [Gy] 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
Lungs
Dmean [Gy] 0.72 (0.72 - 0.72) 0.64 (0.64 - 0.64) 0.96 (0.96 - 0.96)
Dmax [Gy] 23.04 (22.95 - 23.13) 23.54 (23.29 - 23.68) 27.02 (26.86 - 27.12)
LCA
Dmean [Gy] 2.80 (2.71 - 2.84) 3.48 (3.47 - 3.52) 3.64 (3.60 - 3.64)
Dmax [Gy] 34.64 (32.93 - 35.46) 22.00 (21.81 - 22.12) 24.48 (23.98 - 24.85)
RCA
Dmean [Gy] 6.40 (6.36 - 6.40) 6.68 (6.63 - 6.72) 7.04 (7.03 - 7.13)
Dmax [Gy] 19.78 (19.62 - 19.87) 20.14 (19.71 - 20.40) 18.56 (18.27 - 18.65)
AVN
Dmean [Gy] 7.72 (7.63 - 7.76) 5.04 (5.00 - 5.08) 0.52 (0.48 - 0.52)
Dmax [Gy] 36.08 (35.02 - 36.82) 31.80 (30.28 - 32.23) 2.10 (2.05 - 2.16)
Pericard
Dmean [Gy] 2.96 (2.96 - 2.96) 2.44 (2.44 - 2.44) 3.44 (3.44 - 3.44)
Dmax [Gy] 42.94 (42.52 - 43.47) 42.24 (41.75 - 42.84) 43.00 (42.60 - 43.68)
SVC
Dmean [Gy] 1.72 (1.72 - 1.72) 0.00 (0.00 - 0.00) 0.08 (0.08 - 0.08)
Dmax [Gy] 13.68 (13.63 - 13.77) 0.08 (0.08 - 0.08) 1.30 (1.24 - 1.48)
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Table A.18.: Doses deposited in the OARs for the inhomogeneous rescanning simulations of the LV pa-
tient cohort. Corresponding dose volume limits are given in Table 2.2.
OAR Pig 15 Pig 16 Pig 17
Skin
Dmean [Gy] 0.24 (0.24 - 0.24) 0.24 (0.24 - 0.24) 0.28 (0.28 - 0.28)
Dmax [Gy] 15.52 (15.48 - 15.52) 16.80 (16.76 - 16.80) 17.56 (17.44 - 17.68)
DoseVolume [Gy] 4.00 (4.00 - 4.00) 3.82 (3.82 - 3.83) 4.13 (4.13 - 4.13)
Myo
Dmean [Gy] 4.12 (4.12 - 4.12) 3.04 (3.04 - 3.04) 4.22 (4.20 - 4.24)
Dmax [Gy] 43.76 (43.32 - 44.59) 43.10 (42.87 - 43.74) 44.12 (43.22 - 45.36)
DoseVolume [Gy] 10.42 (10.40 - 10.46) 9.78 (9.75 - 9.80) 10.65 (10.62 - 10.72)
Lungs
Dmean [Gy] 0.76 (0.76 - 0.76) 0.40 (0.36 - 0.40) 0.60 (0.60 - 0.60)
Dmax [Gy] 42.54 (42.20 - 42.90) 41.72 (41.55 - 41.85) 42.58 (42.44 - 42.89)
PA
Dmean [Gy] 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
Dmax [Gy] 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
LCA
Dmean [Gy] 0.44 (0.44 - 0.45) 2.28 (2.28 - 2.28) 2.64 (2.64 - 2.68)
Dmax [Gy] 10.68 (10.63 - 10.81) 17.70 (17.68 - 17.77) 16.68 (16.50 - 16.84)
RCA
Dmean [Gy] 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
Dmax [Gy] 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
Pericard
Dmean [Gy] 2.80 (2.80 - 2.80) 2.16 (2.16 - 2.16) 2.72 (2.72 - 2.72)
Dmax[Gy] 42.58 (42.26 - 43.02) 42.08 (41.92 - 42.22) 42.98 (42.44 - 43.56)
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Figure A.5.: Dose volume limits for the AVN irradiation. The corresponding dose threshold for each OAR
is marked with a horizontal dashed gray line.
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Figure A.6.: Dose volume limits for the LV irradiation. The corresponding dose threshold for each OAR is
marked with a horizontal dashed gray line.
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Figure A.7.: Dose volume limits for the SPV irradiation. The corresponding dose threshold for each OAR
is marked with a horizontal dashed gray line.
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Table B.1.: γ-Indices (2mm + 2%) for the 2D dose measurements carried out at HIT. Technical problems
during the measurements not allowing the calculation of the γ-index are indicated by a dash.
Pig 12 Pig 14 Liver A Liver B Liver C Liver D Liver E
DICI vs DICII - Original 1.00 - 0.98 0.92 0.99 0.99 0.99
DICI vs DICII - Rescanning 1.00 1.00 0.66 - 0.66 0.74 0.61
DICI vs DICII - Large Points 1.00 1.00 1.00 1.00 1.00 1.00 1.00
DICI vs DICII - Small Points 1.00 1.00 0.71 0.99 0.41 0.24 0.10
DICI vs DICII - Large + Small 1.00 1.00 1.00 1.00 1.00 1.00 1.00
DICI - Original vs Rescanning 1.00 1.00 0.68 - 0.67 0.63 0.63
DICII - Original vs Rescanning 1.00 - 1.00 0.94 1.00 0.97 1.00
DICII - NewPath vs Rescanning 1.00 1.00 0.34 1.00 1.00 1.00 1.00
DICII - Original vs NewPath 1.00 - 0.27 0.88 0.95 0.94 0.94
DICII - Rescanning vs Large+Small 0.99 1.00 0.60 - 0.73 0.69 0.70
DICII - Original vs Big+Small 1.00 - 1.00 0.94 1.00 1.00 1.00
DICII - NewPath vs Big+Small 1.00 1.00 0.31 0.98 0.98 0.98 0.97
Table B.2.: Deviations found in the 2D dose measurements between the constant intensity rescanning
plan and other plans delivering the same dose with higher intensities.
Pig 12 Pig 14 Liver A
DICI vs DICII - Rescanning 0.02 (0.01 – 0.15) 0.01 (0.00 – 0.09) 0.12 (0.09 – 0.15)
DICI vs DICII - Small 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.02) 0.18 (0.11 – 0.26)
DICI - Original vs Rescanning -0.03 (-0.11 – -0.02) -0.03 (-0.10 – -0.01) -0.17 (-0.23 – -0.12)
DICI - Rescanning vs Big+Small 0.02 (0.01 – 0.09) 0.01 (0.00 – 0.04) 0.13 (0.08 – 0.19)
Liver B Liver C Liver D Liver E
0.78 (0.77 – 0.94) 0.12 (0.08 – 0.17) 0.09 (0.07 – 0.15) 0.12 (0.10 – 0.18)
-0.06 (-0.18 – 0.0) 0.25 (0.17 – 0.35) 0.37 (0.28 – 0.51) 0.31 (0.24 – 0.43)
-3.51 (-4.14 – -3.31) -0.17 (0.23 – -0.12 -0.16 (-0.25 – -0.12) -0.16 (-0.23 – -0.12)
0.78 (0.76 – 0.81) 0.10 (0.05 – 0.15) 0.10 (0.06 – 0.17) 0.11 (0.07 – 0.17)
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Figure B.1.: For all three target groups the results for interplay and rescanning simulations showing the
influence of SPO and DIC on the target coverage. Each box includes 48 simulations, median
values are indicated by solid lines. The whisker represent 1.5 times the inner quartile range
and outliers are marked with dots. The legend shown in part (a) is valid for all subfigures.
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Figure B.2.: Results for interplay and rescanning simulations of catheter-free ablations in humans showing
the influence of SPO and DIC on the target coverage in five patients. Each box includes 8
simulations, median values are indicated by solid lines. The whisker represent 1.5 times the
inner quartile range and outliers are marked with dots.. The legend shown in part (a) is valid
for all subfigures.
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Figure B.3.: Results for interplay and rescanning simulations of five lung cancer patients showing the
influence of SPO and DIC on the target coverage. Each box includes 8 simulations, median
values are indicated by solid lines. The whisker represent 1.5 times the inner quartile range
and outliers are marked with dots.. The legend shown in part (a) is valid for all subfigures.
80
90
100
V9
5 
[%
]
80
90
100
D9
5 
[%
]
1 2 3 4 5
0
10
20
D5
-D
95
 [%
]
128 B. Appendix Chapter 5
Table B.3.: Resulting p-values comparing the target coverage and dose homogeneity of the pig cohort
between different speed-up methods
Target Simulation Type D95 V95 D5-D95
CTV
SPOI 0.898 0.504 0.000
DIC 0.002 0.259 0.395
DIC + SPO II 0.272 0.647 0.000
PTV
SPOI 0.000 0.066 0.000
DIC 0.000 0.763 0.037
DIC + SPO II 0.00 0.011 0.000
Table B.4.: Resulting p-values comparing the target coverage and dose homogeneity of the human co-
hort between different speed-up methods
Target Simulation Type D95 V95 D5-D95
LPV
SPOI 0.024 0.853 0.075
DIC 0.002 0 548 0.017
DIC + SPO II 0.034 0.122 0.105
RPV
SPOI 0.812 0.482 0.055
DIC 0.552 0.265 0.046
DIC + SPO II 0.364 0.229 0.007
Table B.5.: Resulting p-values comparing the target coverage and dose homogeneity of the lung caner
patient cohort between different speed-up methods
Simulation Type D95 V95 D5-D95
SPOI 0.003 0.172 0.679
DIC 0.012 0.271 0.218
DIC + SPO II 0.046 0.130 0.532
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